

University of Vermont

ScholarWorks @ UVM

Graduate College Dissertations and Theses

Dissertations and Theses

2020

A Chemical Genetics Approach To Understand The Regulation Of Cryptosporidium Sexual Differentiation

Md Mahmudul Hasan
University of Vermont

Follow this and additional works at: <https://scholarworks.uvm.edu/graddis>



Part of the [Cell Biology Commons](#), [Microbiology Commons](#), and the [Parasitology Commons](#)

Recommended Citation

Hasan, Md Mahmudul, "A Chemical Genetics Approach To Understand The Regulation Of Cryptosporidium Sexual Differentiation" (2020). *Graduate College Dissertations and Theses*. 1278.
<https://scholarworks.uvm.edu/graddis/1278>

This Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact donna.omalley@uvm.edu.

A CHEMICAL GENETICS APPROACH TO UNDERSTAND THE REGULATION OF
CRYPTOSPORIDIUM SEXUAL DIFFERENTIATION

A Dissertation Presented

by

Md Mahmudul Hasan

to

The Faculty of the Graduate College

of

The University of Vermont

In Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
Specializing in Cellular, Molecular and Biomedical Sciences

August, 2020

Defense Date: July 17, 2020
Dissertation Examination Committee:

Christopher D. Huston, M.D., Advisor
Jonathan E. Boyson, Ph.D., Chairperson
Gary E. Ward, Ph.D.
Markus Thali, Ph.D.
Dawei Li, Ph.D.

Cynthia J. Forehand, Ph.D., Dean of the Graduate College

ABSTRACT

Cryptosporidium species are eukaryotic intracellular parasites belonging to the phylum Apicomplexa. *C. hominis* and *C. parvum* cause diarrhea in humans which is self-limiting in immunocompetent adults but can have severe consequences in immunocompromised individuals and malnourished children. In developing countries, *Cryptosporidium* is one of the leading causes of moderate to severe diarrhea in children under five years of age. There is an urgent need for novel therapeutics against this parasite as the current treatment option is inadequate to treat the most vulnerable population to *Cryptosporidium* infection. Better understandings of the biology of *Cryptosporidium* would greatly enhance our capability to design effective control measures.

The parasite initially multiplies through several rounds of asexual replication within the intestinal epithelial cells before differentiating into sexual forms. Here we have tested the ReFRAME library, a set of ~12,000 biologically active compounds, for activities against the asexual and sexual forms of *C. parvum* separately. We identified and validated compounds that inhibit and/or induce the growth of either or both life cycle stages. Compounds that inhibit both stages are potentially good drug candidates. Other compounds have promising tool-like properties that can be utilized to probe different aspects of *C. parvum* sexual differentiation. Several inhibitors of host cell oxidative phosphorylation and purine nucleotide biosynthesis disproportionately inhibited the sexual differentiation of *C. parvum*, highlighting the necessity of these processes in facilitating *C. parvum* sexual differentiation.

All the apicomplexan parasites differentiate into distinct forms in the course of their life cycle and each of the differentiation steps is associated with large scale changes in gene expression. To identify such stage specific genes and pathways associated with *C. parvum* sexual differentiation, we performed mRNA-seq of host cells infected with *C. parvum* in the presence of nine differentiation inhibitors. Ribosomal proteins were the most significantly enriched group of genes that were upregulated with multiple differentiation inhibitors, which suggested that the downregulation of these genes is associated with *C. parvum* sexual differentiation. Comparison of our results with a publicly available stage-specific mRNA-seq dataset of *C. parvum* validated this conclusion and analysis of transcriptomic datasets from other apicomplexan parasites revealed that this is a common mechanism of regulating life cycle stage differentiation in these parasites. In addition, identification of significantly enriched DNA motifs at promoters of dysregulated genes coupled with the expression pattern of several apicomplexan AP2 transcription factors strongly suggested that they play a critical role in regulating *C. parvum* sexual differentiation.

ACKNOWLEDGEMENTS

First of all, thanks to the almighty Allah for giving me the opportunity to pursue doctoral research in the Huston Lab of the University of Vermont. I cannot think of a better place than this to come to work every day. It is, therefore, a kind of bittersweet feeling for me to finally write this acknowledgment section, knowing that my time in the Huston lab has come to an end.

Chris has been the most wonderful mentor that anyone can think of. Besides having all the cliched qualities of a great scientist, he has this way of becoming infectiously excited about trying out new methodologies to tackle research questions, which made my work challenging but incredibly fun at the same time. Also, I have always been amazed by his ability to quickly understand complex explanations, which I tended to do regularly, and then simplify the idea and put it into a tangible context. I am still trying to understand if it is something that can be learned or not.

I really felt blessed to have the best lab mates throughout my duration in the Huston Lab. Ze taught me most of the techniques that I used in the lab and I am yet to find a technical problem that he cannot fix. I think Rajiv's passion about our work rubbed off a little on me and made me care about my work more. Erin is the person who gets the job done, with meticulous planning and and seemingly effortless executions. Peter

just churns out data after data from the mouse model experiments that requires working in the most uncommon hours day after day and I sometime wonder how does he get the time to do all the other things that he does in the lab. All these people were not just great lab mates, they were my mentors in many different aspects of life in USA. It was a wonderful experience to work with Ethan, Bethany and Kirtika, the latest additions to the huston lab, in my last year. All these super intelligent people brought with them much required fresh ideas and energy, and I am really excited to see where they take the lab in the next few years (and slightly sad for not to be a part of it).

I think I compiled a line up of the nicest people in UVM to be my committee members. At times, I felt like they were more sure about my ability than I ever can be and I came out from each of my committee meeting with renewed belief in myself and exciting new ideas to try. And last but not the least, I thank my wife, Tushiba, for putting up with me all this time in the midst of occasional crazy work hours and always support me when I felt down. My parents has also been a constant source of support for me and always helped me to keep my focus.

This dissertation is a combined effort to all the above mentioned people and numerous other people, both from in and out of the UVM community. I will forever be grateful for their support.

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS.....	II
LIST OF FIGURES	VIII
CHAPTER 1: A REVIEW OF THE MECHANISMS THAT REGULATE STAGE DIFFERENTIATION DURING THE LIFE CYCLE PROGRESSION OF APICOMPLEXAN PARASITES.....	1
1.1: Purpose of this Review	1
1.2: Origin and Classification of Apicomplexan Parasites	1
1.3: Significance of the Research on Apicomplexan Stage Differentiation and Scope of this Review	5
1.4: <i>Plasmodium</i> Stage Differentiation.....	8
1.4.1: Sporozoite to Liver Stage Differentiation	9
1.4.2: Liver Stage to Erythrocytic Stage Differentiation	13
1.4.3: Sexual Differentiation of <i>Plasmodium</i>	14
1.4.4: Sex-specific Maturation for Differentiation into Zygote.....	19
1.4.5: Zygote to Ookinete, Ookinete to Oocyst, and Oocyst to Sporozoite differentiation	23
1.5: <i>Toxoplasma gondii</i> Stage Differentiation.....	24
1.5.1: Tachyzoite-Bradyzoite differentiation.....	26
1.5.1.1.: Lessons from the Induction Signals.....	26
1.5.1.2: Lessons from the -Omics Studies	29
1.5.1.3: Role of Epigenetic Regulators and Transcription Factors	30
1.5.2: <i>T. gondii</i> Sexual Differentiation	32

1.6: <i>Cryptosporidium</i> Stage Differentiation	35
1.7: <i>Eimeria</i> Stage Differentiation.....	41
1.8: Stage Differentiation of Piroplasms	45
1.8.1: <i>Theileria</i>	46
1.8.2: <i>Babesia</i>	48
1.9: Similarities and Differences in Stage Differentiation Between Apicomplexan Parasites	49
1.10: Future perspectives	52
1.11: Summary of our approach	53
1.12: References	60
CHAPTER 2: A CHEMICAL GENETICS APPROACH TO UNDERSTAND THE REGULATION OF CRYPTOSPORIDIUM SEXUAL DIFFERENTIATION.....	100
2.1: Abstract.....	100
2.2: Introduction	101
2.3: Results	105
2.3.1: Optimizing the Identification of Sexually Differentiated <i>C. parvum</i>	105
2.3.2: Screening and Validation of the ReFRAME Library	107
2.3.3: Several Differentiation Inhibitors Share Common Modes of Action and Activity Kinetics.....	109
2.3.4: mRNA-seq Analysis of Compound Effects on Gene Expression	111
2.3.5: Female-specific Genes are Down-regulated and Asexual Stage-specific Genes are Upregulated Following Treatment with Differentiation Inhibitors	113

2.3.6: Proteins Involved in Ribosome Formation are Upregulated in Response to Differentiation Inhibitors	115
2.3.7: Ribosomal Proteins are Generally Downregulated in Response to Translational Repression Programs During Differentiation in Apicomplexan Parasites	118
2.3.8: The DNA Recognition Motif of Four ApiAp2 Transcription Factors is Significantly Enriched in the Promoter Regions of Commonly Downregulated Genes	119
2.4: Discussion.....	120
2.5: Material and Methods.....	131
2.5.1: In vitro <i>C. parvum</i> Infection Model.....	131
2.5.2: Compound Screening and Dose Response Validation	131
2.5.3: mRNA-seq Sample Preparation and Sequencing	132
2.5.4: mRNA-seq Data Analysis	133
2.5.5: Pathway Analysis and Gene Expression Heatmap Generation	134
2.5.6: <i>C. parvum</i> genes' Upstream and Downstream Sequence Analysis.....	134
2.6: Figure legends.....	135
2.7: References	162
CHAPTER 3: DISCUSSION AND FUTURE DIRECTION.....	173
3.1: Potential Function and Stage Specificity of the <i>C. parvum</i> DMC1 protein	173
3.2: The Rationale for Focusing on Differentiation Inhibitors for Follow-up Experiments	176
3.3: Potential Follow-up Experiments with Other Compound Classes	177

3.4: Other Potential Utilities of Differentiation Inhibitors	178
3.5: Potential Genetic Validation of The Chemical Genomics Approach.....	179
3.5.1: eIF2 α Phosphorylation Plays a Key Regulatory Role in <i>C. parvum</i> Sexual Differentiation.....	181
3.5.2: ApiAP2 Transcription Factors Regulate <i>C. parvum</i> Sexual Differentiation	182
3.5.3: <i>C. parum</i> DMC1 is a Female Specific Protein Involved in Meiotic Cell Division of the Zygotes	182
3.6: Concluding Remarks	183
3.7: References	189
COMPREHENSIVE BIBLIOGRAPHY	193

LIST OF FIGURES

Figure	Page
CHAPTER 1	
Figure 1: <i>Plasmodium</i> life cycle.....	55
Figure 2: <i>Toxoplasma gondii</i> life cycle.....	56
Figure 3: <i>Cryptosporidium</i> life cycle.....	57
Figure 4: <i>Eimeria</i> life cycle.....	58
Figure 5: <i>Babesia</i> life cycle.....	59
CHAPTER 2	
Figure 1: Stage specific assay development and library screening	144
Figure 2: Categories of the validated hits and example dose response curves.....	145
Figure 3: Differentiation inhibitors share common putative targets and they selectively inhibit sexual differentiation across a range of concentrations	146
Figure 4: Differentiation inhibitors are required to be added before parasite sexual differentiation	148
Figure 5: Treatment with differentiation inhibitors dysregulates a set of core genes involved in parasite differentiation.....	149
Figure 6: <i>C. parvum</i> sexual differentiation is associated with suppression of ribosome formation, which is indicative of a translational repression program	150
Figure 7: Promoters of downregulated genes of <i>C. parvum</i> harbor a recognition site for several ApiAP2 transcription factors that are also dysregulated by differentiation inhibitor treatments	152

Figure 8: A proposed model of repressing <i>C. parvum</i> sexual differentiation by the two Methionine aminopeptidase 2 (MetAP2) inhibitors	152
Supplementary Figure 1: Dose response curves of all the screening hits	153
Supplementary Figure 2: Volcano plots of dysregulated genes by AGM-1470 and Oligomycin A treatment.	160
Supplementary Figure 3: <i>C. parvum</i> asexual stage specific genes are upregulated and female specific genes are downregulated with differentiation inhibitor treatments.....	160
Supplementary Figure 4: Stage specificity of genes dysregulated by differentiation inhibitor treatments	161
 CHAPTER 3	
Figure 1: Expression time course of selected genes.....	186
Figure 2: <i>C. parvum</i> oocysts stained with anti DMC1 antibody.	187
Figure 3: Parasite numbers after 7 days post infection with differentiation inhibitor treatments.....	188

CHAPTER 1: A REVIEW OF THE MECHANISMS THAT REGULATE STAGE DIFFERENTIATION DURING THE LIFE CYCLE PROGRESSION OF APICOMPLEXAN PARASITES

1.1: Purpose of this Review

The major goal of this thesis was to identify mechanisms underlying differentiation of the apicomplexan parasite *Cryptosporidium*. For this, we relied heavily on the main strengths of our laboratory, which are in the areas of high throughput assay development and drug screening. We describe development of a microscopy-based screening assay for asexual to sexual stage development of *Cryptosporidium*, its use to screen a library of biologically active small molecules, and then follow up studies to characterize the effects of identified inhibitors using RNA-seq. This literature review chapter provides background on parasites related to *Cryptosporidium* within the phylum Apicomplexa, what is known about differentiation of major apicomplexan parasites, and general themes that have emerged from prior research on apicomplexan differentiation.

1.2: Origin and Classification of Apicomplexan Parasites

Apicomplexa is a phylum of unicellular eukaryotes that are obligate intracellular parasites. The defining characteristic of this phylum is that they all harbor an apical complex, a structure composed of specialized organelles and cytoskeletal

structures, during at least one stage of their life cycle. It is present at the anterior end of the parasite and is required to invade the host cell. Apicomplexans infect almost all vertebrates and invertebrates and the host specificity of each species is relatively restricted, with some notable exceptions (1-3).

Another feature of apicomplexans beside the apical complex is the apicoplast, a non-photosynthetic plastid, that is present in most of the apicomplexan parasites. The apicoplast genome has given us major clues about the origin and evolution of apicomplexans. The four membrane enclosure of the apicoplast suggests a secondary endosymbiotic origin of the organelle (4). Such an organelle is, however, not completely unique in apicomplexans. Around half of the members of Dinoflagellata, a sister phylum of Apicomplexa consisting of unicellular planktons, are among the other groups of organisms that contain a secondary endosymbiotic plastid (4). Interestingly, even though phylogenetic analysis of plastid rRNAs shows that apicomplexan and dinoflagellate plastids came from the same origin, their gene sets do not overlap a lot (5). Discovery of the unicellular photosynthetic organisms *Chromera velia* and *Vitrella brassicaformis* provided the missing link between apicomplexans and dinoflagellates (6, 7). Both of them have a secondary endosymbiotic plastid that encode a superset of genes present in the plastids of apicomplexans and dinoflagellates. Phylogenetic analysis of their plastid genome reinforced the already widely supported notion that their plastid, just like the plastids of apicomplexans and dinoflagellates, originated from red algal plastids (6). Phylogenetic trees constructed using the 18S rRNA and nuclear

genes also point towards a common ancestor of apicomplexans, dinoflagellates and chrompodellids (*Chromera velia*, *Vitrella brassicaformis*, and other related genera) (8, 9). Therefore, the currently held view is that the common ancestor of all three above mentioned groups was a free-living photosynthetic unicellular eukaryote with a secondary endosymbiotic plastid of red algal origin. Subsequent evolution of this ancestor gave rise to several lines, some keeping the photosynthetic capability while apicomplexans lost it (10, 11). Importantly, there are groups of organisms in different lineages originating from this ancestor that have also completely lost the plastid (9).

Transfer of genes between organelle genome and nuclear genome, termed endosymbiotic gene transfer, is very common in eukaryotes, including apicomplexans (12, 13). A class of transcription factors (TFs), the Apetala 2 (AP2) domain-containing TFs, exemplify such a mode of gene transfer between apicoplast and nuclear genome. Several apicomplexans severely lack common TF families normally present in animal cells (14). In silico identification of DNA binding proteins followed by searching their homologs in all life forms identified that several apicomplexan DNA binding proteins share homology to plant Apetala 2 domain-containing transcription factors (14). The apicomplexan orthologues are named Apicomplexan AP2 (ApiAP2) TFs. Genomes of all apicomplexans, as well as their apicoplast bearing cousins sequenced so far, have this family of TFs in their genome, some more than the others (14, 15). This suggests that after an initial endosymbiotic transfer, this family of TFs later expanded in a lineage-specific manner (14). The role of ApiAP2 TFs in apicomplexan gene

regulation has been studied extensively and several of them play key regulatory roles in the progression of the apicomplexan life cycle.

Apicomplexans can be broadly divided into four different groups based on phylogenetic analyses, structural features and host range (1, 2, 16, 17). The most understudied among them are the gregarines, which are parasites of invertebrates. Advances in environmental DNA sequencing are slowly unearthing an abundance of gregarine parasites in diverse environments; however, molecular characterization of the members of this group is scarce (8, 18, 19). Phylogenetically, gregarines are difficult to group together among themselves, leading to them being called deep-branching apicomplexans (8, 9). The apicoplast is presumed to be lost in many gregarines (9). Members of the sole genus *Cryptosporidium* constitutes the second major group of apicomplexans. These are parasites of the vertebrate gastrointestinal tract. None of the *Cryptosporidium* species harbors an apicoplast and they have also lost a fully functional mitochondrion. Instead, they have a mitochondrion-like organelle called a mitosome that lacks its own genome. Several nuclear-encoded genes are nonetheless targeted to this relict mitochondrion and its primary function seems to be Fe-S cluster generation (20-22). Until recently, *Cryptosporidium* species were considered to be members of another major apicomplexan group called the coccidians (17). Coccidians are parasites of both vertebrates and invertebrates. Their similarity to *Cryptosporidium* is that they produce cysts that are the infective form of the parasite. However, unlike *Cryptosporidium*, they have functional apicoplasts and mitochondria. Coccidians are

very diverse in their host range; some of them are specific for certain host species, while others have a broader host range (23, 24). The most well-studied coccidian parasite is *Toxoplasma gondii*, which is often used as a model apicomplexan due to the availability of well-established genetic manipulation systems for this parasite. Finally, the other group of apicomplexans, haematozoa, are parasites of the vertebrate circulatory system that are transmitted by blood-sucking insect vectors. The insect vectors are the definitive hosts of this group of parasites, as sexual replication occurs within them, while vertebrates are intermediate hosts where they replicate asexually. The apical complex of haematozoans lacks a conoid, a special arrangement of microtubules, that is present in the apical complex of all the other groups of apicomplexan parasites (25, 26). *Plasmodium* parasites, the causative agents of malaria, belong to this group.

1.3: Significance of the Research on Apicomplexan Stage Differentiation and Scope of this Review

One of the common aspects of the life cycle of all the apicomplexan parasites is that they differentiate into distinct forms at various stages of their life cycle. All of them have at least three different forms, namely, sporozoites, asexual replicative forms, and sexual replicative forms. The term for asexual replicative forms varies by species. There is no sex chromosome in apicomplexans, but mature gametes are dimorphic. Most commonly, one gamete is comparatively larger than the other gamete, which is

called the macrogamete or the female gamete. The comparatively smaller gamete, which is usually formed from a gametocyte containing multiples of them, is called the microgamete or male gamete. A gamete within a host cell is called a gametocyte. Additionally, based on the species, they take other special forms through the progression of their life cycle.

Apicomplexan differentiation has been an active area of research. The fact that each of these unicellular intracellular parasites can transform into very different forms characterized by altered structures and phenotypic characteristics, as well as different modes of replication and metabolism, while maintaining essentially the same genetic makeup makes apicomplexan parasites ideal candidates to study the regulation of gene expression and basic cell biology. From an evolutionary and ecological perspective, how apicomplexans survive in diverse conditions and each establishes its own ecological niche are of huge interest.

Several apicomplexans cause significant diseases in humans that are of major public health and economic concern. *Plasmodium* parasites cause malaria, which still kills thousands of people every year. Blocking *Plasmodium* differentiation in people is central to transmission-blocking strategies (27). Around one third of the population in the world are thought to be chronically infected with *T. gondii gondii*, an opportunistic pathogen of humans. The secret behind this astonishingly high prevalence is its ability to differentiate into a cyst form, which is untreatable with the current therapeutics (28). *Cryptosporidium* has recently been identified as one of the major causes of childhood

diarrhea in the developing world (29). There is no efficacious therapeutic available for *Cryptosporidium* infection of immunocompromised patients and malnourished children, the two most vulnerable populations to *Cryptosporidium* infection (30). Our current understanding of *Cryptosporidium* biology suggests that blocking differentiation would be an effective therapeutic strategy against this parasite.

Early development of apicomplexan parasites within the human body involves differentiation from the environmentally resistant form or vector transmissive form to a more human adapted form capable of establishing an infection. Each of the pathogenic Apicomplexa subsequently differentiate further to rapidly replicating forms that are more associated with the pathologies of the diseases they cause. While inhibiting the later stages are straightforward strategies in drug development, understanding the early stages are more important towards vaccine development. Development of attenuated strains incapable of early differentiation as well as using early stage-specific cell surface markers as subunit vaccines are two of the most common strategies employed in anti-apicomplexan vaccine development (31, 32).

Unsurprisingly, detailed studies on the molecular mechanism of differentiation have been mainly performed on apicomplexan genera that are pathogens of human or economically important pathogens of livestock and poultry. In this review, we will discuss the differentiation of three haematozoans (*Plasmodium*, *Babesia*, *Theileria*), two coccidians (*T. gondii* and *Eimeria*) and the sole genus of the group *Cryptosporidium*. Notable pathogens that are not discussed due to relative scarcity of

differentiation-related literature include two coccidian parasites, the human pathogen *Cyclospora* and the livestock pathogen *Neospora*. No gregarine parasite has been discussed, as their molecular mechanism of differentiation has not been studied yet (33).

A key aspect of the apicomplexan differentiation processes is the extensive change in the global gene expression pattern associated with differentiation. Emphasis has been given in this review about characterizing these global changes, as well as key components that play master regulatory roles in bringing about these changes. However, numerous studies have also been performed to understand the structures and functions of components that have roles in the developmental progression of each of the distinct differentiated stages. Several comprehensive reviews have been published discussing such components for a particular stage of each of the parasites' life cycles. Instead of repeating the same information in this review, we have referred to those articles wherever appropriate.

1.4: *Plasmodium* Stage Differentiation

Plasmodium parasites are the causative agents of malaria, which killed more than 400 thousand people in 2018. Vertebrates are the intermediate hosts and mosquitos are the definitive hosts of *Plasmodium* species. Six *Plasmodium* species infect humans, among them *P. falciparum* is the most well-studied species. Several simian, avian and rodent *Plasmodium* species are used as model organisms in

laboratory settings to understand its biology (34). Notable among them are the rodent parasites *P. berghei* and *P. yoelii*. Continuous in vitro cultivation of several species of *Plasmodium* is performed within red blood cells (RBCs) (35).

1.4.1: Sporozoite to Liver Stage Differentiation

Sporozoites, the form of *Plasmodium* parasites that initiates infection of the vertebrate host, encounter the most diverse conditions among all the life cycle stages of *Plasmodium* (Figure 1). They are developed inside oocysts residing at basal lamina of the mosquito midgut, and after egressing from the oocyst, they travel via hemolymph to the mosquito salivary gland and invade it. Salivary gland sporozoites are inoculated into vertebrate skin during a mosquito bite, traverse the dermis to gain entry into the blood circulation, and then, in mammalian hosts, sporozoites again traverse the endothelial cells in liver sinusoids to access hepatocytes where they can start the exoerythrocytic phase of the infection (36, 37). It is not surprising that sporozoites at different stages of this process differ from each other. Many *Plasmodium* genes have been identified that are essential for a specific part of the sporozoite's life while dispensable for the others. It suggests a model of stepwise maturation of sporozoites capable of establishing infection in the liver (36, 37).

Interestingly, commitment to the exoerythrocytic phase seems to be attained even before the sporozoites contact the vertebrate host. First shown in the rodent parasite *Plasmodium berghei*, sporozoites from the salivary gland are 10,000 times more infectious to the mammalian host than sporozoites from oocysts (38). The same

phenomenon was subsequently shown in several other *Plasmodium* species, and, with the avian parasite *P. gallinaceum*, it was shown that salivary gland sporozoites lose infectivity for the mosquito salivary gland once they were reintroduced into the mosquito hemocoel (39). Sporozoites in the hemolymph show intermediate infectivity and other intermediate phenotypic characteristics that fall between the characteristics of salivary gland sporozoites and oocyst sporozoites (40).

Comparative transcriptomics and proteomics analyses between oocyst sporozoites and salivary gland sporozoites to determine the regulation of this commitment have identified multiple genes upregulated in one population compared to others (41-44). Knockout of several of the genes upregulated in infectious sporozoites (UIS) formed parasites that are capable of infecting hepatocytes, but then fail to successfully replicate inside them (45-49). The most studied among them, which has often been used as a marker for salivary gland oocyst and liver stage *Plasmodium*, is UIS4 (45). UIS4 regulation in sporozoites and liver stage *Plasmodium* provides important mechanistic details about *Plasmodium* sporozoite to liver stage differentiation (45). Even though UIS4 mRNA is highly expressed in salivary gland sporozoites, it is post-transcriptionally repressed in sporozoites and the protein level eventually goes up in the liver stage (50). The RNA binding protein Puf2 binds to the UIS4 transcript and keeps it in a repressed state (51). Puf2 knockout sporozoites reach the salivary gland, but cannot infect the liver (47, 48, 52). This mutant also differentiates into a form that resembles early liver stage *Plasmodium* while still

residing in the mosquito salivary gland (47, 48, 52).

Several studies suggest that this transcriptionally active but translationally repressed state is not a unique feature of UIS4, and that this is a general strategy of *Plasmodium* to be prepared for infection upon switching hosts (44, 48, 53, 54). Indeed, the kinase IK2 that phosphorylates and inactivates translation initiation factor eIF2 α has been shown to be an important regulator of this process in *Plasmodium* (54). IK2 knockout parasites showed reduced phosphorylation of eIF2 α and an overall upregulated protein translation, including translation of UIS4, in sporozoites (54). Phenotypically, the IK2 knockout mutant also prematurely develops into a liver stage like form (54). Translationally repressed UIS mRNAs, including UIS4, are actively protected from degradation in salivary gland sporozoites, and a *Plasmodium* protein called SAP is involved in that process (49). Like the other mutants mentioned before, SAP knockout also inhibits liver stage development (49).

Recently, RNA-seq based transcriptomics, quantitative proteomics, and high throughput screening of knockout mutant libraries have verified some of those earlier findings, while also generating a clearer landscape of metabolic changes during differentiation (55-58). For example, a mutant library screening demonstrated essentiality of the type II fatty acid biosynthetic pathway in liver stage development (58). Some of the members in this pathway are upregulated in salivary gland sporozoites, and were previously shown to be essential in parasite development into the liver stage (59, 60). Another study performed comparative RNA-seq and proteomics

analyses of oocyst sporozoites and salivary gland sporozoites of both *P. yoelii* and *P. falciparum*, and validated the translational repression program in salivary gland sporozoites (57). Interestingly, this study also suggests an independent translational repression program in oocyst sporozoites that is released after sporozoite invasion of the salivary gland (57). This might be the explanation for the inability of salivary gland sporozoites to reinfect the salivary gland as mentioned before (39). Follow up genetic experiments based on these high throughput sequencing analyses (57) would likely help in identifying genes and pathways critical for differentiation.

The stimulus for sporozoite to liver stage differentiation has been suggested to be dependent on time (i.e. after a certain time, a sporozoite is committed to differentiation) and space (i.e. the environment around a sporozoite determines its stage of commitment); however, no definite molecular signal has been established yet. In terms of a transcriptional regulator, AP2-L is an AP2 transcription factor that is necessary for liver-stage development (61-63). AP2-L protein is expressed in blood stage, sporozoite and liver-stage *P. berghei*, but the AP2-L knockout mutant showed complete developmental arrest only in Liver stage (61). Knockout mutants of three other AP2 TFs in *P. berghei* failed to form sporozoites from oocysts, or the sporozoites failed to reach the salivary gland (62-64). Detailed identification and characterization of the targets of these transcription factors would likely provide more information about the differentiation of sporozoites.

1.4.2: Liver Stage to Erythrocytic Stage Differentiation

The exoerythrocytic cycle for mammalian *Plasmodium* species takes place within hepatic cells (Figure 1). A sporozoite first transforms into a trophozoite, which then replicates into thousands of merozoites within a single hepatic cell. Packets of merozoites called merozoites bud out from the hepatic cells into the blood, and are ultimately released to start the erythrocytic cycle of *Plasmodium* infection (65, 66). Numerous individual proteins are implicated at different stages of this development process through single-gene knockout studies (nicely summarized in Table 1 of (67)). However, identification of master regulatory elements involved in exoerythrocytic to erythrocytic stage differentiation is still absent. One potential reason for this is the scarcity of transcriptomic and proteomics data in high enough temporal or phenotypic resolution as to differentiate different stages of the exoerythrocytic phase. Fortunately, such experiments are starting to come out (55, 56). Another reason that is likely hampering the characterization of master regulatory elements is the standard genetic manipulation system of *Plasmodium*. The erythrocytic phase parasite has largely been the starting point of genetic modification and clonal selection in *Plasmodium* (68). As such, essential genes for erythrocytic growth are not suitable for straight knockout. The liver stage directly precedes the erythrocytic phase, and it is highly likely that factors involved in differentiation from liver stage to the erythrocytic stage are also essential during erythrocytic schizogony. In addition, knockout of any gene that is also essential in the sexual and/or sporozoite stage would never produce viable liver stage

Plasmodium. Therefore, targeted analysis of any gene function in liver stage *Plasmodium* with the aid of a knockout mutant of that gene would only be possible if the gene is not essential in any other stages of the *Plasmodium* life cycle. The development of several conditional knockout systems in *Plasmodium* has huge potential to overcome this limitation (69, 70).

Several *Plasmodium* species, including the human pathogen *P. vivax*, differentiate into a latent form termed a hypnozoite after infecting liver cells (71). A hypnozoite culture system and omics data have just started to emerge in the past few years (72-74), but the induction and relapse mechanism is still largely unknown.

1.4.3: Sexual Differentiation of *Plasmodium*

Plasmodium sexual differentiation is one of the most heavily studied differentiation processes among apicomplexans. The merozoites from the liver infect RBCs to start the erythrocytic cycle of *Plasmodium* infection. Upon infection, the parasite takes on a flat disk-like morphology called a ring phase, then it rounds up to form a trophozoite, which then replicates multiple times through erythrocytic schizogony to produce up to 32 merozoites that are released into the blood after RBC rupture. The merozoites start another cycle of RBC infection, and either repeat the asexual cycle again or develop into gametocytes. RBCs enclosing mature gametocytes circulate in the bloodstream until taken up by a mosquito (Figure 1). Gametocytogenesis, the process of developing mature gametocytes, takes 24 to 60 hours in most *Plasmodium* species and 9 to 12 days for *P. falciparum* (34, 75).

Interestingly, the commitment to gametocytogenesis occurs one schizogony cycle before the ultimate gametocytogenesis. Seminal experiments, first with Giemsa staining and then with stage-specific antibody staining of *Plasmodium* on RBC monolayers demonstrated that all the progeny merozoites from a single schizont either develop into gametocytes or asexual merozoites (76, 77). Therefore, even though the schizonts are morphologically indistinguishable, they are already committed to form either sexual or asexual forms. Subsequently, using gender-specific antibody staining, it was shown that a sexually committed schizont gives rise to either male or female gametocytes exclusively (78, 79).

Several laboratory clones of *Plasmodium* do not form gametocytes. Comparative genomic analysis of these clones followed by targeted gene knockouts identified two master regulators of this commitment, AP2-G and GDV-1 (80-82). AP2-G, a member of the AP2 transcription factor family, is expressed in the sexually committed schizonts and acts as a transcriptional activator for several early gametocyte genes (81, 82). In *P. falciparum*, the expression of AP2-G itself is under the control of heterochromatin protein 1 (HP-1), which epigenetically represses the expression of AP2-G by binding at the ap2g locus (83). GDV-1 has been shown to interact and evict HP-1, and thus release the transcriptional repression of AP2-G (84). This puts GDV-1 upstream to AP2-G in terms of gametocytogenesis regulation. This epigenetic mode of gametocytogenesis control is well supported by other studies. For example, several histone post-transcriptional modifications are exclusively enriched during

gametocytogenesis (85), and several epigenetic modifiers selectively inhibit the sexual and asexual stages of *Plasmodium* (86).

A forward genetic approach using *piggyBac* transposon mutagenesis identified 16 genes essential for gametocytogenesis (87). Targeted analysis of AP2 gene family members in *P. berghei* showed that knockout of AP2-G2, a transcriptional repressor, results in a developmental arrest of gametocytes following commitment (88), and knockout of AP2-FM, potentially a transcriptional activator, results solely in a failure of female gametocyte development (89).

Comparative genomics, mutant library screening and targeted mutagenesis approaches led to the identification of several other *Plasmodium* genes that have roles in general gametocytogenesis, as well as male and female gametocyte production (Table 1 in (90), (34)). However, comparative transcriptomics is arguably a more powerful tool to understand the dynamic genetic regulation of the differentiation process. Microarray analysis of tightly controlled timepoints has revealed a picture of cyclic changes in the gene expression pattern in *Plasmodium* during erythrocytic schizogony (91). However, similar transcriptomic or proteomic comparison between sexual and asexual stages of *Plasmodium* is challenging, because gametocytogenesis is a rare event during the erythrocytic replication stage of *Plasmodium*, which makes it difficult to capture clean ‘-omics’ data from gametocytes using simple time point resolutions (92, 93). This challenge has been partially met by FAC (Fluorescent activated cell) sorting transgenic parasites expressing fluorescent proteins under male

or female specific promoters (94-96). It allowed the identification of male and female specific proteins and pathways in *Plasmodium* (94-96). However, male and female gametocytes are comparatively late stages of the gametocytogenesis process in which the sexual conversion has already taken place. But as mentioned before, the commitment to those stages occurs earlier in a sexual/asexual indistinguishable schizont stage.

There is still no clean early sexually committed schizont marker. Single cell transcriptomics has proven to be a particularly well suited technique to address this challenge, as it allows the analysis of transcriptome from rare cell populations. The first single cell transcriptomic experiment focusing on sexually committed schizonts identified, among other things, two additional AP2 transcription factors and four chromatin modifiers differentially upregulated in sexually committed schizonts, reaffirming the role of AP2 TFs and epigenetics in *Plasmodium* sexual commitment (97). It also described a more detailed expression pattern of AP2-G. AP2-G is expressed in a low level in both early sexually and asexually committed schizonts. Following a trough in expression in both populations, it is expressed highly only in mature sexually committed schizonts (97). Since then, other studies have used this technique to characterize the early stages of gametogenesis, and implications and validation of their findings would surely paint a clearer picture of sexual commitment in *Plasmodium* (84, 98). Importantly, one of them reported that gametocytogenesis can happen without a committed schizont stage, which results in the formation of mixed

plaques containing both sexual and asexual merozoites, questioning the decade-old standard theory of gametocytogenesis commitment (98). The proposed theory behind this mechanism is in line with the detailed temporal AP2-G expression pattern mentioned before. The study proposes that in early schizonts, if AP2-G expression reaches a threshold, it allows AP2-G to express again in mature schizonts, committing them to gametogenesis. In support of this theory, they showed that artificial AP2-G stabilization during schizogony can induce gametogenesis without going through a committed schizogony cycle (98).

Stress on both host and parasite has long been considered to be a major signal for gametocytogenesis (99). This belief radiates from the observation that high doses of anti *Plasmodium* drugs increase the rate of sexual conversion (100) and that *P. falciparum* gametocytes are preferentially developed in reticulocytes, which are immature erythrocytes that are more readily available in anemic blood (101, 102). Based on several empirical datasets that analysed the relationship between stress and *Plasmodium* sexual conversion, a model proposed that reducing gametocyte conversion during low levels of stress actually increase the chance of future successful transmission whereas under highly stressed condition, the parasite allot more resources to gametocytogenesis as a way of terminal investment for successful transmission. High drug pressure is such a stress condition for the parasite when mortality rate exceeds the parasite proliferation rate or severe anaemia is such a stress condition of the host when the mortality is imminent (99). Recently, depletion of a serum factor called

lysoPC has been shown to be a signal for gametocytogenesis in *P. falciparum* but not in *P. berghei* (103). The relationship of this molecule to stress is unclear. In any case, this aspect of gametocytogenesis requires further focus.

1.4.4: Sex-specific Maturation for Differentiation into Zygote

The gametocytes are taken up by the mosquito during a blood meal. In the mosquito midgut, gametocytes are activated to form gametes, actively come out of the RBC, and mate to form the zygote (Figure 1). Gamete activation or gametogenesis involves rounding up of the gametocyte, disrupting the RBC membrane, and the egress of mature gametes in the mosquito midgut. Change of temperature and pH from mammalian blood to mosquito midgut, as well as the mosquito derived factor xanthurenic acid, act as signals for gametogenesis (104, 105). A meiotic nuclear division without diakinesis occurs within three hours of zygote formation, and the diploid zygote transforms into a motile tetraploid ookinete (106). The ookinete traverses the mosquito midgut epithelium to reach the basal lamina, transforms into an immotile oocyst, and multiple haploid sporozoites are formed. The initial stages in the mosquito vector are quite rapid; within 15 minutes the gametes come out, and the zygotes are formed within two hours in the mosquito midgut. Ookinete development takes 20 h to 35 h, and the oocyst development is a long process, taking around 10 to 12 days (107).

Two distinct maturation programs run in parallel in male and female gametocytes, culminating in male and female gamete formation at the same time and

space. Multiple proteins have been characterized that are expressed differentially in male and female gametocytes and are essential at different stages of development of *Plasmodium* gametocytes in a sex-specific manner. Knockout of these genes usually results in a deficiency in gametocyte maturation/ gamete activation/ zygote formation/ ookinete conversion or dysfunctional ookinete formation (Table 1 in (107), (108-110)). Indeed, global transcriptomic and proteomic comparisons of male and female gametocytes uncover distinct expression profiles for them that are shaped by their distinct needs (94-96). For example, upon activation, a male gametocyte divides mitotically three times to produce eight microgametes. The motile microgametes lyse and egress from the RBC in a distinct fashion called exflagellation. The formation and motility of microgametes require assembly of an axoneme, a microtubule-based structure. The transcriptome and proteome of male gametocytes are overwhelmingly enriched for DNA replication and axoneme formation machinery compared to the female gametocyte (94, 96). On the other hand, the cytoplasm of zygote and early ookinete is derived from female gamete, as the smaller male gametes mostly only supply a copy of the genome to the female gamete during fertilization. The zygote and early ookinete express a lot of new proteins, which is a hallmark of the stage conversion (111, 112). To support this rapid transformation, a lot of cellular energy is also required. In line with this point of view, the female gametocyte transcriptome and proteome are enriched for pathways of protein synthesis and degradation, as well as energy metabolism (94-96).

The phenomenon of “just in time” expression observed for the mosquito to mammalian transition in *Plasmodium*, where mRNAs overexpressed in salivary gland sporozoites are kept in a translationally repressed form that are to be expressed upon host switch, is also observed in female gametocytes during host switch. An RNA helicase, DOZI (development of zygote inhibited) was found to be important for this process in *P. berghei* (113, 114). DOZI knockout female gametocytes produced normal female gametes and zygotes; however, zygote to ookinete differentiation was halted before meiosis (114). DOZI is localized with CITH and 14 other core components to a cytoplasmic assemblies called P granules (113). These granules protect overexpressed but untranslated mRNAs in female gametocytes. In DOZI knockout female mutants, those mRNAs are degraded (113, 114). DOZI knockout male mutants produce ookinetes normally, suggesting this translational repression is a female-specific program (114). A wide variety of mRNAs including known transcription factors required for maturation of ookinetes as well as ookinete cell surface markers required for diverse ookinete functions are protected by these P granules (113). A matched transcriptomics and proteomics analysis of female gametocytes corroborates the existence of this phenomenon, where a large number of protein products from overexpressed mRNA are undetectable in female gametocytes (94). Gene ontology enrichment analysis on putatively transcriptionally repressed genes in female gametocytes identifies meiosis as the highest enriched biological process, which is consistent with ookinete developmental arrest before meiosis in

female DOZI knockout mutants (94, 114).

The energy metabolism of male and female gametocytes is also divergent. Chemical inhibition or genetic disruption of the TCA cycle and oxidative phosphorylation is very deleterious for *Plasmodium* in mosquito stages but well-tolerated in the asexual blood stage, as glycolysis is the overwhelmingly major source of energy in RBC stage *Plasmodium* (115, 116). The gametocytes, however, show an intermediate phenotype. Gender independent analysis of the proteome of gametocytes suggests the presence of the TCA cycle and ETS components in them (117). Male gametocyte activation, usually measured through the exflagellation rate of male gametocytes, is affected by chemical inhibition of glycolysis while female gamete activation remains unaffected (116, 118). If components of oxidative phosphorylation are knocked out, the female gametocyte development and zygote to ookinete transformation are disrupted, but male exflagellation is unhampered (119, 120). Taken together, it suggests that male gametocytes depend on glycolysis-based energy production, just like asexual *Plasmodium*, but the female gametocytes are not completely dependent on glycolysis and start to shift towards mitochondrial energy production as used by the ookinete stage.

Importantly, male and female gametocyte maturation and release are synchronized in space and time, so that both male and female gametes can come out together in the mosquito midgut and find each other. Therefore, even though the gametes develop differently, they most likely respond to the same or similar

extracellular stimuli, using similar intracellular components. For example, calcium and cGMP signaling plays critical roles in the egress of both gametes (107, 121). Chemical inhibition, as well as genetic disruption of cGMP-dependent protein kinase PKG and cGMP phosphodiesterase, causes inhibition of both male and female gamete activation (121-123). Conditional disruption of calcium-dependent protein kinase CDPK1 leads to delayed microgamete emergence from male gametocytes, as well as a severe arrest in ookinete development (124, 125). Molecular characterization of the later phenotype showed that CDPK1 activity acts as a switch to turn off the transcriptional silencing program in female gametocytes (125).

1.4.5: Zygote to Ookinete, Ookinete to Oocyst, and Oocyst to Sporozoite differentiation

Global transcriptomic and proteomic comparison between zygote and ookinete is inherently difficult, as gametocyte to ookinete transformation occurs very rapidly. A few studies where this aspect of differentiation was analyzed reported the presence of several enriched mRNAs and proteins in ookinetes stages with potential function in invasion and metabolism (111, 112). Several gene knockouts in *Plasmodium* resulted in ookinete maturation defects, but a substantive number of them are also transcribed specifically in female gametocytes, suggesting they are likely to be regulated via the P body mediated translational repression program (107, 126, 127). For example, the most

commonly used ookinete markers, P25 and P28, are important for ookinete maturation and function (128). Their transcription occurs in female gametocytes, but they are translated only after the transcriptional repression program is turned off (114).

The differentiation of ookinete to oocyst is scarcely studied in *Plasmodium*, and recent data suggest that large scale transcriptional differences exist between these two stages (129). Targeted disruption of several AP2 transcription factors resulted in dysfunctional ookinete or oocyst formation (62, 63). However, temporal regulation of these mutants along the ookinete development trajectory has not been studied in fine detail.

Targetted analyses of AP2 TFs in *P. berghei* and *P. yoelii* suggest that a continuous spectrum of progression from female to ookinete to oocyst is controlled by different AP2 TFs (62-64, 89). For example, in *Plasmodium berghei*, AP2-FG is required for female gametocyte maturation, AP2-O1,2,3,4 are required for ookinete maturation and oocyst establishment, and AP2 SP1,2,3 are required for oocyst maturation to form sporozoites (62). In *P. yoelii*, another putative TF, HMGB2, was found that regulates ookinete maturation (130). An AP2 TF specifically required for male gametogenesis has not been described yet.

1.5: *Toxoplasma gondii* Stage Differentiation

T. gondii gondii has extensively been used as a model apicomplexan parasite due to relative ease of in vitro culture, earlier development of genetic tools, and

availability of well-established animal models compared to other apicomplexans (131). It is reported to be capable of infecting any nucleated animal cell, and is routinely cultured in human foreskin fibroblast (HFF) cells in laboratory settings (132). Warm-blooded animals are intermediate hosts of the parasites, which become infected by ingestion of oocysts (found in the feces of cats, the definitive host) or tissue cysts residing in the tissues of an animal (Figure 2). In the gut, tissue cysts release merozoites that infect intestinal epithelial cells where they asexually replicate by endodyogeny, a special form of replication characterized by forming two daughter cells within a mother cell and ultimately consuming it. Asexual replication usually gives rise to eight tachyzoites that lyse the host cell and infect nearby cells. If tachyzoites gain access to leukocytes, they migrate to different tissues. In immunocompetent hosts, tachyzoites ultimately differentiate into bradyzoites, a slowly replicating quiescent form that is subsequently enclosed by a cyst wall within the host cell. The number of bradyzoites in the tissue cysts range from two to hundreds. This encystation process establishes a lifelong asymptomatic chronic infection of *T. gondii*. In the case of immune suppression of the host, e.g. by infection or chemotherapy, tissue cysts can be reactivated and the bradyzoites differentiate back into tachyzoites. Eating raw meat containing tissue cyst disseminates the infection to a new host (28).

1.5.1: Tachyzoite-Bradyzoite differentiation

1.5.1.1.: Lessons from the Induction Signals

Stress has been established as the key environmental stimulus for tachyzoite to bradyzoite differentiation. It can be applied in various forms like temperature or P^H change, drug administration, activation of the host immune system, and metabolic inhibition (133). Interrogation of how such diverse stresses induce the same phenotype of tachyzoite to bradyzoite differentiation led to the characterization of eIF2 α (eukaryotic Initiation Factor 2 alpha) phosphorylation, a known marker of the eukaryotic stress response, in *T. gondii* (134). eIF2 α is a highly conserved transcription initiation factor in eukaryotes that is repressed by phosphorylation (135). Several above-mentioned stressor classes induce phosphorylation of eIF2 α in *T. gondii*, and this phosphorylation mark is kept in bradyzoites, suggesting a link to this phosphorylation to bradyzoite differentiation (136). Chemical inhibition of phosphorylation led to reduced bradyzoite conversion, and also reduced tachyzoite lytic proliferation both in vivo and in vitro (137). On the other hand, inhibition of eIF2 α dephosphorylation increases the bradyzoite conversion rate and inhibits the reactivation of bradyzoites (138). These data indicate that eIF2 α phosphorylation is necessary for bradyzoite differentiation. Four classes of eIF2 α kinases have been identified in *T. gondii* that phosphorylate eIF2 α in under distinct stress conditions (134, 136, 139-141). Gene knockout of two of these kinases inhibits eIF2 α phosphorylation and the mutant tachyzoites showed reduce infectivity in in-vitro cell culture after specific stress

inductions (139, 140). Replacing the wild type eIF2 α with a phosphorylation deficient eIF2 α phenocopies both of the kinase knockouts (139, 140, 142). Additionally, death is delayed in mice infected with these mutants (139, 140, 142). Therefore, eIF2 α phosphorylation is also important for the lytic tachyzoite. In several other systems, phosphomimetic versions of eIF2 α have been described (143-146). In *T. gondii*, such mutant eIF2 α expression has not been described yet. It would be interesting to observe if phosphomimetic eIF2 α expression is possible in *T. gondii* and if yes, would it be sufficient to drive tachyzoite to bradyzoite differentiation.

Several stressors that induce bradyzoite differentiation hamper mitochondrial function. Atovaquone, a drug that targets apicomplexan mitochondrial activity, was found to be ineffective against a clone of *T. gondii* that spontaneously differentiates into bradyzoites (147). It led to the testing and validation of atovaquone and some other drugs that supposedly act on mitochondria to be inducers of bradyzoite differentiation (147). IFN γ , another inducer of bradyzoite differentiation, induces macrophages to produce nitric oxide, which in turn reacts with Fe-S clusters of the mitochondrial respiratory chain, rendering the organelle dysfunctional (148). When bradyzoite and tachyzoite extracts were tested for the enzymatic activity of several glycolytic and TCA cycle enzymes, bradyzoite extracts showed higher activity for glycolytic enzymes (149). Recently, it has been shown that knocking out hexokinase, the first enzyme in the glycolytic breakdown of glucose, severely blocks bradyzoite formation in mouse brain, but only modestly affects lytic replication of tachyzoites

(150). Isotope-labeled metabolite tracking showed that tachyzoites can use glutamine in the TCA cycle to generate energy in the absence of glucose utilization, and also synthesize glycolytic intermediates from gluconeogenic pathways (150). Taken together, all these observations suggest that mitochondrial respiration is important for tachyzoite energy production, but not so critical for bradyzoite energy production.

One bradyzoite inducing compound, called compound 1, greatly exemplifies the role of the host cell on bradyzoite differentiation (151). This compound was initially identified as an inhibitor of cGMP-dependent PKG (152, 153). Interestingly, pretreatment of HEF cells with compound 1 resulted in the induction of bradyzoite differentiation (151). Microarray analysis of host cells revealed that the expression of cell division autoantigen-1 (CDA1) is 47-fold upregulated in response to compound 1 treatment. RNAi-mediated silencing of CDA1 rendered parasites insensitive to compound 1, whereas overexpression of CDA1 induced differentiation similar to the level of compound treatment (151). CDA1 can inhibit cellular growth, and also is implicated in tumorigenic and DNA damage response pathways in mammalian cells (154). Indeed, cell types that do not grow rapidly, like terminally differentiated neurons or muscle cells, are more permissive to bradyzoite cyst formation (155, 156). The molecular mechanism of how the host cell's replicative potential is transmitted to the parasite is still unknown. Different cell types respond differently in terms of their global gene expression pattern and common pathways have not been identified that can robustly explain the host cell-type tropism of bradyzoite differentiation (155, 157).

1.5.1.2: Lessons from the -Omics Studies

Tachyzoites and bradyzoites differ extensively in the global gene expression pattern. Early realization of this fact came from stage-specific antigen detections in these two forms. It led to stage-specific cDNA library constructions and the identification of stage-specific genes (158-161). The highly used tachyzoite specific marker SAG1 and bradyzoite specific marker BAG1 were identified in such a manner (159, 161). Subsequently, the development of techniques like suppression subtraction hybridization (SSH) (162), microarray (163-171), comparative RNA-seq (172-176), and mass spectrometry-based comparative proteomics (177) have allowed comparison of the global gene expression patterns in tachyzoites and bradyzoites in high temporal resolution along the pathway of differentiation. Several major insights are gained from these “-omics” data that are also validated by other more targeted experiments. For example:

- 1) The transcriptome and proteome of bradyzoites remain dynamic for a long time even after the formation of bradyzoites in the mouse brain, and only become more static three months post-infection (173). This goes well with the observation that bradyzoites within tissue cysts are not completely dormant; instead, they continue to replicate and run other metabolic functions at a very low rate (169, 178, 179).

- 2) Several metabolic enzymes and some other proteins have isoforms in *T. gondii*, and they are differentially expressed in tachyzoites and bradyzoites. This was a well-known phenomenon that was discovered even before the use of -omics studies on

T. gondii (180, 181).

3) The cell cycle progression of tachyzoites shows two distinct stages of transcriptome, G1 phase and S/M phase (182). The transcriptome of a bradyzoite formation deficient mutant under stress condition has more similarity to S/M phase (169, 171). This supports the notion that during bradyzoite differentiation, a G2-like phase of the cell cycle is activated that is normally present in the eukaryotic cell cycle in between S and M phase but is not observed in the *T. gondii* cell cycle (183).

4) The tachyzoite transcriptome is differentially enriched for proteins in the TCA cycle and oxidative phosphorylation (174). This supports the currently held view that bradyzoites are more dependent on anaerobic glycolysis for energy production (149, 150).

1.5.1.3: Role of Epigenetic Regulators and Transcription Factors

The high number of differentially expressed genes between tachyzoite and bradyzoite suggests the presence of a global regulator of gene expression in this differentiation process. Epigenetic changes and transcription factors are obvious suspects that can bring such a high variation of global gene expression. A common epigenetic DNA modification in eukaryotes is cytosine methylation, catalyzed by DNA methyltransferases. DNA is more methylated in the bradyzoite stage compared to the tachyzoite stage. There are two DNA methyltransferases in *T. gondii*, both of which

are upregulated in the bradyzoite stage (184). On the other hand chemical inhibition or genetic knockout of epigenetic histone modifiers also affected the bradyzoite differentiation rate (171, 184-186).

The well-established role of AP2 TFs in *Plasmodium* differentiation motivated researchers to look for the role of their *T. gondii* homologs in bradyzoite differentiation. Knockout or overexpression of several AP2 TFs in *T. gondii* positively or negatively affected bradyzoite differentiation and cyst formation. However, none of these mutants could completely turn on or turn off the differentiation despite affecting the expression of several stage-specific genes (187-191). For example, AP2IX-9 expression peaks at two days post bradyzoite induction and declines thereafter, whereas AP2IV-3 expression rapidly increases also at day two and slowly keeps increasing or is maintained thereafter (189). AP2IX-9 is a putative transcriptional repressor that is shown to repress the expression of bradyzoite marker BAG1 (191). On the other hand, AP2IV-3 is a putative transcriptional activator that is demonstrated to activate BAG1 expression (189). In accordance with their role in BAG1 transcriptional regulation, AP2IX-9 and AP2IV-3 knockout mutants enhanced and reduced bradyzoite differentiation respectively (189). The overlap in the expression pattern of these two transcription factors exemplifies the highly dynamic nature of the early stages of bradyzoite differentiation. Indeed, parasites within a single vacuole or even a single parasite express markers of tachyzoites and bradyzoites together, during both bradyzoite-to-tachyzoite and tachyzoite-to-bradyzoite differentiation (192, 193).

The development of the CRISPR-Cas9 mediated forward genetic approach has been developed recently in *T. gondii* (194). With this approach, the bradyzoite formation phenotype was analyzed in ~200 knockout mutants (176). The tested gene set contained stage-specific genes, as well as known and putative transcription factors. Knockout of a single TF, BFD1, showed a bradyzoite formation deficiency phenotype. Furthermore, targeted disruption of BFD1 followed by single-cell RNA-seq based phenotypic characterization demonstrated that BFD1 is both necessary and sufficient for bradyzoite differentiation (176). This is the first identification of a master regulator of bradyzoite differentiation. How this TF itself is regulated in response to different classes of stress is still to be determined.

1.5.2: *T. gondii* Sexual Differentiation

Cats are the definitive host of *T. gondii*. They can get infected by tachyzoites, bradyzoite containing tissue cysts, and sporozoite containing oocysts. The preferred form for causing feline infections seems to be tissue cysts, as its prepatent period (time to shed oocyst in the feces) is 3 to 10 days, followed by tachyzoites (prepatent period >13 days), and oocysts (>18 days) (28). Life cycle progression in cat intestinal epithelial cells, determined by electron micrograph and described in only a few publications, is as follows:

The sporozoites from oocysts start infection, and replicate asexually via the tachyzoite replication cycle. Tachyzoites differentiate into bradyzoites, most likely due to immune system derived stress. The bradyzoites differentiate into five

morphologically distinct forms in a stepwise manner, potentially asexually replicating multiple times within each form. Finally, from a schizont-like form, merozoites appear that differentiate into male and female gamonts in the cat intestinal epithelium. Male gametes fertilize female gamonts to form zygotes, which are then differentiated into oocysts. Rupture of infected epithelial cells releases oocysts into the lumen that are ultimately excreted in the feces. Mitosis and meiosis produce two sporocysts, each containing four sporozoites (Figure 2). For a more detailed description of this life cycle with a description of each form, see reference (28). Until very recently, the bradyzoite to oocyst differentiation could only be observed in feline intestinal epithelial cells in vivo, which is a difficult experimental system to get access to (195). Therefore, molecular characterization of the intermediate stages is very limited (196, 197).

Despite the fact that cats are not a readily accessible experimental system, several comparative transcriptomics studies have been performed along this line of differentiation. Transcriptomes from three stages of oocyst maturation and merozoites were compared with in vitro tachyzoites and bradyzoites using microarray (198, 199). More recently, RNA-seq has been used to compare the transcriptome of merozoites, five separate timepoint samples along the sexual differentiation path from *T. gondii* infected cat intestinal epithelial cells, and tachyzoites (31, 200). Combining data from these experiments, stage-specific expression profile was determined for each of the stages and was used heavily to characterize a mutant parasite whose MORC gene can be conditionally knocked out (201). MORC is an ATPase protein that provides energy

for epigenetic modification of histone by histone deacetylase 3 (HDAC3) (201). Conditional knockdown of MORC, as well as chemical inhibition of HDAC3, silenced a large set of target genes (validated by Chip-seq), which are mostly enriched in gamonts and somewhat enriched in oocysts and bradyzoites (184, 201). It led to the conclusion that epigenetic histone modification by the HDAC-MORC complex suppresses parasite differentiation towards sexual replication. These are the only characterized global regulators of the *T. gondii* sexual differentiation pathway so far (201).

A long-standing question in the field of *T. gondii* was why the sexual cycle only takes place in the feline intestine. Recently, it was shown that the cat is the only mammal that lacks a specific fatty acid breakdown enzyme, which allows the buildup of linoleic acid in cats that triggers the sexual differentiation (202). Both linoleic acid supplementation in in vitro culture and inhibiting the degradation of linoleic acid in mice allowed the sexual cycle to commence both in vitro and in vivo in a mouse model (202). Even though the molecular detail of this signaling is still unknown, this discovery has made the experimental system of *T. gondii* sexual differentiation hugely accessible compared to the previous state (203). It could potentially lead to a better molecular characterization of *T. gondii* differentiation along the route of sexual stages.

1.6: *Cryptosporidium* Stage Differentiation

Cryptosporidium species are parasites of the vertebrate gastrointestinal tract (204). They can complete their life cycle within a single host. Many of the reported species can infect multiple hosts, both naturally and experimentally. For example, *C. hominis* is the major human pathogen of the genus and can also infect gnotobiotic piglets experimentally. *C. parvum* can infect both humans and cows naturally, and immunocompromised mouse models experimentally (205). Once considered as a coccidian, phylogenetic analysis now shows that this single genus constitutes a separate clade of Apicomplexa, which is phylogenetically more similar to gregarines than coccidians (206).

Oocysts are the infectious forms of the parasite that disseminate through the fecal oral route (Figure 3). Four sporozoites come out from an oocyst and infect intestinal epithelial cells (IECs). They form a parasitophorous vacuole (PV) within the host cell that is localized just under the plasma membrane, a peculiar localization that has often been described as intracellular but extracytoplasmic (207). Within the vacuole, *Cryptosporidium* transforms into trophozoites that develop into type I meronts containing six to eight type I merozoites, which come out and infect nearby IECs within a day post infection. After several rounds of this asexual replication, they differentiate into type II meronts containing type II merozoites, which in turn develop into gametocytes after infecting the IECs. Microgametocytes produce around 16 male gametes that come out and fertilize uninucleate female gametocytes residing in a host

cell. Gametocytes start to emerge 42 hours post *C. parvum* infection in vitro and they are the terminal form of *Cryptosporidium* differentiation in the human colorectal carcinoma cell line HCT-8, which is commonly used for in vitro cultivation. In vivo, fertilized zygotes differentiate into oocysts and, during their development, meiotic cell division within the PV forms four sporozoites. Two types of oocysts have been described for *Cryptosporidium*, thin-walled oocysts that autoinfect the host and thick-walled oocyst that are excreted into the environment (204, 208, 209).

Cryptosporidium infection is asynchronous, which makes it difficult to determine the number of asexual cycles before commitment to gametogenesis (204, 208, 209). The different stages are mainly described via electron microscopic observations (208, 210). Until very recently, there were no clear markers to differentiate different stages of the *Cryptosporidium* life cycle using light microscopy. The dogmatic view in the field is that sexual differentiation is an obligate step following several rounds of asexual replication. However, it is hard to determine if asexual cycles continue in parallel to sexual differentiation within the vertebrate host, because even if they are observed together, the asexual forms might result from subsequent rounds of infection from the autoinfective thin walled oocysts. Commonly used cell culture methods cannot support the life cycle completion in vitro, and cultures collapse after the majority of the parasites progress into gametocytes (211). Without molecular characterization, it is also difficult to determine if in vitro progression to gametocytes is predetermined or an induced event caused by in vitro culture conditions.

Recently, using a cleverly designed transgene cassette for *Cryptosporidium* that only supports fluorescent protein expression upon fertilization, it was shown that fertilization is blocked in the HCT8 cell culture system (212). One of the possible explanations for this observation can be that the gametocytes do not fully mature in the culture. Transcriptome comparison of *Cryptosporidium* at 48 hours and 96 hours post infection using RNA-seq reported that around 500 genes are differentially expressed between in vivo and in vitro conditions (213). However, the asynchronous nature of the parasite infection inhibited assigning differentially regulated genes to specific stages of the life cycle. 59 of the upregulated proteins in vivo are secreted proteins that include one of the major oocyst wall proteins and several other uncharacterized large glycoproteins that are potential oocyst wall components. In comparison, only six upregulated proteins in vitro are secreted proteins. While the proteins upregulated in vivo might be required for female gamete formation, they also might be expressed following fertilization. Therefore, macrogamete formation deficiency could not be completely verified in this study (213). A cleaner comparison of macrogamete development was performed by expressing a fluorescent protein under a female specific promoter and FAC sorting macrogametes from in vivo and in vitro conditions for RNA seq (212). This comparison did not suggest any major dysregulation of female gametocyte specific gene sets except that in terms of global gene expression in vivo females had comparatively more similarity to sporozoites compared to in vitro females (212). This observation can be explained by the fact that FAC sorting of the in vivo

population also isolated zygotes and immature oocysts, as they also fluoresce in this system (212). Potential microgamete development deficiency in vitro has not been tested robustly yet.

One of the recently developed stem cell-derived platforms that supports oocyst production in vitro utilizes differentiation of mouse intestinal stem cells at air-liquid interface (ALI) as a culture platform (214). The host cell differentiation is blocked in the absence of ALI condition, and consequently, *Cryptosporidium* growth is also significantly affected. This system is well suited to test the effect of host cell gene expression on *Cryptosporidium* differentiation. Comparison of ALI and non-ALI culture host cell transcriptomes suggest that several pathways are significantly differentially regulated between those two conditions. Specifically, the energy metabolism of the ALI culture significantly shifts from glycolytic to mitochondrial respiration (214). Taken together with the above-mentioned studies about macrogamete development, this suggests that the discontinuation of *Cryptosporidium* growth in different cancer cell lines may actually result from the differences in host cell characteristics rather than gametocyte development deficiency. However, the exact molecular mechanism of this phenomenon is still to be elucidated.

The transcriptome of sporozoites at varying in vitro culture time points has revealed that *Cryptosporidium* has a highly dynamic transcriptional regulation as it progresses through its life cycle, and there are numerous stage specific genes (213, 215, 216). A high throughput qRT-PCR based analysis has the highest temporal resolution

of transcripts so far (215). This study captured seven different time points ranging from 2 hours to 72 hpi in vitro. In combination, two RNA-seq studies also assayed the transcriptome of 2, 24, 48 and 96 hpi, as well as oocysts and sporozoites (212, 216). Despite differences in host cell lines, sampling times, methods used, and analyses modules, these three sets of data are fairly consistent and provide similar conclusions regarding several broad aspects of life cycle progression. For example, the gene expression pattern in intracellular stages is more diverse compared to sporozoites and oocysts, with a huge shift towards rapid transcriptional activities observed at early intracellular timepoints. Later time points in all the experiments showed enrichment of oocyst wall proteins and meiosis associated proteins. Importantly, the later time points contain a mixture of both male and female gametocytes in these experiments (213, 215, 216). RNA-seq mediated comparison between FAC sorted female parasites and asexual stages verified that both of the above-mentioned protein classes are enriched in female gametocytes (212). One interesting observation from both of the bulk RNA-seq experiments was that mRNA of one paralogue of two lactate dehydrogenase genes of *Cryptosporidium* is selectively highly expressed in the sporozoite population (213, 216). In a microarray experiment of oocysts, the same observation was reported (217). The potential functional significance of this observation is still to be realized.

The high temporal resolution of the qRT PCR dataset noted above makes it suitable for the exploration of co-expressed gene clusters. Indeed, in the original publication, they divided the genes into nine clusters based on their temporal

expression profiles (215). Subsequently, another study used the same dataset and, using an optimized parameter for clustering it described 200 different clusters of co-expressed genes (218). Several short DNA motifs were enriched in the promoter elements of several clusters (218). An in vitro AP2 TF DNA binding assay showed that some of the identified motifs are recognized by multiple *Cryptosporidium* AP2 TFs (219). For example, the motif “GCATGCA” was found to be overrepresented in 33 of 200 clusters (218). The DNA binding assay showed that slight variations of this motif are identified by four different AP2 TFs. Taken together, it suggests that AP2 TFs play important roles in stage-specific transcription of *Cryptosporidium* genes.

Several recent breakthroughs have made studying the differentiation of *Cryptosporidium* life cycle progression more amenable. The parasite is now genetically manipulatable using CRISPR-Cas9 technology (220), distinct phases of its life cycle can be identified by stage specific antibodies (221), completion of its life cycle is possible in vitro (214, 222-226) and stage specific assays are available (209). Together, these developments constitute a strong toolbox to progress our understanding of the *Cryptosporidium* life cycle beyond microscopic observation to molecular characterization.

1.7: *Eimeria* Stage Differentiation

Eimeria species are coccidian apicomplexans that can infect all classes of vertebrates and some invertebrates (227). Each species is considered to be specific for a single host, within which they complete their whole life cycle (227). Several *Eimeria* species are parasites of chickens that cause huge economic losses in the poultry industry. The most well studied species of them is *Eimeria tennela*.

Eimeria oocysts form sporocysts within them in the environment (Figure 4). Upon ingestion, they are released in the chicken gastrointestinal tract. Sporozoites come out of the sporocyst in the small intestine and infect the intestinal epithelial cells. After several rounds of asexual schizogony, where multiple merozoites from a schizont start another round of replication, gametes emerge, fertilization takes place, and subsequently, the zygotes differentiate into oocysts that are excreted in the feces (228). Based on the observations of morphologically different schizonts that emerge in a time-dependent manner after chicken infection, the dogmatic view is that *Eimeria* species are genetically programmed to replicate for a fixed number of asexual schizogony cycles before differentiating into gametocytes (228, 229). For example, upon *E. tennela* infection, first generation schizonts are observed at day 1 and 2 post-infection, the second generation of schizonts, which are larger and contain more nuclei than the first generation, are observed on day 3 and 4 post-infection, and third generation schizonts, which are smaller than both of the earlier schizont stages and contain up to 16 merozoites, are observed after 4 days of infection (228, 230). Merozoites from the

third stage schizont develop into gametocytes that start to emerge at day 5, which ultimately form the zygote. Oocysts are abundant in the feces on day 6 to 7 post infection (228, 230).

Several controlled experiments support the theory of preexisting genetic programs for the number of asexual replication cycles. For example, in a study testing this theory, merozoites were collected from chicken intestine 94 hpi (hours post-infection) and used to infect naïve chickens by direct intestinal injection (231). This inoculum is supposedly enriched for the second generation of merozoites and, in agreement with the theory, none of the earlier stage schizonts were observed in the naïve chicken. Third stage schizonts, gametocytes, and oocysts emerged at earlier time points compared to chickens infected with oocysts (231). Recently, RNA-seq and SSH techniques were used to determine the gene expression pattern of *E. necatrix* merozoites collected at 136 and 144 hpi. The two populations were considered the second and the third generation of merozoites respectively. A high number of genes were found to be differentially expressed and they were classified into second or third generation-specific genes (232, 233).

However, in vivo infection of *Eimeria* is asynchronous which makes it difficult to differentiate different stages of schizont based on size only (228, 229). Consequently, merozoite isolation at a certain time point post-infection would likely result in a diverse set of merozoites from different replication cycles. Additionally, instead of a replication number clock, there might be environmental signals that drive

the differentiation and as such, the parasites at different timepoints post infection might be at different stages of development/differentiation, irrespective of the number of schizogony cycles that they went through. Therefore, in the absence of specifically defined markers for each schizogony cycle and/or without genetic validations about the existence of distinct schizogony stages, the theory of a genetically determined replication number cannot be properly tested.

Attempts of attenuated vaccine development present another approach to test this phenomenon. It has been shown that repeated isolation of early oocysts and their selection by serial passage gives rise to less virulent precocious lines of *Eimeria* whose prepatent time decrease significantly from the parent parasites (234-237). Most commonly, fewer asexual replication cycles have been attributed to such shortened prepatent time of precocious lines (234, 237, 238). Searching for a potential genetic basis of the fewer asexual cycles that occur, one study crossed a precocious line with its parent and identified a genetic linkage in chromosome 2 associated with the shorter prepatent time phenotype (239). Recently, another study looked for differences in transcriptional activity of a precocious and its parent line and suggested potential differences exist in the expression of DNA replication related genes at merozoite stages (234). Heritable epigenetic changes can also cause such a phenomenon; however, epigenetic comparison between a parent and a precocious line has not been described yet.

To probe the commitment towards sexual differentiation in *Eimeria*, a study

used periodic acid-Schiff (PAS) staining in primary chicken kidney cell culture and reported that PAS-positive third generation schizonts form PAS-positive third generation merozoites that ultimately form PAS-positive macrogametocytes (240). The opposite was observed for microgametocyte development. This suggests that parasites are committed to forming either male or female gametocytes one replication cycle before the ultimate differentiation, similar to the *Plasmodium* parasites. However, this phenomenon has not been tested robustly with modern techniques.

Several studies have used comparative transcriptomics and proteomics analysis to understand the regulation of the life cycle progression of *Eimeria* (200, 232-234, 241-243). Analysis of the proteome of oocysts, in vitro sporulated sporozoites, and merozoites isolated from infected chickens suggested that merozoites express proteins involved in oxidative phosphorylation more abundantly, whereas glycolytic enzymes are expressed almost equally between sporozoites and merozoites (242). Another study used RNA-seq to determine differential expression of genes between sporozoites, asexual merozoites (collected 112 hpi) and gametocytes (gender independent, 134 and 144 hpi) (200). Genes that were upregulated in gametocytes contained enzymes for protein glycosylation and proteases, both of which classes were previously described as upregulated in gametocytes in independent studies (244, 245). Comparison of this dataset with *Plasmodium* sex-specific transcriptomic datasets showed that homologs of both male and female specific *Plasmodium* genes were upregulated in gametocytes in this dataset (200). Antisera raised against some of these proteins successfully

differentially identified male and female gametocytes (200), which could be very helpful for future differentiation studies.

Recently, a breakthrough publication in *E. tenella* described new gene knockout techniques in *Eimeria* using CRISPR-Cas9 mediated genetic manipulation techniques (246). The Cas9 protein was also successfully integrated into the genome, which creates a very amenable system for mutant library preparation (246). This study also demonstrated a successful knockout of 10 of the 33 putative AP2 TFs in the *E. tenella* genome, suggesting the others were essential (246). With this newly developed technique, long-standing questions in *Eimeria* life cycle progression can be addressed in a more comprehensive way. One still standing roadblock in the field is the absence of an easily manipulatable continuous culture system.

1.8: Stage Differentiation of Piroplasms

Piroplasms are a group of hematozoan apicomplexan parasites that infect blood cells of vertebrates for asexual replication and blood-sucking ticks for sexual replication (247). Phylogenetically, they are the closest relatives of *Plasmodium* among the parasites discussed in this review. *Babesia* and *Theileria* infect cattle while *Babesia* can also infect humans as a dead-end host (Figure 5). Hard ticks of the family Ixodidae are their definitive host who takes up the mature gametocytes of these parasites residing in RBCs of mammalian hosts (248). In the tick midgut, gametogenesis and fertilization takes place, zygotes are formed in the midgut cells,

followed by meiosis to produce kinetes. Kinetes migrate to the salivary gland of the tick via hemolymph, and differentiate into sporoblasts that contain sporozoites, which are the vertebrate infective form. *Babesia* sporozoites directly infect RBCs, while *Theileria* sporozoites first infect leukocytes. *Theileria* merozoites released from leukocytes then infect RBCs. The asexual replication cycle and occasional gametocytogenesis occur within RBCs, ultimately forming mature gametocytes. Even though there are several steps in the piroplasm life cycle where differentiation occurs, our knowledge about molecular mechanisms governing these steps is extremely limited (248).

1.8.1: *Theileria*

Most of the pathogenic *Theileria* species can cause an oncogenic transformation of the leukocytes that they infect (249). They replicate via schizogony inside the parasitophorous vacuole within a transformed cell, and when the host cell is mitotically divided, they are distributed into daughter cells (250). Importantly, this transformation is reversible. Typically, *Theileria* are cultivated in vitro in transformed leukocytes (249). Different aspects of this transformation process have been studied relatively more extensively than progression of the parasite beyond this stage of the life cycle (251). They progress to the RBC stage by producing merozoites that egress from the leukocytes. The observation that the number of nuclei in the schizont increases before merozoite formation led to the theory that a high ratio of DNA compared to protein in the parasitophorous vacuole signals merozoite differentiation (252). Inhibition of DNA

synthesis using a cell cycle progression inhibitor induced early differentiation, whereas a mitochondrial protein synthesis inhibitor prolonged the time before differentiation (253). This led to a more refined theory that when specific protein factors in the parasitophorous vacuole reach a threshold, it induces commitment and the higher ratio of DNA in the earlier theory on commitment is just a facilitator for higher transcriptional activity (i.e. higher number of genomic copy allows higher transcription of a specific factor) in the multiple nuclei containing parasitophorous vacuole (253). It was subsequently shown that a protein overexpressed during differentiation is transcriptionally regulated by putative transcription factors that are also enriched during differentiation (254). This supported the notion that reaching the threshold of specific factors drives differentiation (254). Increasing culture temperature is the most common way of inducing merozoite differentiation in *Theileria* (252-255). It was shown that the protein synthesis rate of the parasite increases at the higher temperature (253). Finally, stage-specific overexpression of 3 genes was verified by northern blotting (255).

All these pre-omics era studies suggest that there is a stage specific expression of genes that drives differentiation. Indeed, transcriptomic and proteomics studies confirm that there are stage specific expression profiles of genes in different stages of the *Theileria* life cycle, just like all the other Apicomplexa (256-258). However, even though there are markers of different stages, wet lab experimental identification of a master regulatory element is still missing. In silico analyses have shown that *Theileria* contains several AP2 TFs, and expression profiles of several of those AP2 TFs are also

stage specific (259, 260). The genetic knockout system is still not developed for *Theileria*, however, so potential experimental validation approaches are limited at this point (261).

1.8.2: *Babesia*

Several species of *Babesia* can be continuously cultured in-vitro within RBCs during their asexual replication cycle (262). No schizogonic replication has been documented for *Babesia* yet (248). In the mammalian blood, some parasites differentiate into gametocytes, which are activated in the tick midgut to form gametes (248). Induction of gametocytogenesis, as well as gametogenesis, can be achieved in in vitro blood culture of *Babesia* (263-265). Stressing the parasites with anti-*Babesia* drugs induces gametocytogenesis, whereas induction with xanthurenic acid or tick extract induces both gametocytogenesis and gametogenesis (265, 266). There are three validated marker genes of gametocytogenesis, two of them are expressed in kenetes also (267, 268).

Hap2 is a well documented male gamete specific protein in different systems, and it is functionally important for gamete fertilization (269). Reducing Hap2 activity, either by functional inhibition using antibodies or by genetic knockout, inhibits zygote formation, suggesting a similar role for Hap2 in *Babesia* as seen in the other systems (270, 271). A putative methyltransferase is only expressed in tick stages (268). In addition to these markers, there are other potential stage specific proteins in *Babesia* that are identified through proteomics based analysis (272-274).

Global regulators of differentiation have yet to be identified for *Babesia*, and none of the AP2 TFs have been studied for differentiation in a targeted way yet (260). As a gene knockout system in *Babesia* is available (271, 275), knockout mutant derived validation of a master regulator is possible, and the already established stage specific markers would greatly help in that process.

1.9: Similarities and Differences in Stage Differentiation Between Apicomplexan Parasites

During almost the entirety of their life cycle, all the discussed apicomplexan parasites have a haploid nucleus. Zygotes are the only diploid stage, and in most cases, they are very short-lived because of the subsequent meiotic division. Whether there are common underlying mechanisms of initiation of meiosis in response to the diploid state of the nucleus is not known.

Sexual differentiation of the Apicomplexa starts with gametocytogenesis, which gives rise to male and female gametocytes. The two gametocytes develop with highly divergent gene expression patterns, but they normally emerge together during the course of infection. This suggests a two-step process of gametocytogenesis induction. First, a gender independent commitment step, and subsequently, a gender-specific differentiation pathway. This has been well characterized in *Plasmodium* where Δ ap2-g mutants do not form any gametocytes whereas Δ ap2-fg are only deficient in female gametocyte maturation. A sexually committed schizont stage is observed in

Plasmodium within which the two above mentioned steps likely take place. Hints of the same phenomenon have been also observed in *Eimeria*, where the schizonts in the last cycle are morphologically distinct from the earlier cycles, and in *Cryptosporidium*, where a type II meront is observed before the emergence of gametocytes. Whether these two stages are analogous to the sexually committed schizont of *Plasmodium* has not yet been tested with molecular techniques.

The time interval between commitment to gametocyte formation and the ultimate release of gametocytes differs between different apicomplexan species. For hematozoans, mature gametocytes of both sexes need to come out from the host cell at the same time in the vector midgut. In the case of Coccidians and *Cryptosporidium*, only the male gametes egress from the host cells, after which they fertilize mature female gametocytes residing in other host cells. In any case, gametocyte maturation of both sexes must be synched in time for successful fertilization.

Gametocyte development pathways seem to be well conserved within apicomplexans, as multiple transcriptomics and proteomics studies have shown that homologous proteins are expressed in a sex-specific manner for all the apicomplexans. For example, meiosis-related genes are expressed during the maturation of female gametocytes in different parasites, presumably so that the proteins for meiotic division are readily available soon after the fertilization. On the other hand, expression of HAP2, a well-characterized gamete fusion protein, is restricted to male gametocytes in different apicomplexans.

Commitment to the next step of differentiation occurs before the ultimate stage conversion in almost all of the differentiation processes. The only exception seems to be the tachyzoite to bradyzoite differentiation, which is more dynamic. However, this particular differentiation is also unique in the sense that it is reversible. Even including bradyzoite differentiation, identified global regulators of differentiation in different apicomplexans are highly common between species. The family of AP2 TFs plays key roles in all the differentiation processes. Post-translational regulation is also commonly observed in many differentiation processes. For example, inhibition of translation initiation by phosphorylation of eIF2 α is observed for *Plasmodium* sporozoite to liver stage conversion, and in tachyzoite to bradyzoite conversion. However, this conservation can be artificially biased, as the selection of global regulators for in-depth studies is often guided by what is already known in other apicomplexans. Indeed, when a relatively unbiased mutant library screen was used to identify key regulators for bradyzoite differentiation, it identified a myb domain containing TF, which was never implicated in apicomplexan differentiation before (176).

Stage specific alteration in energy metabolism is also a well conserved feature of apicomplexan differentiation. Some stages are more dependent on anaerobic glycolysis for energy production, whereas other stages are more reliant on oxidative phosphorylation. The role of epigenetic modification of chromatin structure in differentiation is starting to emerge in apicomplexans, and will likely be recognized to play a role in many apicomplexans after further study.

1.10: Future perspectives

Several technological advances in recent years have made studies of apicomplexan differentiation more accessible. Two techniques have potential high values in understanding differentiation across multiple apicomplexan species—namely, single cell RNA-seq and CRISPR-Cas9 mediated mutant library preparation.

It is often difficult to differentiate different stages of the apicomplexan life cycle due to their asynchronous growth and lack of robust stage-specific markers. In addition, the lack of an easily manipulatable in vitro culture system hinders studies of different apicomplexans. Theoretically, single cell transcriptomics can overcome all these challenges. Great examples of this are the two single cell transcriptional atlases of *Plasmodium* and *T. gondii* (129, 172). From both of these studies, it is apparent that single cell transcriptomes from parasites at different stages of their life cycle cluster with unguided algorithms in a stage specific manner. Deductive reasoning can be applied to such datasets from our knowledge on well-studied apicomplexans to determine the identity of each cluster. As transcriptomes are generated from single cells rather than a population, they are theoretically more suitable for identifying sets of co-expressed genes. Additionally, it is almost the ultimate phenotypic characterization tool when the phenotype is the differentiation capability .

The second technique, CRISPR-Cas9 mediated mutant library preparation, is relatively restricted to parasites with already established robust transfection and genetic manipulation systems. It is already available for *Plasmodium* and *T. gondii*, and also

probably for *Eimeria* (58, 194, 246). CRISPR-Cas9 mediated library generation allows preparation of an unbiased mutant library, as well as relatively straightforward determination of library composition in various conditions. The utility of this technique has already been seen for *Plasmodium* liver stage metabolic map construction, as well as in the identification of a master regulator of *T. gondii* bradyzoite differentiation (58, 176).

There are still a lot of unanswered questions in apicomplexan differentiation. With the techniques that are now available together with unprecedented access to a wealth of “-omics” data, a lot of those questions are ready to be answered.

1.11: Summary of our approach

We have applied a systemic chemical genomics approach to understand the regulation of *C. parvum* differentiation. Using a stage specific differentiation assay, we screened a library of more than 10,000 compounds and identified compounds that specifically inhibit the sexual differentiation or maturation of *C. parvum*. The transcriptomic responses of the parasites to these sexual stage specific inhibitors were then determined using mRNA-seq. To our knowledge, this is the first time a chemical genomic approach has been used to study the process of differentiation in apicomplexans. Our data greatly complement the already published transcriptomics data available on *Cryptosporidium* life cycle progression. By robustly comparing our dataset with already published datasets of *Cryptosporidium* differentiation and other

apicomplexans, as well as analyzing the already known mode of actions of several sexual stage specific inhibitors, we have put forward several hypotheses regarding potential master regulatory elements and metabolic alteration of *Cryptosporidium* in the course of sexual differentiation. Our data highlight the potential commonalities of *Cryptosporidium* and other apicomplexans in driving differentiation, as well as suggesting some unique aspects of *Cryptosporidium* biology.

Malaria
(*Plasmodium* spp.)




Figure 1: *Plasmodium* life cycle.

See section 1.4 for detailed description. The illustration is a public domain image by “CDC - DPDx/ Alexander J. da Silva, PhD; Melanie Moser” and downloaded from Public Health Image Library (PHIL)

Toxoplasmosis

(*Toxoplasma gondii*)




Figure 2: *Toxoplasma gondii* life cycle.

See section 1.5 for detailed description. The illustration is a public domain image by “CDC - DPDx/ Alexander J. da Silva, PhD; Melanie Moser” and downloaded from Public Health Image Library (PHIL).

Cryptosporidiosis

(*Cryptosporidium*)




Figure 3: *Cryptosporidium* life cycle.

See section 1.6 for detailed description. The illustration is a public domain image by “CDC - DPDx/ Alexander J. da Silva, PhD; Melanie Moser” and downloaded from Public Health Image Library (PHIL).




Figure 4: *Eimeria* life cycle.

See section 1.7 for detailed description. The illustration is licensed under “CNX OpenStax / CC BY (<https://creativecommons.org/licenses/by/4.0>)” and is downloaded from <https://commons.wikimedia.org>.




Figure 5: *Babesia* life cycle.

See section 1.8 for detailed description. The illustration is a public domain image and is downloaded from cdc.gov.

1.12: References

1. Adl SM, Bass D, Lane CE, Lukes J, Schoch CL, Smirnov A, et al. Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes. *The Journal of eukaryotic microbiology*. 2019;66(1):4-119.
2. Šlapeta JaVM-A. Apicomplexa Levine 1970. Sporozoa Leucart 1879. Version 18 May 2011. 2011 [Available from: <http://tolweb.org/Apicomplexa/2446/2011.05.18>].
3. Blackman MJ, Bannister LH. Apical organelles of Apicomplexa: biology and isolation by subcellular fractionation. *Molecular and biochemical parasitology*. 2001;117(1):11-25.
4. Archibald JM. The puzzle of plastid evolution. *Current biology : CB*. 2009;19(2):R81-8.
5. Zhang Z, Green BR, Cavalier-Smith T. Phylogeny of ultra-rapidly evolving dinoflagellate chloroplast genes: a possible common origin for sporozoan and dinoflagellate plastids. *Journal of molecular evolution*. 2000;51(1):26-40.
6. Janouskovec J, Horak A, Obornik M, Lukes J, Keeling PJ. A common red algal origin of the apicomplexan, dinoflagellate, and heterokont plastids. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(24):10949-54.
7. Moore RB, Obornik M, Janouskovec J, Chrudimsky T, Vancova M, Green DH, et al. A photosynthetic alveolate closely related to apicomplexan parasites. *Nature*. 2008;451(7181):959-63.
8. Del Campo J, Heger TJ, Rodriguez-Martinez R, Worden AZ, Richards TA,

- Massana R, et al. Assessing the Diversity and Distribution of Apicomplexans in Host and Free-Living Environments Using High-Throughput Amplicon Data and a Phylogenetically Informed Reference Framework. *Frontiers in microbiology*. 2019;10:2373.
9. Janouskovec J, Paskerova GG, Miroljubova TS, Mikhailov KV, Birley T, Aleoshin VV, et al. Apicomplexan-like parasites are polyphyletic and widely but selectively dependent on cryptic plastid organelles. *eLife*. 2019;8.
 10. Arisue N, Hashimoto T. Phylogeny and evolution of apicoplasts and apicomplexan parasites. *Parasitology international*. 2015;64(3):254-9.
 11. Rueckert S, Pipaliya SV, Dacks JB. Evolution: Parallel Paths to Parasitism in the Apicomplexa. *Current biology : CB*. 2019;29(17):R836-R9.
 12. Timmis JN, Ayliffe MA, Huang CY, Martin W. Endosymbiotic gene transfer: organelle genomes forge eukaryotic chromosomes. *Nature reviews Genetics*. 2004;5(2):123-35.
 13. Kishore SP, Stiller JW, Deitsch KW. Horizontal gene transfer of epigenetic machinery and evolution of parasitism in the malaria parasite *Plasmodium falciparum* and other apicomplexans. *BMC evolutionary biology*. 2013;13:37.
 14. Balaji S, Babu MM, Iyer LM, Aravind L. Discovery of the principal specific transcription factors of Apicomplexa and their implication for the evolution of the AP2-integrase DNA binding domains. *Nucleic acids research*. 2005;33(13):3994-4006.
 15. Aurrecochea C, Barreto A, Basenko EY, Brestelli J, Brunk BP, Cade S, et al.

EuPathDB: the eukaryotic pathogen genomics database resource. *Nucleic acids research*. 2017;45(D1):D581-D91.

16. Kuo CH, Wares JP, Kissinger JC. The Apicomplexan whole-genome phylogeny: an analysis of incongruence among gene trees. *Molecular biology and evolution*. 2008;25(12):2689-98.

17. Morrison DA. Evolution of the Apicomplexa: where are we now? *Trends in parasitology*. 2009;25(8):375-82.

18. de Vargas C, Audic S, Henry N, Decelle J, Mahe F, Logares R, et al. Ocean plankton. Eukaryotic plankton diversity in the sunlit ocean. *Science (New York, NY)*. 2015;348(6237):1261605.

19. Mahe F, de Vargas C, Bass D, Czech L, Stamatakis A, Lara E, et al. Parasites dominate hyperdiverse soil protist communities in Neotropical rainforests. *Nature ecology & evolution*. 2017;1(4):91.

20. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, et al. Complete genome sequence of the apicomplexan, *Cryptosporidium parvum*. *Science (New York, NY)*. 2004;304(5669):441-5.

21. Chalmers RM, Davies AP, Tyler K. *Cryptosporidium*. *Microbiology (Reading, England)*. 2019;165(5):500-2.

22. Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, et al. The genome of *Cryptosporidium hominis*. *Nature*. 2004;431(7012):1107-12.

23. Dubey JP, Lindsay DS, Lappin MR. Toxoplasmosis and other intestinal

coccidial infections in cats and dogs. *The Veterinary clinics of North America Small animal practice*. 2009;39(6):1009-34, v.

24. Berto BP, McIntosh D, Lopes CW. Studies on coccidian oocysts (Apicomplexa: Eucoccidiorida). *Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria*. 2014;23(1):1-15.

25. Morrissette NS, Sibley LD. Cytoskeleton of apicomplexan parasites. *Microbiology and molecular biology reviews : MMBR*. 2002;66(1):21-38; table of contents.

26. Šlapeta JaVM-A. Hematozoa Vivier 1982. Aconoidasida Mehlhorn, Peters & Haberkorn 1980. Version 18 May 2011 2011 [Available from: <http://tolweb.org/Hematozoa/68058>].

27. Sinden RE. Developing transmission-blocking strategies for malaria control. *PLoS pathogens*. 2017;13(7):e1006336.

28. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clinical microbiology reviews*. 1998;11(2):267-99.

29. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet (London, England)*. 2013;382(9888):209-22.

30. Huston CD, Spangenberg T, Burrows J, Willis P, Wells TN, van Voorhis W. A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. *PLoS neglected tropical diseases*. 2015;9(10):e0003987.
31. Ramakrishnan C, Maier S, Walker RA, Rehrauer H, Joekel DE, Winiger RR, et al. An experimental genetically attenuated live vaccine to prevent transmission of *Toxoplasma gondii* by cats. *Scientific reports*. 2019;9(1):1474.
32. Mahmoudi S, Keshavarz H. Malaria Vaccine Development: The Need for Novel Approaches: A Review Article. *Iranian journal of parasitology*. 2018;13(1):1-10.
33. Boisard J, Florent I. Why the -omic future of Apicomplexa should include gregarines. *Biology of the cell*. 2020.
34. Ngotho P, Soares AB, Hentzschel F, Achcar F, Bertuccini L, Marti M. Revisiting gametocyte biology in malaria parasites. *FEMS microbiology reviews*. 2019;43(4):401-14.
35. Schuster FL. Cultivation of plasmodium spp. *Clinical microbiology reviews*. 2002;15(3):355-64.
36. Frischknecht F, Matuschewski K. Plasmodium Sporozoite Biology. *Cold Spring Harbor perspectives in medicine*. 2017;7(5).
37. Ejigiri I, Sinnis P. Plasmodium sporozoite-host interactions from the dermis to the hepatocyte. *Current opinion in microbiology*. 2009;12(4):401-7.
38. Vanderberg JP. Development of infectivity by the Plasmodium berghei sporozoite. *The Journal of parasitology*. 1975;61(1):43-50.

39. Touray MG, Warburg A, Laughinghouse A, Krettli AU, Miller LH. Developmentally regulated infectivity of malaria sporozoites for mosquito salivary glands and the vertebrate host. *The Journal of experimental medicine*. 1992;175(6):1607-12.
40. Sato Y, Montagna GN, Matuschewski K. *Plasmodium berghei* sporozoites acquire virulence and immunogenicity during mosquito hemocoel transit. *Infection and immunity*. 2014;82(3):1164-72.
41. Matuschewski K, Ross J, Brown SM, Kaiser K, Nussenzweig V, Kappe SH. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. *The Journal of biological chemistry*. 2002;277(44):41948-53.
42. Kaiser K, Matuschewski K, Camargo N, Ross J, Kappe SH. Differential transcriptome profiling identifies *Plasmodium* genes encoding pre-erythrocytic stage-specific proteins. *Molecular microbiology*. 2004;51(5):1221-32.
43. Mikolajczak SA, Silva-Rivera H, Peng X, Tarun AS, Camargo N, Jacobs-Lorena V, et al. Distinct malaria parasite sporozoites reveal transcriptional changes that cause differential tissue infection competence in the mosquito vector and mammalian host. *Molecular and cellular biology*. 2008;28(20):6196-207.
44. Lasonder E, Janse CJ, van Gemert GJ, Mair GR, Vermunt AM, Douradinha BG, et al. Proteomic profiling of *Plasmodium* sporozoite maturation identifies new proteins essential for parasite development and infectivity. *PLoS pathogens*. 2008;4(10):e1000195.

45. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(8):3022-7.
46. Silvie O, Goetz K, Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. *PLoS pathogens*. 2008;4(6):e1000086.
47. Muller K, Matuschewski K, Silvie O. The Puf-family RNA-binding protein Puf2 controls sporozoite conversion to liver stages in the malaria parasite. *PloS one*. 2011;6(5):e19860.
48. Gomes-Santos CS, Braks J, Prudencio M, Carret C, Gomes AR, Pain A, et al. Transition of Plasmodium sporozoites into liver stage-like forms is regulated by the RNA binding protein Pumilio. *PLoS pathogens*. 2011;7(5):e1002046.
49. Aly AS, Lindner SE, MacKellar DC, Peng X, Kappe SH. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. *Molecular microbiology*. 2011;79(4):929-39.
50. Silvie O, Briquet S, Muller K, Manzoni G, Matuschewski K. Post-transcriptional silencing of UIS4 in Plasmodium berghei sporozoites is important for host switch. *Molecular microbiology*. 2014;91(6):1200-13.
51. Silva PA, Guerreiro A, Santos JM, Braks JA, Janse CJ, Mair GR. Translational Control of UIS4 Protein of the Host-Parasite Interface Is Mediated by the RNA Binding

- Protein Puf2 in *Plasmodium berghei* Sporozoites. *PloS one*. 2016;11(1):e0147940.
52. Lindner SE, Mikolajczak SA, Vaughan AM, Moon W, Joyce BR, Sullivan WJ, Jr., et al. Perturbations of *Plasmodium* Puf2 expression and RNA-seq of Puf2-deficient sporozoites reveal a critical role in maintaining RNA homeostasis and parasite transmissibility. *Cellular microbiology*. 2013;15(7):1266-83.
53. Cui L, Lindner S, Miao J. Translational regulation during stage transitions in malaria parasites. *Annals of the New York Academy of Sciences*. 2015;1342:1-9.
54. Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister S, et al. The *Plasmodium* eukaryotic initiation factor-2alpha kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. *The Journal of experimental medicine*. 2010;207(7):1465-74.
55. Toro-Moreno M, Sylvester K, Srivastava T, Posfai D, Derbyshire ER. RNA-Seq Analysis Illuminates the Early Stages of *Plasmodium* Liver Infection. *mBio*. 2020;11(1).
56. Caldelari R, Dogga S, Schmid MW, Franke-Fayard B, Janse CJ, Soldati-Favre D, et al. Transcriptome analysis of *Plasmodium berghei* during exo-erythrocytic development. *Malaria journal*. 2019;18(1):330.
57. Lindner SE, Swearingen KE, Shears MJ, Walker MP, Vrana EN, Hart KJ, et al. Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites. *Nature communications*. 2019;10(1):4964.
58. Stanway RR, Bushell E, Chiappino-Pepe A, Roques M, Sanderson T, Franke-Fayard B, et al. Genome-Scale Identification of Essential Metabolic Processes for

- Targeting the Plasmodium Liver Stage. *Cell*. 2019;179(5):1112-28 e26.
59. Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. *Cellular microbiology*. 2009;11(3):506-20.
60. van Schaijk BC, Kumar TR, Vos MW, Richman A, van Gemert GJ, Li T, et al. Type II fatty acid biosynthesis is essential for *Plasmodium falciparum* sporozoite development in the midgut of *Anopheles* mosquitoes. *Eukaryotic cell*. 2014;13(5):550-9.
61. Iwanaga S, Kaneko I, Kato T, Yuda M. Identification of an AP2-family protein that is critical for malaria liver stage development. *PloS one*. 2012;7(11):e47557.
62. Modrzynska K, Pfander C, Chappell L, Yu L, Suarez C, Dundas K, et al. A Knockout Screen of ApiAP2 Genes Reveals Networks of Interacting Transcriptional Regulators Controlling the Plasmodium Life Cycle. *Cell host & microbe*. 2017;21(1):11-22.
63. Zhang C, Li Z, Cui H, Jiang Y, Yang Z, Wang X, et al. Systematic CRISPR-Cas9-Mediated Modifications of *Plasmodium yoelii* ApiAP2 Genes Reveal Functional Insights into Parasite Development. *mBio*. 2017;8(6).
64. Yuda M, Iwanaga S, Shigenobu S, Kato T, Kaneko I. Transcription factor AP2-Sp and its target genes in malarial sporozoites. *Molecular microbiology*. 2010;75(4):854-63.
65. Baer K, Klotz C, Kappe SH, Schnieder T, Frevert U. Release of hepatic *Plasmodium yoelii* merozoites into the pulmonary microvasculature. *PLoS pathogens*.

2007;3(11):e171.

66. Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. *The Journal of clinical investigation*. 2012;122(10):3618-28.
67. Vaughan AM, Kappe SHI. Malaria Parasite Liver Infection and Exoerythrocytic Biology. *Cold Spring Harbor perspectives in medicine*. 2017;7(6).
68. Kaiser G, De Niz M, Burda PC, Niklaus L, Stanway RL, Heussler V. Generation of transgenic rodent malaria parasites by transfection of cell culture-derived merozoites. *Malaria journal*. 2017;16(1):305.
69. Knuepfer E, Napiorkowska M, van Ooij C, Holder AA. Generating conditional gene knockouts in Plasmodium - a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9. *Scientific reports*. 2017;7(1):3881.
70. Polino AJ, Nasamu AS, Niles JC, Goldberg DE. Assessment of Biological Role and Insight into Druggability of the Plasmodium falciparum Protease Plasmeprin V. *ACS infectious diseases*. 2020.
71. Hulden L, Hulden L. Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival. *Malaria journal*. 2011;10:90.
72. Voorberg-van der Wel A, Roma G, Gupta DK, Schuierer S, Nigsch F, Carbone W, et al. A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi. *eLife*. 2017;6.
73. Chua ACY, Ananthanarayanan A, Ong JJY, Wong JY, Yip A, Singh NH, et al.

Hepatic spheroids used as an in vitro model to study malaria relapse. *Biomaterials*. 2019;216:119221.

74. Gural N, Mancio-Silva L, Miller AB, Galstian A, Butty VL, Levine SS, et al. In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites. *Cell host & microbe*. 2018;23(3):395-406 e4.

75. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and Disease. *Cell*. 2016;167(3):610-24.

76. Bruce MC, Alano P, Duthie S, Carter R. Commitment of the malaria parasite Plasmodium falciparum to sexual and asexual development. *Parasitology*. 1990;100 Pt 2:191-200.

77. Inselburg J. Gametocyte formation by the progeny of single Plasmodium falciparum schizonts. *The Journal of parasitology*. 1983;69(3):584-91.

78. Silvestrini F, Alano P, Williams JL. Commitment to the production of male and female gametocytes in the human malaria parasite Plasmodium falciparum. *Parasitology*. 2000;121 Pt 5:465-71.

79. Smith TG, Lourenco P, Carter R, Walliker D, Ranford-Cartwright LC. Commitment to sexual differentiation in the human malaria parasite, Plasmodium falciparum. *Parasitology*. 2000;121 (Pt 2):127-33.

80. Eksi S, Morahan BJ, Haile Y, Furuya T, Jiang H, Ali O, et al. Plasmodium falciparum gametocyte development 1 (Pfgdv1) and gametocytogenesis early gene identification and commitment to sexual development. *PLoS pathogens*.

2012;8(10):e1002964.

81. Kafsack BF, Rovira-Graells N, Clark TG, Bancells C, Crowley VM, Campino SG, et al. A transcriptional switch underlies commitment to sexual development in malaria parasites. *Nature*. 2014;507(7491):248-52.
82. Sinha A, Hughes KR, Modrzynska KK, Otto TD, Pfander C, Dickens NJ, et al. A cascade of DNA-binding proteins for sexual commitment and development in *Plasmodium*. *Nature*. 2014;507(7491):253-7.
83. Brancucci NMB, Bertschi NL, Zhu L, Niederwieser I, Chin WH, Wampfler R, et al. Heterochromatin protein 1 secures survival and transmission of malaria parasites. *Cell host & microbe*. 2014;16(2):165-76.
84. Filarsky M, Fraschka SA, Niederwieser I, Brancucci NMB, Carrington E, Carrio E, et al. GDV1 induces sexual commitment of malaria parasites by antagonizing HP1-dependent gene silencing. *Science (New York, NY)*. 2018;359(6381):1259-63.
85. Coetzee N, Sidoli S, van Biljon R, Painter H, Llinas M, Garcia BA, et al. Quantitative chromatin proteomics reveals a dynamic histone post-translational modification landscape that defines asexual and sexual *Plasmodium falciparum* parasites. *Scientific reports*. 2017;7(1):607.
86. Coetzee N, von Gruning H, Opperman D, van der Watt M, Reader J, Birkholtz LM. Epigenetic inhibitors target multiple stages of *Plasmodium falciparum* parasites. *Scientific reports*. 2020;10(1):2355.
87. Ikadai H, Shaw Saliba K, Kanzok SM, McLean KJ, Tanaka TQ, Cao J, et al.

Transposon mutagenesis identifies genes essential for *Plasmodium falciparum* gametocytogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(18):E1676-84.

88. Yuda M, Iwanaga S, Kaneko I, Kato T. Global transcriptional repression: An initial and essential step for *Plasmodium* sexual development. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(41):12824-9.

89. Yuda M, Kaneko I, Iwanaga S, Murata Y, Kato T. Female-specific gene regulation in malaria parasites by an AP2-family transcription factor. *Molecular microbiology*. 2020;113(1):40-51.

90. Josling GA, Llinas M. Sexual development in *Plasmodium* parasites: knowing when it's time to commit. *Nature reviews Microbiology*. 2015;13(9):573-87.

91. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. *PLoS biology*. 2003;1(1):E5.

92. Young JA, Fivelman QL, Blair PL, de la Vega P, Le Roch KG, Zhou Y, et al. The *Plasmodium falciparum* sexual development transcriptome: a microarray analysis using ontology-based pattern identification. *Molecular and biochemical parasitology*. 2005;143(1):67-79.

93. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. *Science (New York, NY)*. 2003;301(5639):1503-8.

94. Lasonder E, Rijpma SR, van Schaijk BC, Hoeijmakers WA, Kensche PR, Gresnigt MS, et al. Integrated transcriptomic and proteomic analyses of *P. falciparum* gametocytes: molecular insight into sex-specific processes and translational repression. *Nucleic acids research*. 2016;44(13):6087-101.
95. Khan SM, Franke-Fayard B, Mair GR, Lasonder E, Janse CJ, Mann M, et al. Proteome analysis of separated male and female gametocytes reveals novel sex-specific *Plasmodium* biology. *Cell*. 2005;121(5):675-87.
96. Yeoh LM, Goodman CD, Mollard V, McFadden GI, Ralph SA. Comparative transcriptomics of female and male gametocytes in *Plasmodium berghei* and the evolution of sex in alveolates. *BMC genomics*. 2017;18(1):734.
97. Poran A, Notzel C, Aly O, Mencia-Trinchant N, Harris CT, Guzman ML, et al. Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. *Nature*. 2017;551(7678):95-9.
98. Bancells C, Llorca-Batlle O, Poran A, Notzel C, Rovira-Graells N, Elemento O, et al. Revisiting the initial steps of sexual development in the malaria parasite *Plasmodium falciparum*. *Nature microbiology*. 2019;4(1):144-54.
99. Carter LM, Kafsack BF, Llinas M, Mideo N, Pollitt LC, Reece SE. Stress and sex in malaria parasites: Why does commitment vary? *Evolution, medicine, and public health*. 2013;2013(1):135-47.
100. Peatey CL, Skinner-Adams TS, Dixon MW, McCarthy JS, Gardiner DL, Trenholme KR. Effect of antimalarial drugs on *Plasmodium falciparum* gametocytes. *The*

- Journal of infectious diseases. 2009;200(10):1518-21.
101. Joice R, Nilsson SK, Montgomery J, Dankwa S, Egan E, Morahan B, et al. Plasmodium falciparum transmission stages accumulate in the human bone marrow. Science translational medicine. 2014;6(244):244re5.
102. Trager W, Gill GS, Lawrence C, Nagel RL. Plasmodium falciparum: enhanced gametocyte formation in vitro in reticulocyte-rich blood. Experimental parasitology. 1999;91(2):115-8.
103. Brancucci NMB, Gerdt JP, Wang C, De Niz M, Philip N, Adapa SR, et al. Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the Human Malaria Parasite Plasmodium falciparum. Cell. 2017;171(7):1532-44 e15.
104. Garcia GE, Wirtz RA, Barr JR, Woolfitt A, Rosenberg R. Xanthurenic acid induces gametogenesis in Plasmodium, the malaria parasite. The Journal of biological chemistry. 1998;273(20):12003-5.
105. Billker O, Shaw MK, Margos G, Sinden RE. The roles of temperature, pH and mosquito factors as triggers of male and female gametogenesis of Plasmodium berghei in vitro. Parasitology. 1997;115 (Pt 1):1-7.
106. Sinden RE, Hartley RH, Winger L. The development of Plasmodium ookinetes in vitro: an ultrastructural study including a description of meiotic division. Parasitology. 1985;91 (Pt 2):227-44.
107. Bennink S, Kiesow MJ, Pradel G. The development of malaria parasites in the mosquito midgut. Cellular microbiology. 2016;18(7):905-18.

108. Marin-Mogollon C, van de Vegte-Bolmer M, van Gemert GJ, van Pul FJA, Ramesar J, Othman AS, et al. The Plasmodium falciparum male gametocyte protein P230p, a paralog of P230, is vital for ookinete formation and mosquito transmission. *Scientific reports*. 2018;8(1):14902.
109. Liu F, Liu Q, Yu C, Zhao Y, Wu Y, Min H, et al. An MFS-Domain Protein Pb115 Plays a Critical Role in Gamete Fertilization of the Malaria Parasite Plasmodium berghei. *Frontiers in microbiology*. 2019;10:2193.
110. Zhu X, Sun L, He Y, Wei H, Hong M, Liu F, et al. Plasmodium berghei serine/threonine protein phosphatase PP5 plays a critical role in male gamete fertility. *International journal for parasitology*. 2019;49(9):685-95.
111. Raibaud A, Brahim K, Roth CW, Brey PT, Faust DM. Differential gene expression in the ookinete stage of the malaria parasite Plasmodium berghei. *Molecular and biochemical parasitology*. 2006;150(1):107-13.
112. Patra KP, Johnson JR, Cantin GT, Yates JR, 3rd, Vinetz JM. Proteomic analysis of zygote and ookinete stages of the avian malaria parasite Plasmodium gallinaceum delineates the homologous proteomes of the lethal human malaria parasite Plasmodium falciparum. *Proteomics*. 2008;8(12):2492-9.
113. Mair GR, Lasonder E, Garver LS, Franke-Fayard BM, Carret CK, Wiegant JC, et al. Universal features of post-transcriptional gene regulation are critical for Plasmodium zygote development. *PLoS pathogens*. 2010;6(2):e1000767.
114. Mair GR, Braks JA, Garver LS, Wiegant JC, Hall N, Dirks RW, et al.

Regulation of sexual development of Plasmodium by translational repression. *Science* (New York, NY). 2006;313(5787):667-9.

115. Ke H, Lewis IA, Morrissey JM, McLean KJ, Ganesan SM, Painter HJ, et al. Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle. *Cell reports*. 2015;11(1):164-74.

116. Srivastava A, Philip N, Hughes KR, Georgiou K, MacRae JI, Barrett MP, et al. Stage-Specific Changes in Plasmodium Metabolism Required for Differentiation and Adaptation to Different Host and Vector Environments. *PLoS pathogens*. 2016;12(12):e1006094.

117. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, et al. A proteomic view of the Plasmodium falciparum life cycle. *Nature*. 2002;419(6906):520-6.

118. Talman AM, Prieto JH, Marques S, Ubaida-Mohien C, Lawniczak M, Wass MN, et al. Proteomic analysis of the Plasmodium male gamete reveals the key role for glycolysis in flagellar motility. *Malaria journal*. 2014;13:315.

119. Hino A, Hirai M, Tanaka TQ, Watanabe Y, Matsuoka H, Kita K. Critical roles of the mitochondrial complex II in oocyst formation of rodent malaria parasite Plasmodium berghei. *Journal of biochemistry*. 2012;152(3):259-68.

120. Sturm A, Mollard V, Cozijnsen A, Goodman CD, McFadden GI. Mitochondrial ATP synthase is dispensable in blood-stage Plasmodium berghei rodent malaria but essential in the mosquito phase. *Proceedings of the National Academy of Sciences of the*

United States of America. 2015;112(33):10216-23.

121. Kawamoto F, Alejo-Blanco R, Fleck SL, Kawamoto Y, Sinden RE. Possible roles of Ca²⁺ and cGMP as mediators of the exflagellation of *Plasmodium berghei* and *Plasmodium falciparum*. *Molecular and biochemical parasitology*. 1990;42(1):101-8.

122. Taylor CJ, McRobert L, Baker DA. Disruption of a *Plasmodium falciparum* cyclic nucleotide phosphodiesterase gene causes aberrant gametogenesis. *Molecular microbiology*. 2008;69(1):110-8.

123. McRobert L, Taylor CJ, Deng W, Fivelman QL, Cummings RM, Polley SD, et al. Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase. *PLoS biology*. 2008;6(6):e139.

124. Bansal A, Molina-Cruz A, Brzostowski J, Liu P, Luo Y, Gunalan K, et al. PfCDPK1 is critical for malaria parasite gametogenesis and mosquito infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115(4):774-9.

125. Sebastian S, Brochet M, Collins MO, Schwach F, Jones ML, Goulding D, et al. A *Plasmodium* calcium-dependent protein kinase controls zygote development and transmission by translationally activating repressed mRNAs. *Cell host & microbe*. 2012;12(1):9-19.

126. Deligianni E, Silmon de Monerri NC, McMillan PJ, Bertuccini L, Superti F, Manola M, et al. Essential role of *Plasmodium* perforin-like protein 4 in ookinete midgut passage. *PloS one*. 2018;13(8):e0201651.

127. Curra C, Kehrer J, Lemgruber L, Silva P, Bertuccini L, Superti F, et al. Malaria transmission through the mosquito requires the function of the OMD protein. *PloS one*. 2019;14(9):e0222226.
128. Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Koning-Ward TF, Sinha R, et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. *The EMBO journal*. 2001;20(15):3975-83.
129. Howick VM, Russell AJC, Andrews T, Heaton H, Reid AJ, Natarajan K, et al. The Malaria Cell Atlas: Single parasite transcriptomes across the complete Plasmodium life cycle. *Science (New York, NY)*. 2019;365(6455).
130. Gissot M, Ting LM, Daly TM, Bergman LW, Sinnis P, Kim K. High mobility group protein HMGB2 is a critical regulator of plasmodium oocyst development. *The Journal of biological chemistry*. 2008;283(25):17030-8.
131. Kim K, Weiss LM. *Toxoplasma gondii*: the model apicomplexan. *International journal for parasitology*. 2004;34(3):423-32.
132. Khan A, Grigg ME. *Toxoplasma gondii*: Laboratory Maintenance and Growth. *Current protocols in microbiology*. 2017;44:20C 1 1-C 1 17.
133. Cerutti A, Blanchard N, Besteiro S. The Bradyzoite: A Key Developmental Stage for the Persistence and Pathogenesis of Toxoplasmosis. *Pathogens*. 2020;9(3):234.
134. Sullivan WJ, Jr., Narasimhan J, Bhatti MM, Wek RC. Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control. *The Biochemical journal*. 2004;380(Pt 2):523-31.

135. Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. *EMBO reports*. 2016;17(10):1374-95.
136. Narasimhan J, Joyce BR, Naguleswaran A, Smith AT, Livingston MR, Dixon SE, et al. Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in *Toxoplasma gondii*. *The Journal of biological chemistry*. 2008;283(24):16591-601.
137. Augusto L, Martynowicz J, Staschke KA, Wek RC, Sullivan WJ, Jr. Effects of PERK eIF2alpha Kinase Inhibitor against *Toxoplasma gondii*. *Antimicrobial agents and chemotherapy*. 2018;62(11).
138. Konrad C, Queener SF, Wek RC, Sullivan WJ, Jr. Inhibitors of eIF2alpha dephosphorylation slow replication and stabilize latency in *Toxoplasma gondii*. *Antimicrobial agents and chemotherapy*. 2013;57(4):1815-22.
139. Konrad C, Wek RC, Sullivan WJ, Jr. A GCN2-like eukaryotic initiation factor 2 kinase increases the viability of extracellular *Toxoplasma gondii* parasites. *Eukaryotic cell*. 2011;10(11):1403-12.
140. Konrad C, Wek RC, Sullivan WJ, Jr. GCN2-like eIF2alpha kinase manages the amino acid starvation response in *Toxoplasma gondii*. *International journal for parasitology*. 2014;44(2):139-46.
141. Nguyen HM, Berry L, Sullivan WJ, Jr., Besteiro S. Autophagy participates in the unfolded protein response in *Toxoplasma gondii*. *FEMS microbiology letters*. 2017;364(15).

142. Joyce BR, Queener SF, Wek RC, Sullivan WJ, Jr. Phosphorylation of eukaryotic initiation factor-2{alpha} promotes the extracellular survival of obligate intracellular parasite *Toxoplasma gondii*. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(40):17200-5.
143. Kedersha N, Chen S, Gilks N, Li W, Miller IJ, Stahl J, et al. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. *Molecular biology of the cell*. 2002;13(1):195-210.
144. Teng Y, Gao M, Wang J, Kong Q, Hua H, Luo T, et al. Inhibition of eIF2alpha dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. *Cell death & disease*. 2014;5(2):e1060.
145. Legrand N, Jaquier-Gubler P, Curran J. The impact of the phosphomimetic eIF2alphaS/D on global translation, reinitiation and the integrated stress response is attenuated in N2a cells. *Nucleic acids research*. 2015;43(17):8392-404.
146. Hendrick HM, Welter BH, Hapstack MA, Sykes SE, Sullivan WJ, Jr., Temesvari LA. Phosphorylation of Eukaryotic Initiation Factor-2alpha during Stress and Encystation in *Entamoeba* Species. *PLoS pathogens*. 2016;12(12):e1006085.
147. Tomavo S, Boothroyd JC. Interconnection between organellar functions, development and drug resistance in the protozoan parasite, *Toxoplasma gondii*. *International journal for parasitology*. 1995;25(11):1293-9.
148. Bohne W, Heesemann J, Gross U. Reduced replication of *Toxoplasma gondii* is

necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion. *Infection and immunity*. 1994;62(5):1761-7.

149. Denton H, Roberts CW, Alexander J, Thong KW, Coombs GH. Enzymes of energy metabolism in the bradyzoites and tachyzoites of *Toxoplasma gondii*. *FEMS microbiology letters*. 1996;137(1):103-8.

150. Shukla A, Olszewski KL, Llinas M, Rommereim LM, Fox BA, Bzik DJ, et al. Glycolysis is important for optimal asexual growth and formation of mature tissue cysts by *Toxoplasma gondii*. *International journal for parasitology*. 2018;48(12):955-68.

151. Radke JR, Donald RG, Eibs A, Jerome ME, Behnke MS, Liberator P, et al. Changes in the expression of human cell division autoantigen-1 influence *Toxoplasma gondii* growth and development. *PLoS pathogens*. 2006;2(10):e105.

152. Nare B, Allocco JJ, Liberator PA, Donald RG. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. *Antimicrobial agents and chemotherapy*. 2002;46(2):300-7.

153. Donald RG, Allocco J, Singh SB, Nare B, Salowe SP, Wiltsie J, et al. *Toxoplasma gondii* cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase. *Eukaryotic cell*. 2002;1(3):317-28.

154. Toh BH, Tu Y, Cao Z, Cooper ME, Chai Z. Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis. *Genes*. 2010;1(3):335-48.

155. Swierzy IJ, Handel U, Kaeffer A, Jarek M, Scharfe M, Schluter D, et al.

- Divergent co-transcriptomes of different host cells infected with *Toxoplasma gondii* reveal cell type-specific host-parasite interactions. *Scientific reports*. 2017;7(1):7229.
156. Luder CG, Giraldo-Velasquez M, Sendtner M, Gross U. *Toxoplasma gondii* in primary rat CNS cells: differential contribution of neurons, astrocytes, and microglial cells for the intracerebral development and stage differentiation. *Experimental parasitology*. 1999;93(1):23-32.
157. Holmes MJ, Shah P, Wek RC, Sullivan WJ, Jr. Simultaneous Ribosome Profiling of Human Host Cells Infected with *Toxoplasma gondii*. *mSphere*. 2019;4(3).
158. Manger ID, Hehl A, Parmley S, Sibley LD, Marra M, Hillier L, et al. Expressed sequence tag analysis of the bradyzoite stage of *Toxoplasma gondii*: identification of developmentally regulated genes. *Infection and immunity*. 1998;66(4):1632-7.
159. Bohne W, Gross U, Ferguson DJ, Heesemann J. Cloning and characterization of a bradyzoite-specifically expressed gene (*hsp30/bag1*) of *Toxoplasma gondii*, related to genes encoding small heat-shock proteins of plants. *Molecular microbiology*. 1995;16(6):1221-30.
160. Parmley SF, Yang S, Harth G, Sibley LD, Sucharczuk A, Remington JS. Molecular characterization of a 65-kilodalton *Toxoplasma gondii* antigen expressed abundantly in the matrix of tissue cysts. *Molecular and biochemical parasitology*. 1994;66(2):283-96.
161. Burg JL, Perelman D, Kasper LH, Ware PL, Boothroyd JC. Molecular analysis of the gene encoding the major surface antigen of *Toxoplasma gondii*. *Journal of*

immunology (Baltimore, Md : 1950). 1988;141(10):3584-91.

162. Friesen J, Fleige T, Gross U, Bohne W. Identification of novel bradyzoite-specific *Toxoplasma gondii* genes with domains for protein-protein interactions by suppression subtractive hybridization. *Molecular and biochemical parasitology*. 2008;157(2):228-32.

163. Cleary MD, Singh U, Blader IJ, Brewer JL, Boothroyd JC. *Toxoplasma gondii* asexual development: identification of developmentally regulated genes and distinct patterns of gene expression. *Eukaryotic cell*. 2002;1(3):329-40.

164. Matrajt M, Donald RG, Singh U, Roos DS. Identification and characterization of differentiation mutants in the protozoan parasite *Toxoplasma gondii*. *Molecular microbiology*. 2002;44(3):735-47.

165. Singh U, Brewer JL, Boothroyd JC. Genetic analysis of tachyzoite to bradyzoite differentiation mutants in *Toxoplasma gondii* reveals a hierarchy of gene induction. *Molecular microbiology*. 2002;44(3):721-33.

166. Lescault PJ, Thompson AB, Patil V, Lirussi D, Burton A, Margarit J, et al. Genomic data reveal *Toxoplasma gondii* differentiation mutants are also impaired with respect to switching into a novel extracellular tachyzoite state. *PloS one*. 2010;5(12):e14463.

167. Buchholz KR, Fritz HM, Chen X, Durbin-Johnson B, Rocke DM, Ferguson DJ, et al. Identification of tissue cyst wall components by transcriptome analysis of in vivo and in vitro *Toxoplasma gondii* bradyzoites. *Eukaryotic cell*. 2011;10(12):1637-47.

168. Patil V, Lescault PJ, Lirussi D, Thompson AB, Matrajt M. Disruption of the expression of a non-coding RNA significantly impairs cellular differentiation in *Toxoplasma gondii*. *International journal of molecular sciences*. 2012;14(1):611-24.
169. Croken MM, Qiu W, White MW, Kim K. Gene Set Enrichment Analysis (GSEA) of *Toxoplasma gondii* expression datasets links cell cycle progression and the bradyzoite developmental program. *BMC genomics*. 2014;15:515.
170. Doskaya M, Liang L, Jain A, Can H, Gulce Iz S, Felgner PL, et al. Discovery of new *Toxoplasma gondii* antigenic proteins using a high throughput protein microarray approach screening sera of murine model infected orally with oocysts and tissue cysts. *Parasites & vectors*. 2018;11(1):393.
171. Naguleswaran A, Elias EV, McClintick J, Edenberg HJ, Sullivan WJ, Jr. *Toxoplasma gondii* lysine acetyltransferase GCN5-A functions in the cellular response to alkaline stress and expression of cyst genes. *PLoS pathogens*. 2010;6(12):e1001232.
172. Xue Y, Theisen TC, Rastogi S, Ferrel A, Quake SR, Boothroyd JC. A single-parasite transcriptional atlas of *Toxoplasma gondii* reveals novel control of antigen expression. *eLife*. 2020;9.
173. Garfoot AL, Wilson GM, Coon JJ, Knoll LJ. Proteomic and transcriptomic analyses of early and late-chronic *Toxoplasma gondii* infection shows novel and stage specific transcripts. *BMC genomics*. 2019;20(1):859.
174. Chen LF, Han XL, Li FX, Yao YY, Fang JP, Liu XJ, et al. Comparative studies of *Toxoplasma gondii* transcriptomes: insights into stage conversion based on gene

- expression profiling and alternative splicing. *Parasites & vectors*. 2018;11(1):402.
175. Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, et al. The *Toxoplasma gondii* cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. *PLoS pathogens*. 2013;9(12):e1003823.
176. Waldman BS, Schwarz D, Wadsworth MH, 2nd, Saeij JP, Shalek AK, Lourido S. Identification of a Master Regulator of Differentiation in *Toxoplasma*. *Cell*. 2020;180(2):359-72 e16.
177. Tu V, Mayoral J, Sugi T, Tomita T, Han B, Ma YF, et al. Enrichment and Proteomic Characterization of the Cyst Wall from In Vitro *Toxoplasma gondii* Cysts. *mBio*. 2019;10(2).
178. Watts E, Zhao Y, Dhara A, Eller B, Patwardhan A, Sinai AP. Novel Approaches Reveal that *Toxoplasma gondii* Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In Vivo. *mBio*. 2015;6(5):e01155-15.
179. Dzierszinski F, Nishi M, Ouko L, Roos DS. Dynamics of *Toxoplasma gondii* differentiation. *Eukaryotic cell*. 2004;3(4):992-1003.
180. Yang S, Parmley SF. *Toxoplasma gondii* expresses two distinct lactate dehydrogenase homologous genes during its life cycle in intermediate hosts. *Gene*. 1997;184(1):1-12.
181. Dzierszinski F, Mortuaire M, Dendouga N, Popescu O, Tomavo S. Differential expression of two plant-like enolases with distinct enzymatic and antigenic properties during stage conversion of the protozoan parasite *Toxoplasma gondii*. *Journal of*

molecular biology. 2001;309(5):1017-27.

182. Behnke MS, Wootton JC, Lehmann MM, Radke JB, Lucas O, Nawas J, et al. Coordinated progression through two subtranscriptomes underlies the tachyzoite cycle of *Toxoplasma gondii*. *PloS one*. 2010;5(8):e12354.

183. Radke JR, Guerini MN, Jerome M, White MW. A change in the premitotic period of the cell cycle is associated with bradyzoite differentiation in *Toxoplasma gondii*. *Molecular and biochemical parasitology*. 2003;131(2):119-27.

184. Bougdour A, Maubon D, Baldacci P, Ortet P, Bastien O, Bouillon A, et al. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. *The Journal of experimental medicine*. 2009;206(4):953-66.

185. Harris MT, Jeffers V, Martynowicz J, True JD, Mosley AL, Sullivan WJ, Jr. A novel GCN5b lysine acetyltransferase complex associates with distinct transcription factors in the protozoan parasite *Toxoplasma gondii*. *Molecular and biochemical parasitology*. 2019;232:111203.

186. Liu M, Li FX, Li CY, Li XC, Chen LF, Wu K, et al. Characterization of protein arginine methyltransferase of TgPRMT5 in *Toxoplasma gondii*. *Parasites & vectors*. 2019;12(1):221.

187. Radke JB, Worth D, Hong D, Huang S, Sullivan WJ, Jr., Wilson EH, et al. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. *PLoS pathogens*. 2018;14(5):e1007035.

188. Huang S, Holmes MJ, Radke JB, Hong DP, Liu TK, White MW, et al.

- Toxoplasma gondii AP2IX-4 Regulates Gene Expression during Bradyzoite Development. *mSphere*. 2017;2(2).
189. Hong DP, Radke JB, White MW. Opposing Transcriptional Mechanisms Regulate Toxoplasma Development. *mSphere*. 2017;2(1).
190. Walker R, Gissot M, Croken MM, Huot L, Hot D, Kim K, et al. The Toxoplasma nuclear factor TgAP2XI-4 controls bradyzoite gene expression and cyst formation. *Molecular microbiology*. 2013;87(3):641-55.
191. Radke JB, Lucas O, De Silva EK, Ma Y, Sullivan WJ, Jr., Weiss LM, et al. ApiAP2 transcription factor restricts development of the Toxoplasma tissue cyst. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(17):6871-6.
192. Bohne W, Heesemann J, Gross U. Coexistence of heterogeneous populations of Toxoplasma gondii parasites within parasitophorous vacuoles of murine macrophages as revealed by a bradyzoite-specific monoclonal antibody. *Parasitology research*. 1993;79(6):485-7.
193. Soete M, Fortier B, Camus D, Dubremetz JF. Toxoplasma gondii: kinetics of bradyzoite-tachyzoite interconversion in vitro. *Experimental parasitology*. 1993;76(3):259-64.
194. Sidik SM, Huet D, Ganesan SM, Huynh MH, Wang T, Nasamu AS, et al. A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. *Cell*. 2016;166(6):1423-35 e12.

195. Sullivan WJ, Jr. Mastering *Toxoplasma* sex and sleep. *Nature microbiology*. 2020;5(4):533-4.
196. Ramakrishnan C, Walker RA, Eichenberger RM, Hehl AB, Smith NC. The merozoite-specific protein, TgGRA11B, identified as a component of the *Toxoplasma gondii* parasitophorous vacuole in a tachyzoite expression model. *International journal for parasitology*. 2017;47(10-11):597-600.
197. Ferguson DJ. Use of molecular and ultrastructural markers to evaluate stage conversion of *Toxoplasma gondii* in both the intermediate and definitive host. *International journal for parasitology*. 2004;34(3):347-60.
198. Fritz HM, Buchholz KR, Chen X, Durbin-Johnson B, Rocke DM, Conrad PA, et al. Transcriptomic analysis of *Toxoplasma* development reveals many novel functions and structures specific to sporozoites and oocysts. *PloS one*. 2012;7(2):e29998.
199. Behnke MS, Zhang TP, Dubey JP, Sibley LD. *Toxoplasma gondii* merozoite gene expression analysis with comparison to the life cycle discloses a unique expression state during enteric development. *BMC genomics*. 2014;15:350.
200. Hehl AB, Basso WU, Lippuner C, Ramakrishnan C, Okoniewski M, Walker RA, et al. Asexual expansion of *Toxoplasma gondii* merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. *BMC genomics*. 2015;16:66.
201. Farhat DC, Swale C, Dard C, Cannella D, Ortet P, Barakat M, et al. A MORC-driven transcriptional switch controls *Toxoplasma* developmental trajectories and sexual

- commitment. *Nature microbiology*. 2020;5(4):570-83.
202. Martorelli Di Genova B, Wilson SK, Dubey JP, Knoll LJ. Intestinal delta-6-desaturase activity determines host range for *Toxoplasma* sexual reproduction. *PLoS biology*. 2019;17(8):e3000364.
203. English ED, Striepen B. The cat is out of the bag: How parasites know their hosts. *PLoS biology*. 2019;17(9):e3000446.
204. Leitch GJ, He Q. Cryptosporidiosis-an overview. *Journal of biomedical research*. 2012;25(1):1-16.
205. Sateriale A, Slapeta J, Baptista R, Engiles JB, Gullicksrud JA, Herbert GT, et al. A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity. *Cell host & microbe*. 2019;26(1):135-46 e5.
206. Carreno RA, Martin DS, Barta JR. Cryptosporidium is more closely related to the gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences. *Parasitology research*. 1999;85(11):899-904.
207. Elliott DA, Clark DP. Cryptosporidium parvum induces host cell actin accumulation at the host-parasite interface. *Infection and immunity*. 2000;68(4):2315-22.
208. Borowski H, Thompson RC, Armstrong T, Clode PL. Morphological characterization of *Cryptosporidium parvum* life-cycle stages in an in vitro model system. *Parasitology*. 2010;137(1):13-26.
209. Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, et al. A

- suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. *Nature communications*. 2019;10(1):1862.
210. Vetterling JM, Takeuchi A, Madden PA. Ultrastructure of *Cryptosporidium wrairi* from the guinea pig. *The Journal of protozoology*. 1971;18(2):248-60.
211. Arrowood MJ. In vitro cultivation of cryptosporidium species. *Clinical microbiology reviews*. 2002;15(3):390-400.
212. Tandel J, English ED, Sateriale A, Gullicksrud JA, Beiting DP, Sullivan MC, et al. Life cycle progression and sexual development of the apicomplexan parasite *Cryptosporidium parvum*. *Nature microbiology*. 2019;4(12):2226-36.
213. Lippuner C, Ramakrishnan C, Basso WU, Schmid MW, Okoniewski M, Smith NC, et al. RNA-Seq analysis during the life cycle of *Cryptosporidium parvum* reveals significant differential gene expression between proliferating stages in the intestine and infectious sporozoites. *International journal for parasitology*. 2018;48(6):413-22.
214. Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, et al. A Stem-Cell-Derived Platform Enables Complete *Cryptosporidium* Development In Vitro and Genetic Tractability. *Cell host & microbe*. 2019;26(1):123-34 e8.
215. Mauzy MJ, Enomoto S, Lancto CA, Abrahamsen MS, Rutherford MS. The *Cryptosporidium parvum* transcriptome during in vitro development. *PloS one*. 2012;7(3):e31715.
216. Matos LVS, McEvoy J, Tzipori S, Bresciani KDS, Widmer G. The transcriptome of *Cryptosporidium* oocysts and intracellular stages. *Scientific reports*.

2019;9(1):7856.

217. Zhang H, Guo F, Zhou H, Zhu G. Transcriptome analysis reveals unique metabolic features in the *Cryptosporidium parvum* Oocysts associated with environmental survival and stresses. *BMC genomics*. 2012;13:647.

218. Oberstaller J, Joseph SJ, Kissinger JC. Genome-wide upstream motif analysis of *Cryptosporidium parvum* genes clustered by expression profile. *BMC genomics*. 2013;14:516.

219. Oberstaller J, Pumpalova Y, Schieler A, Llinas M, Kissinger JC. The *Cryptosporidium parvum* ApiAP2 gene family: insights into the evolution of apicomplexan AP2 regulatory systems. *Nucleic acids research*. 2014;42(13):8271-84.

220. Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, et al. Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature*. 2015;523(7561):477-80.

221. Wilke G, Ravindran S, Funkhouser-Jones L, Barks J, Wang Q, VanDussen KL, et al. Monoclonal Antibodies to Intracellular Stages of *Cryptosporidium parvum* Define Life Cycle Progression In Vitro. *mSphere*. 2018;3(3).

222. DeCicco RePass MA, Chen Y, Lin Y, Zhou W, Kaplan DL, Ward HD. Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of *Cryptosporidium parvum*. *Infection and immunity*. 2017;85(3).

223. Dutta D, Heo I, O'Connor R. Studying *Cryptosporidium* Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection. *Journal of visualized*

experiments : JoVE. 2019(151).

224. Heo I, Dutta D, Schaefer DA, Iakobachvili N, Artegiani B, Sachs N, et al. Modelling Cryptosporidium infection in human small intestinal and lung organoids. *Nature microbiology*. 2018;3(7):814-23.
225. Josse L, Bones AJ, Purton T, Michaelis M, Tsaousis AD. A Cell Culture Platform for the Cultivation of *Cryptosporidium parvum*. *Current protocols in microbiology*. 2019;53(1):e80.
226. Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, et al. Continuous culture of *Cryptosporidium parvum* using hollow fiber technology. *International journal for parasitology*. 2016;46(1):21-9.
227. Cowper B, Matthews S, Tomley F. The molecular basis for the distinct host and tissue tropisms of coccidian parasites. *Molecular and biochemical parasitology*. 2012;186(1):1-10.
228. Burrell A, Tomley FM, Vaughan S, Marugan-Hernandez V. Life cycle stages, specific organelles and invasion mechanisms of *Eimeria* species. *Parasitology*. 2020;147(3):263-78.
229. Dubey JP, Jenkins MC. Re-evaluation of the life cycle of *Eimeria maxima* Tyzzer, 1929 in chickens (*Gallus domesticus*). *Parasitology*. 2018;145(8):1051-8.
230. Chapman HD, Jeffers TK, Williams RB. Forty years of monensin for the control of coccidiosis in poultry. *Poultry science*. 2010;89(9):1788-801.
231. McDonald V, Rose ME. *Eimeria tenella* and *E. necatrix*: a third generation of

schizogony is an obligatory part of the developmental cycle. *The Journal of parasitology*. 1987;73(3):617-22.

232. Su S, Hou Z, Wang L, Liu D, Hu J, Xu J, et al. Further confirmation of second- and third-generation *Eimeria necatrix* merozoite DEGs using suppression subtractive hybridization. *Parasitology research*. 2019;118(4):1159-69.

233. Su S, Hou Z, Liu D, Jia C, Wang L, Xu J, et al. Comparative transcriptome analysis of second- and third-generation merozoites of *Eimeria necatrix*. *Parasites & vectors*. 2017;10(1):388.

234. Hu D, Wang C, Wang S, Tang X, Duan C, Zhang S, et al. Comparative transcriptome analysis of *Eimeria maxima* (Apicomplexa: Eimeriidae) suggests DNA replication activities correlating with its fecundity. *BMC genomics*. 2018;19(1):699.

235. Montes C, Rojo F, Hidalgo R, Ferre I, Badiola C. Selection and development of a Spanish precocious strain of *Eimeria necatrix*. *Veterinary parasitology*. 1998;78(3):169-83.

236. Shirley MW, McDonald V, Bellatti MA. *Eimeria brunetti*: selection and characteristics of a precocious (and attenuated) line. *Avian pathology : journal of the WVPA*. 1986;15(4):705-17.

237. Shirley MW, McDonald V, Chapman HD, Millard BJ. *Eimeria praecox*: selection and characteristics of precocious lines. *Avian pathology : journal of the WVPA*. 1984;13(4):669-82.

238. McDougald LR, Jeffers TK. *Eimeria tenella* (Sporozoa, Coccidia): Gametogony

- following a single asexual generation. *Science* (New York, NY). 1976;192(4236):258-9.
239. Shirley MW, Harvey DA. A genetic linkage map of the apicomplexan protozoan parasite *Eimeria tenella*. *Genome research*. 2000;10(10):1587-93.
240. Klimes B, Rootes DG, Tanielian Z. Sexual differentiation of merozoites of *Eimeria tenella*. *Parasitology*. 1972;65(1):131-6.
241. Han HY, Lin JJ, Zhao QP, Dong H, Jiang LL, Xu MQ, et al. Identification of differentially expressed genes in early stages of *Eimeria tenella* by suppression subtractive hybridization and cDNA microarray. *The Journal of parasitology*. 2010;96(1):95-102.
242. Lal K, Bromley E, Oakes R, Prieto JH, Sanderson SJ, Kurian D, et al. Proteomic comparison of four *Eimeria tenella* life-cycle stages: unsporulated oocyst, sporulated oocyst, sporozoite and second-generation merozoite. *Proteomics*. 2009;9(19):4566-76.
243. Han HY, Lin JJ, Zhao QP, Dong H, Jiang LL, Wang X, et al. [Construction of subtractive cDNA libraries of the sporogony stage of *Eimeria tenella* by suppression subtractive hybridization]. *Sheng wu gong cheng xue bao = Chinese journal of biotechnology*. 2007;23(6):1005-10.
244. Katrib M, Ikin RJ, Brossier F, Robinson M, Slapetova I, Sharman PA, et al. Stage-specific expression of protease genes in the apicomplexan parasite, *Eimeria tenella*. *BMC genomics*. 2012;13:685.
245. Walker RA, Slapetova I, Slapeta J, Miller CM, Smith NC. The glycosylation pathway of *Eimeria tenella* is upregulated during gametocyte development and may play

- a role in oocyst wall formation. *Eukaryotic cell*. 2010;9(1):127-35.
246. Hu D, Tang X, Ben Mamoun C, Wang C, Wang S, Gu X, et al. Efficient Single-Gene and Gene Family Editing in the Apicomplexan Parasite *Eimeria tenella* Using CRISPR-Cas9. *Frontiers in bioengineering and biotechnology*. 2020;8:128.
247. Votýpka J. *Piroplasmorida* Wenyon 1926. Version 18 May 2011 2011
[Available from: <http://tolweb.org/Piroplasmorida/68060>].
248. Jalovecka M, Hajdusek O, Sojka D, Kopacek P, Malandrin L. The Complexity of Piroplasms Life Cycles. *Frontiers in cellular and infection microbiology*. 2018;8:248.
249. Mans BJ, Pienaar R, Latif AA. A review of *Theileria* diagnostics and epidemiology. *International journal for parasitology Parasites and wildlife*. 2015;4(1):104-18.
250. Shaw MK, Tilney LG. How individual cells develop from a syncytium: merogony in *Theileria parva* (Apicomplexa). *Journal of cell science*. 1992;101 (Pt 1):109-23.
251. Cheeseman KM, Weitzman JB. [What makes a parasite "transforming"? Insights into cancer from the agents of an exotic pathology, *Theileria* spp]. *Bulletin de la Societe de pathologie exotique (1990)*. 2017;110(1):55-60.
252. Shiels B, Kinnaird J, McKellar S, Dickson J, Miled LB, Melrose R, et al. Disruption of synchrony between parasite growth and host cell division is a determinant of differentiation to the merozoite in *Theileria annulata*. *Journal of cell science*. 1992;101 (Pt 1):99-107.

253. Shiels B, Aslam N, McKellar S, Smyth A, Kinnaird J. Modulation of protein synthesis relative to DNA synthesis alters the timing of differentiation in the protozoan parasite *Theileria annulata*. *Journal of cell science*. 1997;110 (Pt 13):1441-51.
254. Shiels B, Fox M, McKellar S, Kinnaird J, Swan D. An upstream element of the *TamS1* gene is a site of DNA-protein interactions during differentiation to the merozoite in *Theileria annulata*. *Journal of cell science*. 2000;113 (Pt 12):2243-52.
255. Swan DG, Phillips K, McKellar S, Hamilton C, Shiels BR. Temporal co-ordination of macroschizont and merozoite gene expression during stage differentiation of *Theileria annulata*. *Molecular and biochemical parasitology*. 2001;113(2):233-9.
256. Bishop R, Shah T, Pelle R, Hoyle D, Pearson T, Haines L, et al. Analysis of the transcriptome of the protozoan *Theileria parva* using MPSS reveals that the majority of genes are transcriptionally active in the schizont stage. *Nucleic acids research*. 2005;33(17):5503-11.
257. Nyagwange J, Tijhaar E, Ternette N, Mobegi F, Tretina K, Silva JC, et al. Characterization of the *Theileria parva* sporozoite proteome. *International journal for parasitology*. 2018;48(3-4):265-73.
258. Tonui T, Corredor-Moreno P, Kanduma E, Njuguna J, Njahira MN, Nyanjom SG, et al. Transcriptomics reveal potential vaccine antigens and a drastic increase of upregulated genes during *Theileria parva* development from arthropod to bovine infective stages. *PloS one*. 2018;13(10):e0204047.
259. Pieszko M, Weir W, Goodhead I, Kinnaird J, Shiels B. *ApiAP2* Factors as

Candidate Regulators of Stochastic Commitment to Merozoite Production in *Theileria annulata*. *PLoS neglected tropical diseases*. 2015;9(8):e0003933.

260. Alzan HF, Knowles DP, Suarez CE. Comparative Bioinformatics Analysis of Transcription Factor Genes Indicates Conservation of Key Regulatory Domains among *Babesia bovis*, *Babesia microti*, and *Theileria equi*. *PLoS neglected tropical diseases*. 2016;10(11):e0004983.

261. Suarez CE, Bishop RP, Alzan HF, Poole WA, Cooke BM. Advances in the application of genetic manipulation methods to apicomplexan parasites. *International journal for parasitology*. 2017;47(12):701-10.

262. Schuster FL. Cultivation of *Babesia* and *Babesia*-like blood parasites: agents of an emerging zoonotic disease. *Clinical microbiology reviews*. 2002;15(3):365-73.

263. Gough JM, Jorgensen WK, Kemp DH. Development of tick gut forms of *Babesia bigemina* in vitro. *The Journal of eukaryotic microbiology*. 1998;45(3):298-306.

264. Mosqueda J, Falcon A, Antonio Alvarez J, Alberto Ramos J, Oropeza-Hernandez LF, Figueroa JV. *Babesia bigemina* sexual stages are induced in vitro and are specifically recognized by antibodies in the midgut of infected *Boophilus microplus* ticks. *International journal for parasitology*. 2004;34(11):1229-36.

265. Nguyen TT, Dang-Trinh MA, Higuchi L, Mosqueda J, Hakimi H, Asada M, et al. Initiated *Babesia ovata* Sexual Stages under In Vitro Conditions Were Recognized by Anti-CCp2 Antibodies, Showing Changes in the DNA Content by Imaging Flow Cytometry. *Pathogens*. 2019;8(3).

266. Jalovecka M, Bonsergent C, Hajdusek O, Kopacek P, Malandrin L. Stimulation and quantification of *Babesia divergens* gametocytogenesis. *Parasites & vectors*. 2016;9(1):439.
267. Becker CA, Malandrin L, Depoix D, Larcher T, David PH, Chauvin A, et al. Identification of three CCp genes in *Babesia divergens*: novel markers for sexual stages parasites. *Molecular and biochemical parasitology*. 2010;174(1):36-43.
268. Bohaliga GAR, Johnson WC, Taus NS, Hussein HE, Bastos RG, Suarez CE, et al. Identification of a putative methyltransferase gene of *Babesia bigemina* as a novel molecular biomarker uniquely expressed in parasite tick stages. *Parasites & vectors*. 2018;11(1):480.
269. Wong JL, Johnson MA. Is HAP2-GCS1 an ancestral gamete fusogen? *Trends in cell biology*. 2010;20(3):134-41.
270. Camacho-Nuez M, Hernandez-Silva DJ, Castaneda-Ortiz EJ, Paredes-Martinez ME, Rocha-Martinez MK, Alvarez-Sanchez ME, et al. Hap2, a novel gene in *Babesia bigemina* is expressed in tick stages, and specific antibodies block zygote formation. *Parasites & vectors*. 2017;10(1):568.
271. Hussein HE, Bastos RG, Schneider DA, Johnson WC, Adham FK, Davis WC, et al. The *Babesia bovis* hap2 gene is not required for blood stage replication, but expressed upon in vitro sexual stage induction. *PLoS neglected tropical diseases*. 2017;11(10):e0005965.
272. Johnson WC, Taus NS, Reif KE, Bohaliga GA, Kappmeyer LS, Ueti MW.

Analysis of Stage-Specific Protein Expression during Babesia Bovis Development within Female Rhipicephalus Microplus. *Journal of proteome research*. 2017;16(3):1327-38.

273. Xu B, Liu XF, Cai YC, Huang JL, Zhang RX, Chen JH, et al. Screening for biomarkers reflecting the progression of Babesia microti infection. *Parasites & vectors*. 2018;11(1):379.

274. Bohaliga GAR, Johnson WC, Taus NS, Hussein HE, Bastos RG, Suarez CE, et al. Identification of proteins expressed by Babesia bigemina kinetes. *Parasites & vectors*. 2019;12(1):271.

275. Suarez CE, McElwain TF. Stable expression of a GFP-BSD fusion protein in Babesia bovis merozoites. *International journal for parasitology*. 2009;39(3):289-97.

CHAPTER 2: A CHEMICAL GENETICS APPROACH TO UNDERSTAND THE REGULATION OF CRYPTOSPORIDIUM SEXUAL DIFFERENTIATION

2.1: Abstract

Cryptosporidium is an intracellular protozoan parasite that is a leading cause of childhood diarrhea in Africa and Southeast Asia. It is a member of eukaryotic phylum Apicomplexa, a group of intracellular parasites that replicate both sexually and asexually in the course of their life cycle. Sexual differentiation of *C. parvum* is required for host to host transmission of the parasite as well as for autoinfection of the same host. In this study, we have optimized and utilized an in vitro high content imaging assay to test compounds for activity against the sexual and asexual stages of the parasite separately. The tested compounds comprise the ReFRAME library, a drug repurposing library composed of ~12,000 compounds for which extensive prior knowledge exists including their putative targets and modes of action. Inhibitors of the host cell's electron transport chain and purine nucleotide biosynthesis disproportionately affected the sexual differentiation of *C. parvum*. To identify the stage specific genes and pathways as well as the potential key regulators of the sexual differentiation process, we used RNA-seq following treatments with nine differentiation inhibitor and found that a number of parasite genes were dysregulated with multiple compound treatments. Ribosomal protein genes were upregulated with differentiation inhibitor treatments, which suggests that global repression of protein

translation is associated with *C. parvum* sexual differentiation. Analysis of publicly available RNA-seq datasets of *C. parvum* and other apicomplexan parasites indicates that this is a common mode of regulating apicomplexan stage differentiation. Our data also implicate several apicomplexan AP2 transcription factors as key regulators of *C. parvum* sexual differentiation.

2.2: Introduction

Cryptosporidium species are one of the most significant etiologic agents of childhood diarrhea in developing countries (1). There is an urgent need to develop novel therapeutics, as current treatment options are inadequate for treating malnourished children and immunodeficient patients, the two populations most vulnerable to cryptosporidiosis (2). The parasite is a member of the eukaryotic phylum Apicomplexa, which is comprised of intracellular protozoan parasites. Malaria and toxoplasmosis are two other major human diseases caused by apicomplexan parasites.

Cryptosporidium transmits through the fecal-oral route in the form of environmentally resistant oocysts. In the mammalian gut, the oocysts excyst to release sporozoites that infect the intestinal epithelial cells (IECs). Initially, it replicates asexually where intracellular trophozoites develop into type I meronts that release up to 8 merozoites that can repeat this asexual cycle. After several rounds of asexual replication, parasites differentiate into type II meronts (containing 4 merozoites instead of 8), and merozoites from type II meronts differentiate into gamonts upon infecting

IECs. Gamonts are of two types: uninucleated macrogamonts (i.e. female gamonts), and multinucleated microgamonts (i.e. male gamonts). Male gamonts fertilize female gamonts by infecting a macrogamont-harboring IEC. Meiotic cell division in the fertilized gamont produces 4 sporozoites that are subsequently enclosed by an oocyst wall and released from the host cell. Oocysts either excyst within the same host to cause autoinfection or are released into the environment with feces (3).

In the laboratory setting, oocysts can be excysted by treating with sodium taurocholate, and the sporozoites can infect numerous cell lines (4, 5). A widely used in vitro model of *Cryptosporidium* infection involves infecting the human colorectal carcinoma cell line HCT8 with the human pathogen *C. parvum*. In this system, after initial asexual replication, the gamonts start to emerge at 36 hours post-infection (hpi) and they are the predominant parasitic form at 72 hpi (6-8). However, fertilization does not take place within this system, and parasite replication therefore halts after sexual differentiation (7). Parasitophorous vacuoles of all life cycle stages of *C. parvum* can be stained with *Vicia villosa* lectin (VVL). Previously, we have also reported a marker protein for female gamonts, DNA meiotic recombinase 1 (DMC1), that can be visualized by immunostaining (6). As both male and female gamonts emerge within a similar temporal window post-infection, we used DMC1 expression as a surrogate for *C. parvum* sexual differentiation and developed an assay to test the activity of drug-like small molecules against sexual stages of the parasite. Several anticryptosporidial compounds, initially identified by screening using *Vicia villosa* lectin staining, showed

a diverse range of activity against the sexual stage of the parasite (6).

Like *C. parvum*, all the apicomplexan parasites cyclically differentiate into distinct forms in the course of their complete life cycle. Each of the stages has its own signature global gene expression pattern (7, 9-12). Molecular understanding of stage differentiation could provide an opportunity to develop novel control strategies against human pathogens. *Plasmodium* species, the causative agents of malaria, first replicate in hepatocytes upon infecting humans, then differentiate to infect red blood cells, and finally differentiate into gametocytes that are taken up by mosquito vectors where sexual reproduction takes place. Transmission blocking strategies for malaria therefore include inhibiting sexual differentiation of *Plasmodium*, whereas inhibiting the liver stage development or its differentiation into the blood-stage would be useful strategies for malaria prophylaxis (13, 14). Fast replicating *Toxoplasma gondii* tachyzoites differentiate into slowly replicating bradyzoites and form tissue cysts in response to immune activation in mammalian hosts that can be reactivated upon immune suppression. Intervening with this reversible differentiation could lead to better management of toxoplasmosis (15). *C. parvum* is different from *Plasmodium* and *Toxoplasma* in the sense that it can complete its whole life cycle within a single mammalian host where its sexual differentiation is believed to be an obligatory step (as opposed to the facultative gametocytogenesis observed for *P. falciparum* where only a small subset of total parasites actually differentiate into gametocytes). Therefore, inhibiting *Cryptosporidium* sexual differentiation may be a good therapeutic strategy

(8).

Apicomplexan stage differentiation has been studied with several complementary experimental approaches. Comparative “-omics” analyses between life cycle stages are useful in identifying stage-specific genes and pathways (16-19). Genetic manipulations, either through forward genetic screens or through targeted manipulation of key regulators of differentiation, have also been used to study the regulation of apicomplexan life cycle progression (20-24). Finally, chemical biology approaches have identified numerous tool compounds to study specific aspects of apicomplexan biology (25).

In this study, we have used a chemical genetics approach in combination with mRNA-seq to better understand the regulation of *C. parvum* sexual differentiation. We optimized a high content microscopy screening assay based on DMC1 expression, and screened the ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem) chemical library (26) in order to identify compounds that affect *C. parvum* sexual differentiation. The ReFRAME library is a library of ~12,000 compounds with high potential for drug repurposing, and, since the mechanism of action of many ReFRAME library compounds is known, we reasoned that this approach would enable us to gain mechanistic insights into *C. parvum* sexual differentiation. We then followed screening hit confirmation with mRNA-seq experiments in the presence or absence of selected differentiation inhibitors. Our results indicate that transcriptional repression of proteins involved in ribosome biogenesis is necessary for *C. parvum* sexual differentiation.

2.3: Results

2.3.1: Optimizing the Identification of Sexually Differentiated *C. parvum*

Immunostaining DMC1 protein was used to identify sexually differentiated *C. parvum*. In order to maximize the sexual differentiation of the parasite and optimize the identification of DMC1 expressing (DMC1⁺) parasites in the HCT8 cell infection model, we made several modifications to our standard culture, staining, and image analysis methods. Key changes included supplementing the media with 1% serum instead of 10% serum, addition of the antifungal compound Amphotericin B, using 1% BSA instead of 4% BSA as blocking solution during immunostaining, and creating an image mask for all the parasites in the culture (identified by VVL staining) before locating high DMC1 signal during automated parasite counting. In the end, we managed to obtain a good signal-to-noise ratio for the DMC1⁺ parasites at 72 hours post infection (hpi) (Figure 1A). The *Z'* score, an indicator of assay quality (27), was consistently > 0.7 for the identification of DMC1⁺ parasites when using “no primary antibody” staining as our negative control.

The DMC1⁺ parasite ratio detected with this method at 48 hpi was almost zero when using a 0.45 NA objective as is needed for screening with our automated microscope (Figure 1B). We note that other studies reported a higher proportion of female gamonts at 48 hpi when detected using other methods (7, 8), and, in our previous study, we also detected a higher proportion of DMC1⁺ parasites at 48hpi when visualized through an objective with more resolving power (6). The ratio of sexual

stage parasites to total parasites that we detected with the current method at 72 hpi was very similar to all the prior reports (6-8). This indicated that DMC1 needs to be highly expressed to be detected by our screening method, suggesting that it detects only relatively mature female gamonts.

For compound library screening, we devised a strategy in which we tested each compound in three separate conditions and considered four separate readouts (two asexual growth readouts and two sexual stage specific) (Figure 1C). The asexual stage specific readouts were calculated by counting the total number of parasites at 48 and 72 hpi following the addition of compounds at 3 hpi. The number of parasites was expressed as a ratio to the number of host cell nuclei to control for host cell cytotoxicity, and the effect of compounds on parasite growth was calculated as percent inhibition relative to vehicle control-treated wells on each assay plate. The sexual stage specific conditions and readouts were as follows: 1) addition of compound at 3 hpi and determination of the ratio of DMC1⁺ parasites at 72 hpi; and 2) addition of compound at 48 hpi (when very few DMC1⁺ parasites are detectable) with the determination of the ratio of DMC1⁺ parasites at 72 hpi. We reasoned that compound addition at 3 hpi would allow us to identify compounds that inhibit sexual differentiation but minimally impact asexual replication. Note that this readout identified compounds that affect the commitment to differentiate with minimal effect on asexual growth, but for compounds that inhibit asexual growth, it yielded little useful information about differentiation due to low parasite numbers. The second sexual stage specific readout with compound

addition at 48 hpi addressed this, since it identified compounds that inhibit the development of female gamonts following the commitment to differentiate independently of the compound's effect on asexual growth.

2.3.2: Screening and Validation of the ReFRAME Library

Using the combined stage specific assay strategy, we screened the ReFRAME compound library at 2 μ M concentration. We had multiple DMSO control wells in each plate as well as two wells of known inhibitor control nitazoxanide. Each compound's activity for each readout was determined by normalizing the parasite counts with that of the DMSO wells from the same plate. In the end, we determined the average activity and the standard deviation for all the compounds in the library in each readout and compounds showing activity two standard deviations above or below the library mean were denoted as hits in each readout (Figure 1D and 1E). For initial follow up on compounds meeting this hit definition for at least two of the four screening readouts, we used resupplied compounds to conduct eight-point dose response assays, ranging from 50 nM to 10 μ M for each assay readout (a total of 311 compounds).

The compounds roughly fit into seven different categories based on the dose response curves (Figure 2A). 42 compounds showed inhibitory activity in all four readouts with similar potency. These were denoted as pan-inhibitors, and were felt to be the most straightforward drug-like compounds for the potential treatment of cryptosporidiosis (Figure 2B). 70 compounds showed no dose-dependent activity in

any of the readouts and were considered false positives from the screening (Figure 2C). All the other compounds were differentially potent among the readouts and together they constitute a diverse set of tool compounds for studying the *C. parvum* life cycle. The most common theme (accounting for 102 compounds) was similar potency for inhibition of all readouts except for inhibition of DMC1⁺ parasites upon addition at 48 hpi (Sexual Readout 1 in Figure 1C). These compounds were either completely inactive in this readout (Figure 2D) or showed dose dependent activity that failed to reach complete inhibition at the highest tested concentration (Figure 2E). We categorized these compounds as asexual inhibitors. On the other hand, 23 compounds were highly potent against the sexual stage when added at 3 hpi, but had little effect in the other conditions/readouts (Figure 2F). These compounds were categorized as differentiation inhibitors and were the predominant focus of our follow up experiments. A further 9 compounds showed a narrow but discernable specificity also in the sexual differentiation readout (Figure 2G). 19 compounds induced sexual differentiation (Figure 2H) or sexual development (Figure 2I) or both (Figure 2J) at concentrations that were not inhibitory to asexual stages in a dose dependent manner. We did not classify 46 compounds in any of the above-mentioned categories mainly because they were not tested in all conditions or their dose response curves seemed to be in the exponential phase and did not reach the above 80% inhibition threshold at the highest concentration tested (Figure 2K). Interestingly, a particular differentiation inducer, the Endothelin A receptor agonist S-1255, highly induced the expression of DMC1 at 48

hpi, which was unique among all the compounds that we tested (Figure 2L). Supplementary Table 1 contains the SMILES structures of all compounds tested in follow up, their putative targets and how they were categorized. Supplementary Figure 1 contains their dose response curves for each assay readout.

2.3.3: Several Differentiation Inhibitors Share Common Modes of Action and Activity Kinetics

The compounds categorized as differentiation inhibitors completely inhibited the emergence of DMC1⁺ parasites in a dose dependent manner. However, they did not completely inhibit asexual parasite growth at any concentration tested (Figure 2F). All 23 of them had minimal or no effect on DMC1 expression when added at 48 hpi, suggesting that they worked by inhibiting early steps in the differentiation pathway. Interestingly, four of them were mitochondrial electron transport chain inhibitors (Figure 3A), five of them were inhibitors of nucleotide biosynthesis (Figure 3A, 3B), and two of them were fumagillin analogs that covalently inhibit methionine aminopeptidase 2 (Figure 3A). Interestingly, the confirmed asexual stage inhibitors also included compounds that inhibit nucleotide biosynthesis, but the putative targets of differentiation inhibitors were exclusively involved in the synthesis of purine nucleotides (Figure 3B).

We decided to further probe the mechanisms underlying *C. parvum* sexual differentiation using several of these tool compounds. We purchased seven differentiation inhibitors from independent sources and two were resupplied from the

ReFRAME library (Figure 3A). These nine compounds were selected because they showed a highly selective inhibitory activity against sexual differentiation for a wide range of concentration. We first tested a broader range of concentrations for each for the condition 2 readouts, which reconfirmed the initial dose dependent characterization for all nine compounds (Figure 3C).

Previous experiments looking at *C. parvum* life cycle stages at different time points post infection suggest that sexual differentiation takes place between 36 and 48 hpi (7, 8). This view is consistent with our observation that all the differentiation inhibitors were highly efficacious in inhibiting sexual differentiation when added 3 hpi, but ineffective to do so when added 48hpi. While this roughly indicates that they need to be added before the differentiation takes place, we wanted to test this phenomenon with a higher temporal resolution. To probe if there is a temporal window when the differentiation inhibitors need to be present to exert their effect, we added the nine retested differentiation inhibitors at 3, 12, 24, 34 or 48 hpi, and determined the ratio of DMC1⁺ parasites at 72 hpi (Figure 4A). Six compounds showed highly efficacious dose dependent activity when added up to 34 hpi. On the other hand, three compounds (i.e. pralatrexate, mycophenolate, and TVB-2640) lost that activity if added at or after 24 hpi (Figure 4B), suggesting that prolonged exposure was required and/or that they affect early stages of differentiation such as commitment. Nitazoxanide, which was classified as a pan-inhibitor, had the same effect regardless of the timing of addition. This was consistent with the likelihood that pan inhibitors have a general toxic effect on

C. parvum growth that is independent of the stage of the parasite's life cycle.

2.3.4: mRNA-seq Analysis of Compound Effects on Gene Expression

To gain insights into the genetic regulation of *Cryptosporidium* sexual differentiation, we examined the effects of selected differentiation inhibitors on parasite and host gene expression using mRNA-seq and the *C. parvum* HCT8 cell culture system. A suitable time point was first determined by conducting mRNA-seq in the absence of differentiation inhibitors at 18, 36, 48, and 72 hpi. We aligned the sequencing reads with both human and *C. parvum* genomes using HISAT2 (28), created separate subsets of alignment files uniquely aligned to the parasite or host genome, counted the number of alignments per gene using HTseq (29), and finally performed differential gene expression analysis using DEseq2 (30). Genes with ≥ 2 -fold expression difference at a 10% false discovery rate (FDR) were considered as differentially regulated. Overall, very few parasite genes were differentially regulated between the 18 and 36 hpi samples, but a large number of genes were differentially regulated between the 36 and 48 hpi samples and the 48 and 72 hpi samples. On the other hand, a relatively small number of host genes were differentially expressed (Figure 5A). Given these data, we selected the 48 hpi timepoint for the transcriptomic analysis of the differentiation inhibitor treatments in subsequent experiments. Each compound was used at a dose that was previously found to be highly selective for sexual differentiation (see Figure 3C), and mRNA-seq libraries were prepared at 48 hpi after each of the compounds or vehicle were added at 3 hpi (Figure 5B)(2 biological

replicates each, except for pralatrexate (n=1) for which library preparation failed for one replicate.)

Compound treatment affected both host and parasite gene expression (Figure 5B). The two methionine aminopeptidase2 inhibitors, AGM-1470 and Beloranib hemioxalate, very selectively dysregulated parasite gene expression, whereas the inhibitors of oxidative phosphorylation and mubritinib dysregulated a high number of host genes. We also performed the differential gene expression analysis using the combined expression count files of the host and the parasite genes together, which also confirmed the predominantly parasite-specific dysregulation of genes by the MetAP2 inhibitor AGM-1470 (Supplementary figure 2). Note that in these experiments the proportion of infected and uninfected host cells varied with time point and compound treatments, which complicated comparative analysis of host gene expression. We have therefore not performed any detailed analysis on host gene expression beyond determining the number of affected genes in the host transcriptome.

There was a high degree of identity between genes that were dysregulated by the various differentiation inhibitor treatments (Figure 5C, 5D). Supplementary Table 2 contains the fold changes of parasite genes that met the threshold of statistical cutoff (FDR <0.1). As the nine differentiation inhibitors act upon eight different target proteins, the uniquely dysregulated genes are highly likely to be compound specific effects. In contrast, as all our nine tested compounds causes the same effect of sexual differentiaion inhibition, commonly dysregulated genes by multiple treatments might

be more involved in regulating the sexual differentiation. In line with this reasoning, we compiled a list of parasite genes that were dysregulated with the majority (at least five or more) of the compound treatments. We compared this gene list with the list of significantly dysregulated genes identified through RNA-seq between *C. parvum* asexual and female stage parasites separated by flow cytometry. Our commonly upregulated gene set was highly similar to the gene set overexpressed in the asexual stage compared to female stage and our commonly downregulated gene set had a high degree of similarity with the genes overexpressed in the female parasites (Supplementary figure 3), which validates our dataset and our approach of selecting stage-specific genes.

2.3.5: Female-specific Genes are Down-regulated and Asexual Stage-specific Genes are Upregulated Following Treatment with Differentiation Inhibitors

Life cycle stage specific gene expression is a well-documented phenomenon in apicomplexan parasites. We wanted to check if the dysregulated genes from the compound treated samples were stage specific or not. To putatively identify stage specific genes, we have used two relevant RNA-seq datasets available in the EUPATHdb database (31), one for *C. parvum* and the other one for *Plasmodium*. The *Plasmodium* dataset compared gene expression patterns between the asexual blood stage, and male and female gametocytes (18). We selected *Plasmodium* genes that are differentially expressed between these stages (FDR<0.1; log₂ fold change of ≥ 1). Genes that are upregulated in the asexual stage compared to gametocytes were denoted as asexual

stage specific genes. Genes that are upregulated in both gametocytes or in one of the gametocytes compared to asexual stage were denoted as gametocyte, male and female specific genes accordingly. Ortholog transformation of each of these gene sets identified their homologs in the *C. parvum* genome, and was used to enable comparison of *C. parvum* and *Plasmodium* data. The Eupathdb *C. parvum* dataset contains the gene expression pattern for FAC sorted asexual stage parasites and female gamonts (7). Using the same cutoffs for differential expression, we identified asexual and female specific genes using this dataset. If any gene was putatively identified as asexual stage specific or male specific based on the *Plasmodium* database but marked as female specific from the *C. parvum* dataset or vice versa, we denoted them as divergent genes. All the other genes without any stage specific expression were denoted as unresolved. This set of genes most likely encode proteins that perform essential functions throughout the life cycle of *C. parvum*.

After using these existing datasets to classify all of the *C. parvum* genes as above, we checked if there was any stage specificity in the differentially expressed genes identified following compound treatments. All the compounds showed a similar pattern in our analysis; asexual stage specific genes were upregulated and female stage specific genes were downregulated due to compound treatment (Figure 5E, Supplementary Figure 2). We did not observe any strong effect in the other classes of genes.

2.3.6: Proteins Involved in Ribosome Formation are Upregulated in Response to Differentiation Inhibitors

We performed functional annotation enrichment analysis of the upregulated and downregulated gene sets following treatment with all of the differentiation inhibitors using DAVID Bioinformatics Resources 6.8 (32). As there was a high degree of similarity between gene sets dysregulated by the different compound treatments, the functional annotation enrichment analysis identified similar gene classes enriched with all the treatments (Supplementary Table 3). Therefore, to limit the analysis to common pathways involved in differentiation and exclude potentially misleading effects seen with individual compounds, we repeated the analysis with gene sets significantly dysregulated (FDR<0.1) following treatments with the majority of the compounds (five out of nine treatments). We noticed that for the genes that were significantly dysregulated with multiple treatments, the log₂ fold-change was often marginally below 1 for some treatments, so this cutoff likely resulted in the erroneous exclusion of some biologically relevant differentially expressed genes in the combined gene sets. Therefore, we bypassed setting a fold change cutoff for selecting commonly dysregulated genes and selected them only based on the FDR cutoff, which provided a better representation of all the different compound treatments. Following treatment with differentiation inhibitors, this analysis indicated that genes encoding proteins associated with ribosome biogenesis and structure were commonly upregulated, whereas genes encoding proteins involved with biosynthesis of secondary metabolites

and glycolysis were commonly downregulated (Figure 6A).

We wanted to check whether the upregulation of ribosomal genes was just a response to compound treatment or represented biologically relevant differential expression between *C. parvum* life cycle stages. For this, we reanalyzed the Eupathdb *C. parvum* dataset comparing the female and asexual transcriptomes to determine whether the functional annotation enrichment analysis of our dataset correlated with that dataset or not (7). As compound treatment inhibited sexual differentiation, genes upregulated with compound treatment should be downregulated in female gamonts when compared with the asexual stage and vice versa. Similarly, genes involved in glycolysis should be upregulated in female gamonts. Analysis of the existing *C. parvum* dataset confirmed these predictions (Figure 6A). Furthermore, ribosomal genes were the most significantly downregulated gene class in female gametocytes, strongly suggesting that modulating ribosome formation could be a key regulatory mechanism for parasite differentiation.

We plotted the actual average transcript per million (TPM) values of all the genes that code for proteins that are structural components of the ribosome. This indicated that mRNAs encoding this class of proteins reached their peak concentration at 36 hpi and then decrease rapidly at 48 and 72 hpi (Figure 6B). Compound treatment inhibited the repression of most of the members in this gene set. Interestingly, hierarchical clustering of the expression pattern of this gene set clustered the compound treated samples (prepared from 48 hpi) with 18 hpi and 36 hpi control samples whereas

the 48 hpi control sample clustered with 72 hpi control sample (Figure 6B).

Ribosomal protein genes are scattered across the *C. parvum* genome, yet the mRNA levels were highly correlated with each other across time points and compound treatment. This prompted us to search for conserved sequence signatures within the upstream and downstream regions of these genes. Differential enrichment analysis of the upstream region of the ribosomal protein genes identified a DNA motif, BYGTCTC, that was highly enriched in these genes compared to all the annotated protein coding genes of *C. parvum* (Figure 6C). Other than the ribosome structural proteins (n=78), the motif was found in the promoter region of 455 additional genes. We checked if those genes were consistently upregulated or downregulated (dysregulated in ≥ 5 compound treatment), and, based on a Chi-square test, the motif was more commonly found in the promoter region of genes upregulated following treatment with differentiation inhibitors (Figure 6D). Furthermore, analysis of the motif's location indicated that it is typically located closer to the start codon for genes coding for ribosomal structural proteins and genes that were consistently upregulated, and is generally distally placed for the genes that were downregulated following compound treatment (Figure 6E). A comparison of the downstream sequences of ribosomal genes with other *C. parvum* genes did not identify significantly enriched sequence motifs.

2.3.7: Ribosomal Proteins are Generally Downregulated in Response to Translational Repression Programs During Differentiation in Apicomplexan Parasites

Our mRNA-seq dataset indicated that ribosomal protein genes are downregulated during *C. parvum* sexual differentiation. We checked if this is a common mechanism of regulating differentiation in apicomplexan parasites by using a variety of datasets available via Eupathdb to identify genes that are upregulated or downregulated in different life cycle stages of other apicomplexan parasites (Supplementary Table 4) (11, 18, 33-36). In *Plasmodium*, ribosomal genes are downregulated during female gametocytogenesis as well as in salivary gland sporozoites compared to midgut oocysts. In *T. gondii*, ribosomal genes are downregulated in bradyzoites compared to tachyzoites (Figure 6F). Interestingly, in all the three above mentioned differentiation axes, mechanistic studies indicate that post transcriptional repression of gene expression plays a critical role in the differentiation process. During maturation of *P. berghei* female gametocytes, overexpressed mRNAs are protected at the cytoplasmic P bodies, which also repress their translation (37, 38). In *Plasmodium* salivary gland sporozoites, inhibitory phosphorylation of eukaryotic translation initiation factor alpha (eIF2 α) represses the translation of mRNAs (39). The *T. gondii* eIF2 α is also observed to be phosphorylated in bradyzoites (40, 41). Collectively, these publications indicate that the repression of ribosomal proteins correlates with a translational repression program in *Plasmodium* and *Toxoplasma*. In

Eimeria, ribosomal genes are upregulated in merozoites compared to both sporozoites (the earlier stage) and gametocytes (later stages) (Figure 6F). Overall, in all the three apicomplexan parasites where sexual and asexual stage gene expression has been compared with RNA-seq, ribosomal proteins are enriched in gene sets that are downregulated in sexual stages.

2.3.8: The DNA Recognition Motif of Four ApiAp2 Transcription Factors is Significantly Enriched in the Promoter Regions of Commonly Downregulated Genes

Genes that are commonly downregulated with five or more differentiation inhibitor treatments are potentially overexpressed during or after sexual differentiation. Specific regulatory DNA sequences might control their sexual stage specific expression pattern. To identify such potential regulatory elements, we screened the promoter regions of these genes for significant enrichment of DNA motifs. We found that the motif “CATGCAWH” is the most significantly enriched DNA motif in the promoter region of these genes (Figure 7B).

The family of apicomplexan AP2 transcription factors (TFs) has been extensively studied in *Plasmodium* parasites and several of them have been implicated in regulating parasite differentiation in the course of its life cycle (21, 22). There are 18 putative ApiAP2 TFs in the *C. parvum* genome based on sequence similarity to the AP2 DNA binding domain (42). Previously, using DNA binding microarray, the putative DNA recognition motifs of several *C. parvum* AP2 TFs were identified (42).

Interestingly, the “CATGCAWH” motif that is significantly enriched in the promoters of our downregulated gene set bears a high degree of similarity to the recognition site of four different ApiAP2 TFs (listed in Figure 7A). Two of these TFs (cgd8_3230 and cgd2_3490) themselves are also significantly dysregulated by five or more differentiation inhibitor treatments (Figure 7A), which suggests that they might play key regulatory roles in controlling the expression of sexual stage specific genes in *C. parvum*.

2.4: Discussion

In this study, we have tested the ReFRAME library, a diverse set of biologically active compounds, for activity against the sexual and asexual phases of the *C. parvum* life cycle. We identified compounds with differing modes of activity against the two life cycle stages and performed detailed transcriptomic analyses of a set of compounds that selectively affect the parasite sexual differentiation. We identified that proteins involved in ribosome formation are transcriptionally downregulated as parasites differentiate into sexual stage and treatment with differentiation inhibitors negatively affects this mode of regulation. In addition, we found that an experimentally validated binding site of several *C. parvum* ApiAP2 TFs is significantly enriched in the promoter region of genes that are downregulated with multiple differentiation inhibitor treatments, which indicates that these TFs play key regulatory roles in *C. parvum* sexual differentiation.

The compounds in the ReFRAME library were initially developed to treat a

variety of diseases, with a bias towards cancer therapeutics. Respiratory, cardiovascular, and CNS conditions are also highly featured amongst the disease indications; altogether these indications account for ~86% of ReFRAME compounds, which were primarily developed to treat human conditions not caused by infectious agents (26). Therefore, many ReFRAME compounds target human proteins or RNAs. As an intracellular parasite, *C. parvum* must be sensitive to the altered condition in the host cells. It is therefore highly likely that a lot of validated hits from our screen are acting on *C. parvum* by altering the host cell condition, without directly targeting parasite proteins. A prime example of such mode of action is the four identified compounds that likely inhibit parasite sexual differentiation by acting on mitochondrial function (Figure 3A). *C. parvum* does not contain a fully functional mitochondrion itself; instead, it harbors a relict mitochondrion without a genome that is termed a mitosome (43). Consistent with a primary effect on the host cell, the two of the mitochondrial inhibitors included in our RNA-seq analysis caused dysregulation of a high number of host genes in addition to parasite genes (Figure 5B). This strongly suggests that host cell mitochondrial function is critical for parasite life cycle progression and its dysregulation affects the parasite sexual differentiation more profoundly than general growth. Interestingly, media removal to the establish an air-liquid-interface (ALI) condition during the culture of stem cell derived mouse intestinal epithelial cells supports the continuous cultivation of *C. parvum* in vitro (44). Parasite vacuole number significantly increases under the ALI condition from two days onwards

post infection compared to non-ALI condition, and, in contrast to the HCT8 culture system, both fertilization and production of infectious oocysts occurs. Consistent with our finding that inhibitors of the host cell mitochondria block *C. parvum* sexual development, host cell RNA-seq comparison of the ALI and non-ALI conditions identified oxidative phosphorylation as the most significantly upregulated pathway under ALI conditions (44).

Targets of five differentiation inhibitors are enzymes of interconnected folate metabolism and purine nucleotide biosynthetic pathways (Figure 3A, 3B). We pursued two of these in our follow up experiments, pralatrexate, an inhibitor of mammalian dihydrofolate reductase (DHFR) (45), and mycophenolate mofetil, a prodrug that is converted into mycophenolic acid, which inhibits host inosine-5'-monophosphate dehydrogenase (IMPDH) (46). Recently, it has been shown that knocking out several of the *C. parvum* proteins involved in nucleotide salvage, including DHFR-TS (cgd4_4460) and IMPDH (cgd6_20), has no effect on the replication of *C. parvum* (tested for 48 hpi) (47). However, unlike WT parasites, these mutants are susceptible to pharmacological inhibition of relevant host nucleotide synthesis. Interestingly, both of these enzymes are significantly upregulated at 72 hpi compared to 48 hpi in vehicle treated *C. parvum* infection, which suggests an increased need for nucleotides during the parasite sexual stage (Supplementary Table 2). Phenotypes of nucleotide salvage pathway knockout mutants of *C. parvum* suggest that the parasite has redundant pathways to synthesize pyrimidine nucleotides but not purine nucleotides, which makes

them comparatively more dependent on the host for purines. As a likely cause of this duplicity, it has been proposed that host derived purine nucleotides are directly imported as ATP that fulfills the energy demand of the parasites in addition to serving as nucleic acid building blocks (47). As discussed later, our data suggest that in the sexual stage, either energy demand is more or access to the host nucleotide pool is reduced compared to asexual *C. parvum*. This might be the reason why the sexual stages of the parasite are disproportionately affected by inhibitors of host purine biosynthesis compared to asexual stages. Interestingly, both of the retested nucleotide biosynthesis inhibitors affected sexual differentiation only when added at 3hpi and 12hpi, but failed to completely do so when added later (Figure 4B). Perhaps the host ATP pool is sufficiently depleted for inhibition of sexual differentiation only with prolonged exposure of these compounds.

AGM 1470 and beloranib are fumagillin analogs that covalently bind to human methionine aminopeptidase 2 (MetAP2) (48). MetAP2 is a bifunctional protein and one of its functions is to remove the N-terminal methionine from nascent proteins. Fumagillin analogs covalently bind to a histidine residue in the active site of MetAP2 and block this function (48). The active site histidine and the surrounding residues are conserved in *C. parvum* MetAP2. The other function of MetAP2 is to bind and protect the eukaryotic translation initiation factor 2 alpha (eIF2 α) from inhibitory phosphorylation (49). eIF2 α plays a critical role in the rate-limiting step of translation initiation, and the phosphorylation of eIF2 α inhibits this activity (50). Several kinases

phosphorylate eIF2 α in response to diverse types of stresses (51). Covalent binding of the fumagillin analogs does not directly alter this second function of MetAP2; however, they can indirectly enhance this function as the covalent modification of the protein enhances its stability (52, 53). Treatment with these compounds significantly dysregulated a high number of parasite genes, but, compared to the other differentiation inhibitors, a very small number of host cell genes (Figure 5B). Therefore, while we cannot formally reject the possibility that these fumagillin analogs affect *C. parvum* through effects on host metAP2, it is highly likely that their effect on parasite sexual differentiation results from inhibiting the parasite enzyme.

Consistent with this possibility, regulation of eIF2 α phosphorylation is implicated in controlling stage differentiation in both *Plasmodium* and *Toxoplasma*. *T. gondii* eIF2 α phosphorylation is necessary for tachyzoite to bradyzoite differentiation (40, 41, 54-56). In *Plasmodium*, several proteins required for the liver stage are actually transcribed in salivary gland sporozoites, but their translation is repressed (19, 57, 58). IK2, a kinase of eIF2 α , is critical for this translational silencing (39, 59). Even though MetAP2 has been implicated in the protection of eIF2 α , its role has never been specifically investigated in apicomplexan eIF2 α phosphorylation regulation of stage differentiation. As MetAP2 inhibitors inhibit the sexual differentiation of *C. parvum* and the transcriptional signature of this differentiation inhibition mimics translational silencing in apicomplexan parasites (Figure 6F), it is likely that these fumagillin analogs inhibit *C. parvum* sexual differentiation by inhibiting parasite eIF2 α

phosphorylation (Figure 8). In this model, normal sexual differentiation requires phosphorylation of parasite eIF2 α , which turns on a translational silencing program in the parasites. AGM 1470 and beloranib bind and stabilize parasite MetAP2, which leads to increased protection of eIF2 α from inhibitory phosphorylation. As a result, the translational silencing program fails to activate and sexual differentiation is inhibited.

Among the compounds that induced sexual differentiation or development, common putative targets include DNA topoisomerase (four compounds), cyclin dependent kinases (cdks, three compounds), and Aurora kinases (two compounds). And among other validated hits, two cdk inhibitors are classified as pan-inhibitors and two others as asexual inhibitors. Similarly, five putative topoisomerase inhibitors and two aurora kinase inhibitors are classified as asexual stage specific inhibitors (Supplementary Table 1).

The purpose of the RNA-seq experiments reported here was to identify sexual and asexual stage specific genes and pathways, some of which might be involved in regulating *C. parvum* sexual differentiation. We selected compounds with diverse structures and putative targets for this study, all of which cause the same effect, i.e. inhibition of sexual differentiation (Figure 3A). For each of the compounds, we selected a dose that highly and preferentially inhibits differentiation (Figure 3B). We reasoned that with such a high effective dose for a particular phenotype, dysregulated genes and pathways common in the majority of the treatments would be parasite life cycle stage specific elements, as opposed to compound specific dysregulated elements.

Indeed, there was a high degree of commonality in dysregulated genes (Figure 5C and 5D, supplementary table 2). According to our experimental design, asexual stage specific genes should be upregulated and sexual stage specific genes should be downregulated following treatment with the differentiation inhibitors. We compared the consistency of our approach with the previously published complementary approach of conducting RNA-seq on FAC sorted parasites using a female gamont-specific promoter driven reporter to separate asexual and female sexual stage specific parasites (7). To include the male stage specific gene expression in our comparison, we interpolated stage specificity of *C. parvum* genes from a similar FAC sorting-based dataset of *Plasmodium* (18). A high degree of correlation between our dataset and the two other datasets validates our approach (Figure 5E). At the same time, it also indicates that the sexual stage specific gene expression pattern is reasonably conserved between *Plasmodium* and *Cryptosporidium*.

Functional annotation enrichment analysis of commonly dysregulated genes identified (dysregulated in ≥ 5 compound treatments) glycolysis as the most highly enriched pathway in the downregulated gene set and ribosome biogenesis in the upregulated gene sets (Figure 6A, Supplementary Table 3). The result of this analysis is consistent with the same analysis performed for dysregulated gene sets between asexual and female gamonts (Figure 6B). In the absence of a fully functional mitochondrion, glycolysis is considered to be the main energy generating pathway for *C. parvum*. As our data indicate that this pathway is more active following sexual

differentiation, we propose two mutually non-exclusive models to explain this stage specific energy metabolism in *C. parvum*. One is that the energy demand in sexually differentiated parasites is simply higher compared to the asexual stages. That can arise from the necessity of producing residual bodies, a type of energy storage structure composed of carbohydrates and other metabolites that are observed in both macrogamonts and oocysts (60, 61). Another possibility is that the sexual stages are less efficient in importing energy equivalents from the host, which is compensated by increased energy production by the parasite itself. As mentioned above, it has been proposed that *C. parvum* might harbor transporters that directly take up ATP from the host cell (47). Stage specific differences in the abundance of such a transporter might reduce energy uptake from the host cell following sexual differentiation. Overall, each model is consistent with our observations that inhibition of host oxidative phosphorylation and purine biosynthesis both affect sexual differentiation.

The upregulation of ribosome biogenesis and structural proteins following differentiation inhibitor treatments suggests an overall lower rate of protein synthesis in sexually differentiated parasites (Figure 6A and 6B). This persuaded us to look for similar transcriptional dysregulation patterns in other apicomplexans, as translational repression is a well-documented mechanism of regulating stage differentiation in apicomplexans. In all three differentiation axes where translational silencing has been validated with genetic experiments, the same ribosomal dysregulation signature has been observed (Figure 6F). Collectively, this strongly associates the downregulation of

ribosomal genes in RNA-seq datasets with the establishment of a translational silencing program. Without further experimental validation, however, it is unclear if the downregulation of ribosomal genes is causative for translational silencing or if the establishment of translational silencing somehow causes the transcriptional downregulation of ribosomal genes. Downregulation of ribosomal proteins is also observed in *Eimeria* gametocytogenesis; however, no mechanistic experiment to determine the regulation of this differentiation has been published.

One important point to note here is that all the apicomplexan parasites obviously possess stage specific proteins that are overexpressed under these general transcriptionally silenced and impaired-ribosome-biogenesis conditions. How the expression of those proteins is enhanced under such a condition is an important research question. Perhaps the answer is contained in the fact that ribosomes are not homogenous structures that keep translating all the mRNAs at a constant rate. Rather, they are heterogeneous structures that vary in building blocks between cell types and conditions, and they can selectively translate certain mRNAs over others (62). It would be interesting to experimentally test if such “special ribosomes” play a key regulatory role in apicomplexan stage differentiation.

Differential enrichment of mRNAs between conditions can result from their altered transcription or stability. In our RNA-seq follow up analysis, we focused on transcriptional regulation by looking at the putative promoter regions of *C. parvum* genes. We searched for enriched sequence motifs in the promoter region on various

subsets of *C. parvum* genes that are connected by similar dysregulation patterns and/or are from the same pathway or protein class. We identified very significant enrichment of a DNA motif in the upstream region of the ribosomal structure genes (figure 6C). This suggests that their transcription is controlled by the same transcriptional regulators and putatively explains why these genes are dysregulated as a group (Figure 6B). The other significant promoter motif signal that we observed came from the genes that are downregulated in ≥ 5 compounds treatments (Figure 7B). Interestingly, a part of this motif is identical to the experimentally validated core binding site of four different ApiAP2 transcription factors. TFs of this class are well defined as key regulators of apicomplexan stage differentiation. In both *Plasmodium* and *Toxoplasma*, the binding sites of multiple AP2 TFs are similar. They often function antagonistically to each other and the expression levels of the genes that they regulate are essentially determined by the expression levels of the TFs (63-65). Among the four *C. parvum* AP2 TFS that bind to the “TGCAT” core, *cgd8_3230* is significantly upregulated in six treatments whereas *cgd2_3490* is significantly downregulated with eight different treatments (Figure 7B). Combining all this information, we propose that the expression of a set of sexual stage specific genes is activated by *cgd2_3490* and repressed by *cgd8_3230*.

Among all the validated hits from our screening, we have only used the differentiation inhibitors in this study to better understand the genetic regulation of sexual differentiation of *C. parvum*. Adding the other classes of hits, specifically the

sexual differentiation and development inducers, into the mRNA-seq analysis pipeline may further assist in recognizing the key regulatory factors in parasite sexual differentiation. Moreover, there are still numerous open questions about the parasite life cycle. The different classes of compounds identified in this study can be utilized in diverse ways to answer some of those questions. For example, in an animal model or in a continuous in vitro culture system, differentiation inhibitors can be used to check if sexual differentiation is an obligatory step following several rounds of asexual replication, i.e. whether the parasite would die or continue to grow asexually with a blockade in sexual differentiation. Such an experimental design would address the druggability potential of *C. parvum* sexual differentiation and may also lead to the identification of tool compounds to facilitate continuous cultivation of *C. parvum* in a simpler culture system than is currently available.

Before concluding, we would like to mention that as the ReFRAME library is biased towards human protein targets, applying a similar screening methodology with a less biased library might identify compounds that would more specifically target *C. parvum* proteins. Additionally, other phenotypic patterns may potentially be caused by compound treatment that we have not yet captured. For example, we have not yet identified a selective sexual development inhibitor or a sexual stage specific inhibitor that would inhibit both sexual differentiation and development. The utility of such tool compounds would be immense for the mechanistic understanding of *C. parvum* sexual differentiation.

2.5: Material and Methods

2.5.1: In vitro *C. parvum* Infection Model

Human ileocecal adenocarcinoma (HCT-8) cells (ATCC; catalog# CCL-244) were used as host cells for *C. parvum* infection. The cells were passaged in modified RPMI-1640 medium (Gibco, catalog# A10491-01) supplemented with 10% heat inactivated fetal bovine serum (Sigma) and antibiotic solution (120U/mL penicillin and 120 ug/ml streptomycin; Gibco 15140-122). Cell culture passage number 9 to 36 were used for parasite infection. *C. parvum* oocysts were routinely purchased from Bunchgrass Farm (Deary, ID) and used for up to 6 months. To infect HCT8 cells, oocysts were excysted in vitro by treating them first with 10mM HCL (37C, 10 minutes) and then 2mM sodium taurocholate (16C, 10 minutes; Sigma T4009). Host cells are grown to 90% confluency in appropriate plates for infection. Infection media was same as HCT8 culture media except that it was supplemented with 1% serum instead of 10% and antifungal compound Amphotericin B (0.625 ug/ml; Sigma A2942) was added in addition to the antibiotic solution. Infected cells are incubated at 37C with 5% CO₂.

2.5.2: Compound Screening and Dose Response Validation

Host cells were grown in 384 well plates and infected with 5500 oocysts per well. Following infection, compounds were added at appropriate timepoints using Biotek Precision microplate pipetting system. Cultures were washed with wash solution (0.1% tween 20 in 1X PBS) 3 times before fixing with 4% paraformaldehyde

and permeabilizing with 0.25% triton X-100. 1% BSA was used for blocking before staining with Anti DMC1 antibody clone 1H10G7 (hybridoma supernatant). Plates were incubated at 4°C for at least 24 hours with the primary antibody before washing with the wash solution three times, with five minutes incubation between each wash. Subsequently, the culture was stained with 4 µg/ml Alexa Fluor 568 goat anti-mouse IgG (Invitrogen, A-11004) and 1.33 µg/mL FITC-labeled *Vicia villosa* lectin (Vector Laboratories, FL-1231) in 1% BSA for at least 1 h at 37 °C. Finally, 0.09 mM Hoechst 33258 (AnaSpec, catalog# AS-83219) stain was added to stain the nucleus for 10 minutes. Then the wells were washed with wash solution five times, with five minutes incubation between each wash.

The culture plates were imaged with Nikon Eclipse Ti2000 epifluorescence microscope equipped with automated stage movement, using an objective with 20X magnification and 0.45 numerical aperture. 5 by 5 field of views were captured for each well. Images were analyzed with an automated ImageJ macro (66) to count the number of nucleus, total parasite and DMC1⁺ parasites.

2.5.3: mRNA-seq Sample Preparation and Sequencing

HCT8 cells were grown to 90% confluence on 24 well plates and infected with an appropriate number of excysted oocyst (2, 1, 0.5 and 0.4 million for 18, 36, 48 and 72 hpi samples respectively) in 1 mL of infection media. Compound or DMSO was added at appropriate time points. Before RNA isolation, wells were washed 3 times with the wash buffer. Total RNA was isolated using the Qiagen RNeasy mini kit (cat

#74104). Messenger RNA enrichment and sequencing libraries were prepared using NEXTFLEX Rapid Directional RNA-seq Library Prep kit bundle (cat # NOVA-5138-10) following the kit manufacturer's protocol. The next-generation sequencing (75 Base pair single end) was performed in the Vermont Integrative Genomics Resource Massively Parallel Sequencing Facility and was supported by the University of Vermont Cancer Center, Lake Champlain Cancer Research Organization, UVM College of Agriculture and Life Sciences, and the UVM Larner College of Medicine.

2.5.4: mRNA-seq Data Analysis

Sequences were demultiplexed and provided in “.fastq” format by Vermont Integrative Genomic Resource core facility. The sequences were uploaded to the public server of the Galaxy web platform (usegalaxy.org) and all the subsequent analyses were performed in that server (67). Sequences were quality trimmed using Trimmomatic (68) and then aligned to a combined genome sequence file of Human genome (Gencode release 31, GRCh38, (69)) and *C. parvum* genome (Cryptodb release 44, *C. parvum* IowaII, (70)) using HISAT2 (28). Alignment file was sliced into host part and parasite part using the Slice tool and processed separately in subsequent operations. We used HTseq (29) to determine the number of reads aligned to each gene. Deseq2 was used to analyze differential expression between appropriate samples (30). Deseq2 result files were downloaded, relevant values of the genes that met the differential expression cutoff were combined in a Microsoft excel file.

2.5.5: Pathway Analysis and Gene Expression Heatmap Generation

Functional annotation enrichment analyses with *C. parvum* genes were performed in DAVID Bioinformatics Resources 6.8 (32, 71). Appropriate gene ids were copied as gene list and CRYPTODB_ID was selected as Identifier type. All *C. parvum* genes were used as background and all the other options were used as default. For other apicomplexan parasites, “analyze result” was used from an appropriate apicomplexan parasite database after selecting appropriate genes using gene id search (31). TPM values of *C. parvum* ribosomal proteins were used to generate expression heatmap as well as clustering of samples using shinyheatmap (72). For clustering, the Euclidean distance metric and the “complete” linkage algorithm were used.

2.5.6: *C. parvum* genes’ Upstream and Downstream Sequence Analysis

1 kb upstream and 1 kb downstream region of all the *C. parvum* genes were uploaded in the usegalaxy.org server. All the *C. parvum* coding sequences were then used as adapter sequences in the cutadapter tool to remove any coding part from the up and downstream sequences of the *C. parvum* genes. Such regulatory sequences from the selected genes were used as inputs and regulatory sequences from all the *C. parvum* genes were used as background in the “DREME” tool (73) hosted at “MEME-suite” server (74) to identify significantly enriched motifs. Position of specific motifs at the regulatory sequences of *C. parvum* genes were determined using the “FIMO” tool (75).

2.6: Figure legends

Figure 1: Stage specific assay development and library screening. A) Two replicate experiments showing anti-DMC1 antibody staining is sensitive and specific for quantitative screening purposes. HCT8 cell monolayers grown in 384-well culture plates were infected with *C. parvum*, and then stained for the female gamont-specific marker DMC1 at 72 hours post infection (hpi). The DMC1⁺ parasite ratio was calculated for the 72 hpi timepoint, along with the z' score for each replicate. N=56 for each replicate, 28 each for wells stained with (red) or without (blue) inclusion of anti-DMC1 antibody. B) Representative images of HCT8 cells infected with *C. parvum* and stained with fluorescent conjugated lectin, anti DMC1 antibody and nuclear stain. C) Combined assay strategy, showing compound addition and imaging timepoints as well as the four different readouts. Each readout is normalized to the readout value of vehicle treated wells from the same plate to calculate the “percent inhibition” value. D) Statistics of the primary screening for all the four readouts, showing average and standard deviation (SD) of the percent inhibition of vehicle-treated wells and inhibitor control wells from all the screening plates, as well as all the ReFRAME library compounds. Note that the expected mean percent inhibition by ReFRAME compounds with no activity (the vast majority) is 0. Hits were identified as compounds with a percent inhibition differing from the mean for all compounds by over two standard deviations. The cutoff values (library mean \pm 2 * Standard deviation) for hit identification are given in the bottom two rows. E) Heatmap showing the result pattern

of the primary hits (311 compounds). Compound activity values are z normalized across each readout using the mean and SD of percent inhibitions for all the compounds of the ReFRAME library.

Figure 2: Categories of the validated hits and example dose response curves. A) Pie chart showing categorization of different hits. 2B to 2L show typical dose response curves for compounds representative of the different categories. Each point is from a single biological replicate and each curve shows one of the four readouts, as indicated in the figure. B) Pan-inhibitor, C) False hit, D) Asexual stage inhibitors without any activity in the sexual development readout, E) Asexual stage inhibitors with mid-range efficacy in the sexual development readout, F) Differentiation inhibitor, G) Differentiation inhibitor with narrow selectivity, H) Differentiation inducer, I) Development inducer, J) Inducer of both sexual readouts, K) Compound class undetermined. For 2H and 2J, activity values in the differentiation readout are excluded for the doses with above 70% asexual inhibition at 72hpi, because at these concentrations very few parasites were present. L) The dose response curve of the single compound that induced high DMC1 expression at 48 hours. DMC1⁺ parasite ratio at 48 hpi (which is not one of the four standard readouts) is shown in green along with the four other readouts for this compound only.

Figure 3: Differentiation inhibitors share common putative targets and they selectively inhibit sexual differentiation across a range of concentrations. A)

Putative targets of all the categorized differentiation inhibitors. (*) denotes targets in nucleotide biosynthesis pathways and (**) denotes mitochondrial oxidative phosphorylation inhibitors. The first nine compounds were selected for follow-up experiments due to a large concentration window to enable inhibition of sexual differentiation with minimal effect on parasite asexual growth. B) Simplified nucleotide biosynthesis pathway of human cells. Enzyme names are colored and only enzymes with putative modulators in our validated hits are shown. Inhibitors of (*) marked enzymes are differentiation inhibitors and others are asexual stage inhibitors. Red colored enzymes have identified homologs in the *C. parvum* genome while the blue colored enzymes do not have an identified homolog in the parasite. PRPP: 5-phosphoribosyl pyrophosphate; PPAT: phosphoribosyl pyrophosphate amidotransferase; GARTFase: Glycinamide Ribonucleotide Formyltransferase; GAR: glycinamide ribonucleotide; IMP: Inosine monophosphate; XMP: Xanthosine monophosphate; DHF: Dihydrofolate; DHFR: Dihydrofolate reductase; THF: tetrahydrofolate; DHO: dihydroorotate; DHOD: dihydroorotate dehydrogenase; OMP: orotidine-5'-monophosphate. C) Dose response curves of the nine differentiation inhibitors selected for follow up. Compounds were added at 3 hpi and imaged at 72 hpi. Partially overlapping concentration ranges were tested for each of them in 2 to 3 biological replicates. Each point and error bar denotes mean and standard deviation for readings from 4 separate wells for each concentration in each biological replicate. The dotted reference line in the Y axis denotes the concentration selected for

mRNA-seq experiments.

Figure 4: Differentiation inhibitors are required to be added before parasite sexual differentiation. A) Experimental setup showing compound addition timepoints and measured response. B) Dose response curves showing percent inhibition of the proportion of DMC1⁺ parasites at 72hpi after the addition of differentiation inhibitors at indicated timepoints. Each point and error bar denotes mean and standard error of the mean from 4 replicate well.

Figure 5: Treatment with differentiation inhibitors dysregulates a set of core genes involved in parasite differentiation. A) Experimental setup for the pilot mRNA-seq experiment. The number of genes dysregulated (fold change ≥ 2 at a False Discovery Rate of ≤ 0.1) between subsequent timepoints of the experiment are listed. B) Experimental setup and the number of dysregulated genes (fold change ≥ 2 at a False Discovery Rate of ≤ 0.1) with differentiation inhibitor treatments. C) Percentage of the upregulated *C. parvum* genes in each treatment that is shared by upregulated genes with other differentiation inhibitor treatments. D) Percentage of the downregulated *C. parvum* genes in each treatment that is shared by upregulated genes with other differentiation inhibitor treatments. E) Stage specificity of the genes that are dysregulated in ≥ 5 differentiation inhibitor treatments.

Transcriptome data was generated from 2 biological replicates for each

timepoint and/or treatment, except for 48 hpi control (n=3) and pralatrexate treatment (n=1).

Figure 6: *C. parvum* sexual differentiation is associated with suppression of ribosome formation, which is indicative of a translational repression program. A) DAVID functional annotation results for significantly dysregulated genes in ≥ 5 treatments, and between asexual and female *C. parvum*. Functional annotation enrichments with an FDR of ≤ 0.0001 are included only. Dysregulated genes were identified at a 10% false discovery rate (FDR) B) Heatmap of the average transcript per million (TPM) values of ribosomal protein genes of *C. parvum* at various timepoints (control) and in treatments with differentiation inhibitors (48 hpi). Each row represents a single gene encoding a ribosomal protein. TPM values are Z normalized across each row. Hierarchical clustering between the samples using the expression values of the ribosomal proteins was performed using the “complete” linkage algorithm and Euclidean distance metrics and is shown on the top of the heatmap. C) The most significantly differentially enriched DNA motif in the promoter region of the ribosomal protein genes compared to all *C. parvum* genes. D) Chi-square test of the association between the presence of the DNA motif from (C) in the promoter region of commonly dysregulated *C. parvum* genes (excluding ribosomal protein genes) and the direction of dysregulation. E) The location of the DNA motif from (C) in the promoter region of *C. parvum* genes harboring that motif. Other genes include genes that contain the motif in

their promoter region but are not dysregulated with ≥ 5 differentiation inhibitor treatment (fold change ≥ 1 and FDR ≤ 0.1) and not ribosomal proteins. F) Significant enrichment (p-value cutoff ≤ 0.5) of the two specific gene ontology (GO) terms during gene ontology enrichment analysis of apicomplexan genes that are dysregulated between the listed life cycle stages. Dysregulated genes are defined as genes with a log₂ fold difference of ≥ 1 at 10% false discovery rate (FDR).

Figure 7: Promoters of downregulated genes of *C. parvum* harbor a recognition site for several ApiAP2 transcription factors that are also dysregulated by differentiation inhibitor treatments. A) log₂ fold change of four ApiAP2 transcription factors of *C. parvum* with differentiation inhibitor treatments when FDR is $\leq 10\%$. B) The most significantly differentially enriched DNA motif in the promoter region of the genes that are ≥ 2 fold downregulated in ≥ 5 compound treatments compared to all *C. parvum* genes.

Figure 8: A proposed model of repressing *C. parvum* sexual differentiation by the two Methionine aminopeptidase 2 (MetAP2) inhibitors. Eukaryotic translation initiation factor 2 α is abbreviated eIF2 α . See the discussion section for detailed explanation of the model.

Supplementary Table 1: Structure, categorization, and putative mode of action

of all the compounds selected as hits from the primary screening.

Supplementary Table 2: log₂ fold changes of parasite genes between different treatments and timepoints. Gene names from the Cryptodb database are included along with the gene IDs. Values are included only if the FDR is below 0.1 in differential gene expression analysis by DEseq2.

Supplementary Table 3: DAVID functional annotation enrichment analysis of dysregulated genes (fold change ≥ 2 and FDR ≤ 0.1) with differentiation inhibitor treatment.

Supplementary table 4: Eupathdb Gene ontology (GO) enrichment analysis of various life cycle stages of different apicomplexan parasites. In total, comparisons for 9 different axes of differentiation were performed; 5 from *Plasmodium*, 2 from *Eimeria*, and 1 from *Toxoplasma*. For each, both upregulated and downregulated genes are analyzed separately in “cellular component” and “molecular function”, culminating in a total of 36 comparisons.

Supplementary Figure 1: Dose response curves of all the screening hits. 8-point dose response curves of all the primary screening hits in all 4 readouts. IDs correspond to the compound ids from the first column of Supplementary Table 1.

Duplicate curves (marked with “#”) are included for compounds that induce sexual differentiation or development in a dose dependent manner at a concentration range that is not highly inhibitory to asexual replication. For the duplicate curves, relevant sexual stage readouts are excluded for high asexual stage inhibitory concentrations. IDs marked with asterisks (*) are compounds without a determined dose response in one of the readouts due to imaging quality error.

Supplementary Figure 2: Volcano plots of dysregulated genes by AGM-1470 and Oligomycin A treatment. *C. parvum* genes are shown with a circle and host genes are shown with a “plus” sign. Red colored genes are significantly differentially regulated and blue colored genes are not significantly differentially regulated. P-values were not calculated for the black colored genes.

Supplementary Figure 3: *C. parvum* asexual stage specific genes are upregulated and female specific genes are downregulated with differentiation inhibitor treatments. Two Venn diagrams showing the commonality between genes dysregulated with ≥ 5 differentiation inhibitor treatments with that of genes differentially regulated between FAC-sorted asexual and female stage parasites.

Supplementary Figure 4: Stage specificity of genes dysregulated by differentiation inhibitor treatments. The top panel shows the number of genes in

each class and the number of genes dysregulated by the treatment from that class. The bottom panel plots the log₂ fold changes of significantly dysregulated ($FDR \leq 0.1$) genes from the corresponding class.




Figure 1: Stage specific assay development and library screening




Figure 2: Categories of the validated hits and example dose response curves

A

Name	Putative target
Beloranib hemioxalate	Methionine Aminopeptidase-2 (MetAP2) Inhibitor
AGM-1470	Methionine Aminopeptidase-2 (MetAP2) Inhibitor
Oligomycin A	ATP synthase inhibitor**
Antimycin A	Mitochondrial complex III inhibitor**
BAY 61-3606 dihydrochloride	Tyrosine kinase inhibitor
Mycophenolate mofetil	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors*
Pralatrexate	Dihydrofolate reductase (DHFR) inhibitor*
TVB-2640	Fatty acid synthase inhibitor
Mubritinib	ErbB-2 tyrosine kinase inhibitor
IACS-10759	Mitochondrial Complex I Inhibitors**
PYRIDABEN	Mitochondrial Complex I Inhibitors**
Metoprine	Dihydrofolate reductase (DHFR) inhibitor*
Methylthioinosine	Phosphoribosylpyrophosphate amidotransferase (PPAT) inhibitor*
RWJ-46458	Angiotensin AT1 Antagonists
OCT-1547	RANK ligand inhibitor
Pelitrexol	Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors*
BX-471	CC chemokine receptor 1 antagonist
CAI orotate	PI3 kinase inhibitor/ VEGF receptor antagonist/ Calcium channel antagonist
SCHEMBL10678365	Antidepressant
ZD 2138	Lipoxygenase 5 Inhibitor
FLUFYLLINE	5 Hydroxytryptamine 2 receptor antagonist

B




Figure 3: Differentiation inhibitors share common putative targets and they selectively inhibit sexual differentiation across a range of concentrations

C

■ Total parasite/ host cell nuclei ◆ DMC1⁺ Parasite/ Total parasite




Figure 3 (continued)




Figure 4: Differentiation inhibitors are required to be added before parasite sexual differentiation




Figure 5: Treatment with differentiation inhibitors dysregulates a set of core genes involved in parasite differentiation

Comparison	Category	Term	P Value	Fold Enrichment	FDR
Upregulated in ≥5 compound treatment	UP_KEYWORDS	Ribosomal protein	8.0E-18	4.30	8.0E-17
	UP_KEYWORDS	Ribonucleoprotein	4.5E-16	3.74	4.4E-15
	KEGG_PATHWAY	cpv03008:Ribosome biogenesis in eukaryotes	1.7E-15	4.61	1.2E-14
	KEGG_PATHWAY	cpv03010:Ribosome	2.3E-15	3.50	1.6E-14
	GOTERM_CC_DIRECT	GO:0005840~ribosome	2.4E-15	4.36	2.0E-14
	GOTERM_BP_DIRECT	GO:0006412~translation	2.6E-14	3.90	2.6E-13
	GOTERM_MF_DIRECT	GO:0003735~structural constituent of ribosome	7.6E-14	3.99	7.9E-13
	GOTERM_BP_DIRECT	GO:0042254~ribosome biogenesis	3.5E-08	7.26	3.4E-07
	GOTERM_CC_DIRECT	GO:0005730~nucleolus	7.8E-08	6.54	6.6E-07
	GOTERM_BP_DIRECT	GO:0006364~rRNA processing	1.9E-07	5.94	1.9E-06
Downregulated in ≥5 compound treatment	UP_KEYWORDS	Ribosome biogenesis	9.3E-06	7.47	9.2E-05
	KEGG_PATHWAY	cpv01110:Biosynthesis of secondary metabolites	7.3E-08	3.64	7.2E-07
	KEGG_PATHWAY	cpv00010:Glycolysis / Gluconeogenesis	3.0E-07	6.30	3.0E-06
	KEGG_PATHWAY	cpv01130:Biosynthesis of antibiotics	1.7E-06	4.01	1.7E-05
	KEGG_PATHWAY	cpv01200:Carbon metabolism	5.0E-06	5.72	4.9E-05
Downregulated in female compared to asexual stages	UP_KEYWORDS	Ribosomal protein	9.9E-41	4.15	1.1E-39
	UP_KEYWORDS	Ribonucleoprotein	6.6E-39	3.77	7.1E-38
	GOTERM_CC_DIRECT	GO:0005840~ribosome	4.7E-32	3.75	4.6E-31
	GOTERM_MF_DIRECT	GO:0003735~structural constituent of ribosome	5.0E-32	3.68	5.9E-31
	GOTERM_BP_DIRECT	GO:0006412~translation	5.9E-32	3.41	6.6E-31
	KEGG_PATHWAY	cpv03010:Ribosome	2.0E-28	2.76	1.9E-27
	KEGG_PATHWAY	cpv03008:Ribosome biogenesis in eukaryotes	5.8E-07	2.15	5.4E-06
	GOTERM_BP_DIRECT	GO:0006351~transcription, DNA-templated	4.0E-06	2.36	4.4E-05
Upregulated in female compared to asexual stage	KEGG_PATHWAY	cpv01100:Metabolic pathways	3.5E-06	1.77	3.5E-05
	KEGG_PATHWAY	cpv00010:Glycolysis / Gluconeogenesis	8.6E-06	4.51	8.6E-05

B




Figure 6: *C. parvum* sexual differentiation is associated with suppression of ribosome formation, which is indicative of a translational repression program




Figure 6 (continued)




Figure 7: Promoters of downregulated genes of *C. parvum* harbor a recognition site for several ApiAP2 transcription factors that are also dysregulated by differentiation inhibitor treatments







Figure 8: A proposed model of repressing *C. parvum* sexual differentiation by the two Methionine aminopeptidase 2 (MetAP2) inhibitors




Supplementary Figure 1: Dose response curves of all the screening hits




Supplementary Figure 1 (continued)




Supplementary Figure 1 (continued)




Supplementary Figure 1 (continued)




Supplementary Figure 1 (continued)




Supplementary Figure 1 (continued)




Supplementary Figure 1 (continued)



Supplementary Figure 2: Volcano plots of dysregulated genes by AGM-1470 and Oligomycin A treatment.



Supplementary Figure 3: *C. parvum* asexual stage specific genes are upregulated and female specific genes are downregulated with differentiation inhibitor treatments



Supplementary Figure 4: Stage specificity of genes dysregulated by differentiation inhibitor treatments

2.7: References

1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet* (London, England). 2013;382(9888):209-22.
2. Huston CD, Spangenberg T, Burrows J, Willis P, Wells TN, van Voorhis W. A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. *PLoS neglected tropical diseases*. 2015;9(10):e0003987.
3. Leitch GJ, He Q. Cryptosporidiosis-an overview. *Journal of biomedical research*. 2012;25(1):1-16.
4. Woodmansee DB. Studies of in vitro excystation of *Cryptosporidium parvum* from calves. *The Journal of protozoology*. 1987;34(4):398-402.
5. Arrowood MJ. In vitro cultivation of cryptosporidium species. *Clinical microbiology reviews*. 2002;15(3):390-400.
6. Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, et al. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like *Cryptosporidium* growth inhibitors. *Nature communications*. 2019;10(1):1862.
7. Tandel J, English ED, Sateriale A, Gullicksrud JA, Beiting DP, Sullivan MC, et al. Life cycle progression and sexual development of the apicomplexan parasite *Cryptosporidium parvum*. *Nature microbiology*. 2019;4(12):2226-36.

8. Funkhouser-Jones LJ, Ravindran S, Sibley LD. Defining Stage-Specific Activity of Potent New Inhibitors of *Cryptosporidium parvum* Growth In Vitro. *mBio*. 2020;11(2).
9. Howick VM, Russell AJC, Andrews T, Heaton H, Reid AJ, Natarajan K, et al. The Malaria Cell Atlas: Single parasite transcriptomes across the complete *Plasmodium* life cycle. *Science (New York, NY)*. 2019;365(6455).
10. Xue Y, Theisen TC, Rastogi S, Ferrel A, Quake SR, Boothroyd JC. A single-parasite transcriptional atlas of *Toxoplasma gondii* reveals novel control of antigen expression. *eLife*. 2020;9.
11. Walker RA, Sharman PA, Miller CM, Lippuner C, Okoniewski M, Eichenberger RM, et al. RNA Seq analysis of the *Eimeria tenella* gametocyte transcriptome reveals clues about the molecular basis for sexual reproduction and oocyst biogenesis. *BMC genomics*. 2015;16:94.
12. Tonui T, Corredor-Moreno P, Kanduma E, Njuguna J, Njahira MN, Nyanjom SG, et al. Transcriptomics reveal potential vaccine antigens and a drastic increase of upregulated genes during *Theileria parva* development from arthropod to bovine infective stages. *PloS one*. 2018;13(10):e0204047.
13. Delves MJ, Angrisano F, Blagborough AM. Antimalarial Transmission-Blocking Interventions: Past, Present, and Future. *Trends in parasitology*. 2018;34(9):735-46.
14. Schwartz E. Prophylaxis of malaria. *Mediterranean journal of hematology and*

infectious diseases. 2012;4(1):e2012045.

15. Murata Y, Sugi T, Weiss LM, Kato K. Identification of compounds that suppress *Toxoplasma gondii* tachyzoites and bradyzoites. *PloS one*. 2017;12(6):e0178203.
16. Garfoot AL, Wilson GM, Coon JJ, Knoll LJ. Proteomic and transcriptomic analyses of early and late-chronic *Toxoplasma gondii* infection shows novel and stage specific transcripts. *BMC genomics*. 2019;20(1):859.
17. Chen LF, Han XL, Li FX, Yao YY, Fang JP, Liu XJ, et al. Comparative studies of *Toxoplasma gondii* transcriptomes: insights into stage conversion based on gene expression profiling and alternative splicing. *Parasites & vectors*. 2018;11(1):402.
18. Yeoh LM, Goodman CD, Mollard V, McFadden GI, Ralph SA. Comparative transcriptomics of female and male gametocytes in *Plasmodium berghei* and the evolution of sex in alveolates. *BMC genomics*. 2017;18(1):734.
19. Lindner SE, Swearingen KE, Shears MJ, Walker MP, Vrana EN, Hart KJ, et al. Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites. *Nature communications*. 2019;10(1):4964.
20. Waldman BS, Schwarz D, Wadsworth MH, 2nd, Saeij JP, Shalek AK, Lourido S. Identification of a Master Regulator of Differentiation in *Toxoplasma*. *Cell*. 2020;180(2):359-72 e16.
21. Modrzynska K, Pfander C, Chappell L, Yu L, Suarez C, Dundas K, et al. A Knockout Screen of *ApiAP2* Genes Reveals Networks of Interacting Transcriptional

- Regulators Controlling the Plasmodium Life Cycle. *Cell host & microbe*. 2017;21(1):11-22.
22. Zhang C, Li Z, Cui H, Jiang Y, Yang Z, Wang X, et al. Systematic CRISPR-Cas9-Mediated Modifications of *Plasmodium yoelii* ApiAP2 Genes Reveal Functional Insights into Parasite Development. *mBio*. 2017;8(6).
23. Ikadai H, Shaw Saliba K, Kanzok SM, McLean KJ, Tanaka TQ, Cao J, et al. Transposon mutagenesis identifies genes essential for *Plasmodium falciparum* gametocytogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(18):E1676-84.
24. Radke JB, Worth D, Hong D, Huang S, Sullivan WJ, Jr., Wilson EH, et al. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. *PLoS pathogens*. 2018;14(5):e1007035.
25. Child MA. Chemical biology approaches for the study of apicomplexan parasites. *Molecular and biochemical parasitology*. 2013;192(1-2):1-9.
26. Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115(42):10750-5.
27. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *Journal of biomolecular screening*. 1999;4(2):67-73.

28. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nature methods*. 2015;12(4):357-60.
29. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics (Oxford, England)*. 2015;31(2):166-9.
30. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology*. 2014;15(12):550.
31. Aurrecochea C, Barreto A, Basenko EY, Brestelli J, Brunk BP, Cade S, et al. EuPathDB: the eukaryotic pathogen genomics database resource. *Nucleic acids research*. 2017;45(D1):D581-D91.
32. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature protocols*. 2009;4(1):44-57.
33. Kent RS, Modrzynska KK, Cameron R, Philip N, Billker O, Waters AP. Inducible developmental reprogramming redefines commitment to sexual development in the malaria parasite *Plasmodium berghei*. *Nature microbiology*. 2018;3(11):1206-13.
34. Zanghi G, Vembar SS, Baumgarten S, Ding S, Guizetti J, Bryant JM, et al. A Specific PfEMP1 Is Expressed in *P. falciparum* Sporozoites and Plays a Role in Hepatocyte Infection. *Cell reports*. 2018;22(11):2951-63.
35. Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and *Toxoplasma gondii* during acute and chronic infection. *BMC genomics*. 2014;15:806.
36. Ramakrishnan C, Maier S, Walker RA, Rehrauer H, Joekel DE, Winiger RR, et

- al. An experimental genetically attenuated live vaccine to prevent transmission of *Toxoplasma gondii* by cats. *Scientific reports*. 2019;9(1):1474.
37. Mair GR, Braks JA, Garver LS, Wiegant JC, Hall N, Dirks RW, et al. Regulation of sexual development of *Plasmodium* by translational repression. *Science* (New York, NY). 2006;313(5787):667-9.
38. Mair GR, Lasonder E, Garver LS, Franke-Fayard BM, Carret CK, Wiegant JC, et al. Universal features of post-transcriptional gene regulation are critical for *Plasmodium* zygote development. *PLoS pathogens*. 2010;6(2):e1000767.
39. Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister S, et al. The *Plasmodium* eukaryotic initiation factor-2 α kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. *The Journal of experimental medicine*. 2010;207(7):1465-74.
40. Narasimhan J, Joyce BR, Naguleswaran A, Smith AT, Livingston MR, Dixon SE, et al. Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in *Toxoplasma gondii*. *The Journal of biological chemistry*. 2008;283(24):16591-601.
41. Joyce BR, Queener SF, Wek RC, Sullivan WJ, Jr. Phosphorylation of eukaryotic initiation factor-2 α promotes the extracellular survival of obligate intracellular parasite *Toxoplasma gondii*. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(40):17200-5.
42. Oberstaller J, Pumpalova Y, Schieler A, Llinás M, Kissinger JC. The

- Cryptosporidium parvum ApiAP2 gene family: insights into the evolution of apicomplexan AP2 regulatory systems. *Nucleic acids research*. 2014;42(13):8271-84.
43. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, et al. Complete genome sequence of the apicomplexan, *Cryptosporidium parvum*. *Science (New York, NY)*. 2004;304(5669):441-5.
44. Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, et al. A Stem-Cell-Derived Platform Enables Complete *Cryptosporidium* Development In Vitro and Genetic Tractability. *Cell host & microbe*. 2019;26(1):123-34 e8.
45. Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, et al. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. *British journal of cancer*. 2011;104(2):272-80.
46. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology*. 2000;47(2-3):85-118.
47. Pawlowic MC, Somepalli M, Sateriale A, Herbert GT, Gibson AR, Cuny GD, et al. Genetic ablation of purine salvage in *Cryptosporidium parvum* reveals nucleotide uptake from the host cell. *Proceedings of the National Academy of Sciences of the United States of America*. 2019;116(42):21160-5.
48. Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. *Diabetes, metabolic syndrome and obesity : targets and therapy*. 2014;7:73-84.
49. Datta R, Choudhury P, Bhattacharya M, Soto Leon F, Zhou Y, Datta B.

Protection of translation initiation factor eIF2 phosphorylation correlates with eIF2-associated glycoprotein p67 levels and requires the lysine-rich domain I of p67.

Biochimie. 2001;83(10):919-31.

50. Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. *Progress in molecular and subcellular biology*. 2001;27:57-89.

51. Donnelly N, Gorman AM, Gupta S, Samali A. The eIF2alpha kinases: their structures and functions. *Cellular and molecular life sciences : CMLS*. 2013;70(19):3493-511.

52. Datta B, Majumdar A, Datta R, Balusu R. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. *Biochemistry*. 2004;43(46):14821-31.

53. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. *Chemistry & biology*. 1997;4(6):461-71.

54. Sullivan WJ, Jr., Narasimhan J, Bhatti MM, Wek RC. Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control. *The Biochemical journal*. 2004;380(Pt 2):523-31.

55. Konrad C, Queener SF, Wek RC, Sullivan WJ, Jr. Inhibitors of eIF2alpha dephosphorylation slow replication and stabilize latency in *Toxoplasma gondii*. *Antimicrobial agents and chemotherapy*. 2013;57(4):1815-22.

56. Augusto L, Martynowicz J, Staschke KA, Wek RC, Sullivan WJ, Jr. Effects of PERK eIF2alpha Kinase Inhibitor against *Toxoplasma gondii*. *Antimicrobial agents and chemotherapy*. 2018;62(11).
57. Gomes-Santos CS, Braks J, Prudencio M, Carret C, Gomes AR, Pain A, et al. Transition of *Plasmodium* sporozoites into liver stage-like forms is regulated by the RNA binding protein Pumilio. *PLoS pathogens*. 2011;7(5):e1002046.
58. Muller K, Matuschewski K, Silvie O. The Puf-family RNA-binding protein Puf2 controls sporozoite conversion to liver stages in the malaria parasite. *PloS one*. 2011;6(5):e19860.
59. Cui L, Lindner S, Miao J. Translational regulation during stage transitions in malaria parasites. *Annals of the New York Academy of Sciences*. 2015;1342:1-9.
60. Harris JR, Adrian M, Petry F. Amylopectin: a major component of the residual body in *Cryptosporidium parvum* oocysts. *Parasitology*. 2004;128(Pt 3):269-82.
61. Petry F. Structural analysis of *Cryptosporidium parvum*. *Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada*. 2004;10(5):586-601.
62. Dalla Venezia N, Vincent A, Marcel V, Catez F, Diaz JJ. Emerging Role of Eukaryote Ribosomes in Translational Control. *International journal of molecular sciences*. 2019;20(5).
63. Radke JB, Lucas O, De Silva EK, Ma Y, Sullivan WJ, Jr., Weiss LM, et al. ApiAP2 transcription factor restricts development of the *Toxoplasma* tissue cyst.

Proceedings of the National Academy of Sciences of the United States of America.
2013;110(17):6871-6.

64. Hong DP, Radke JB, White MW. Opposing Transcriptional Mechanisms Regulate Toxoplasma Development. *mSphere*. 2017;2(1).

65. Sinha A, Hughes KR, Modrzynska KK, Otto TD, Pfander C, Dickens NJ, et al. A cascade of DNA-binding proteins for sexual commitment and development in Plasmodium. *Nature*. 2014;507(7491):253-7.

66. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nature methods*. 2012;9(7):676-82.

67. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic acids research*. 2018;46(W1):W537-w44.

68. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics (Oxford, England)*. 2014;30(15):2114-20.

69. Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. *Nucleic acids research*. 2019;47(D1):D766-d73.

70. Heiges M, Wang H, Robinson E, Aurrecoechea C, Gao X, Kaluskar N, et al. CryptoDB: a Cryptosporidium bioinformatics resource update. *Nucleic acids research*. 2006;34(Database issue):D419-22.

71. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic acids research*. 2009;37(1):1-13.
72. Khomtchouk BB, Hennessy JR, Wahlestedt C. shinyheatmap: Ultra fast low memory heatmap web interface for big data genomics. *PloS one*. 2017;12(5):e0176334.
73. Bailey TL. DREME: motif discovery in transcription factor ChIP-seq data. *Bioinformatics (Oxford, England)*. 2011;27(12):1653-9.
74. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME SUITE: tools for motif discovery and searching. *Nucleic acids research*. 2009;37(Web Server issue):W202-8.
75. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. *Bioinformatics (Oxford, England)*. 2011;27(7):1017-8.

CHAPTER 3: DISCUSSION AND FUTURE DIRECTION

Apicomplexan parasites, other than being huge public health concerns, are fascinating biological systems to study cell biology, parasitism, and evolution. These unicellular eukaryotic organisms are obligate intracellular parasites that are capable of morphing into distinct phenotypic structures throughout their life cycle. Epigenetic, transcriptional, and translational control of gene expression, undoubtedly shaped by the condition of the host cell or organism, are the key to achieving this extraordinary feat. In this study, we have used a chemical genomics approach to study the regulation of sexual differentiation of the apicomplexan parasite *Cryptosporidium parvum*. Our data suggest that (i) this differentiation is expectedly associated with large scale changes in the parasite transcriptome; (ii) modulating specific pathways of the host affects the differentiation process; and (iii) global translational control of protein expression likely mediated by altered ribosomal biogenesis plays a key regulatory role in controlling *C. parvum* sexual differentiation, which is perhaps a common mode of regulating stage differentiation in apicomplexan parasites.

3.1: Potential Function and Stage Specificity of the *C. parvum* DMC1 protein

We have used the expression of *C. parvum* DMC1 (Disrupted Meiotic cDNA, cgd7_1690) protein as a marker for the parasite sexual stage. Most eukaryotes have a homolog of DMC1 and it is a meiotic recombinase that facilitates homologous chromosome pairing during meiotic recombination (1). Rad51, which is also a

recombinase, is a paralog of DMC1 that is also present in most eukaryotes, including *Cryptosporidium*. A gene duplication event during early eukaryotic evolution gave rise to the DMC1 and RAD51 recombinase families (2). Knocking out DMC1 in *S. cerevisiae* arrests its growth at meiotic prophase (3) whereas homozygous DMC1 knockout mice are sterile (4). On the other hand, RAD51 knockout is embryonic lethal to mice (5). These and other studies suggest that in most eukaryotes, DMC1 preferentially functions during meiotic recombination whereas RAD51 takes part in both meiotic and mitotic recombination (1). Previously, using qRT-PCR, we showed that DMC1 expression peaks at 72 hours post infection (hpi) and correlates with the emergence of gametocytes in the culture, which was the basis of using DMC1 as a sexual stage marker (6). Our time-course mRNA-seq experiment also confirms this observation (Figure 1). Interestingly, RAD51 (*cgd5_410*) expression also peaks at 72 hpi; however, the level of upregulation from 48 hpi is patently more pronounced for DMC1.

Immunofluorescence microscopy using an anti-DMC1 monoclonal antibody identifies DMC1 in uninucleated parasites, strongly suggesting that it is specifically expressed in female gamonts (6). This conclusion is further supported by the observation that immunofluorescence staining of oocysts locates DMC1 within the oocysts, but outside of the sporozoites (Figure 2). That is because the female gamont containing parasitophorous vacuoles (PV) ultimately differentiate into oocysts following fertilization. We also attempted to perform immunoelectron microscopy of

C. parvum infected HCT8 using our anti-DMC1 antibody clone, but failed to localize the protein with the method. Perhaps the reason behind this is that the tertiary structure of the DMC1 protein is sensitive to alcohol treatment. During our initial staining optimization, we tested different fixatives for the staining and both ethanol and glutaraldehyde fixation resulted in the loss of anti-DMC1 staining.

Determining parasite stages via alternative methods suggests that the ratio of macrogamonts in the HCT8 infection model increases logarithmically between 36 and 48 hpi (7, 8), but then the ratio is relatively unchanged between 48 and 72 hpi (7). By contrast, the DMC1 mRNA level and DMC1+ parasite number increase dramatically between 48 and 72 hpi (Figure 1 and 2). Our interpretation of these observations is that the level of DMC1 protein within female gamonts increases to a detectable level as the gamont matures. Alternatively, it is possible that our specific culture condition delays the emergence of female gamonts or the other methods overcalculated female gamonts at 48 hpi. In that case, the low level of staining and the low mRNA level at 48 hpi compared to 72 hpi might arise from a lower number of female gamonts present at 48 hpi instead of the proposed low level of DMC1 expression by female gamonts. As we determined the number of DMC1+ parasites at 72 hpi and the ratio of DMC1+ parasites is consistent with the ratio of female gamonts at that timepoint determined by other methods, whichever of the above-mentioned explanations is correct does not carry too much significance regarding our subsequent conclusions. However, the implication of the first model, that there is a maturation phase of female gamonts that takes around 24

hours, is in itself an important potential aspect of *Cryptosporidium* biology that is worthy of further experimentation. Understanding the requirements and regulations for the female gamont maturation might give us clues regarding the basis of failed gamont fertilization in the HCT8 infection model.

Another protein that has recently been used as a macrogamont marker is *Cryptosporidium* oocyst wall protein-1 (COWP1, cgd6_2090) (7). Interestingly, its expression level is stably maintained after sexual differentiation and does not vary as dramatically as DMC1 between 48 hpi and 72 hpi (Figure 1). Perhaps the COWP1 is a marker of female gamont that is independent of its developmental stage, which further supports our first model of slow maturation of female gamonts.

3.2: The Rationale for Focusing on Differentiation Inhibitors for Follow-up Experiments

Dose response dependent validation of the screening hits from the ReFRAME library allowed us to classify compounds into several groups. A major initial goal of our screen was to determine if differentiation inhibitors could be used to achieve continuous asexual replication of *C. parvum* within HCT8 cells, which might allow us to establish a continuous asexual culture system of *Cryptosporidium*. Toward that goal, we assayed *C. parvum* growth after a prolonged incubation of 7 days post infection in the presence of the differentiation inhibitors. While the numbers of parasites observed at these late time points were higher for several treatments compared to control (Figure

3), we did not observe the maintenance of logarithmic growth that is generally observed up to 48 hpi. Our tentative conclusion from this set of experiments is that the differentiation inhibitors might induce additional rounds of asexual replication; however, the culture system ultimately becomes unfavorable for continuous parasite replication. Variation of this experimental setup, like testing other concentrations of the compounds or adding the compounds multiple times throughout the experiment might produce a different outcome. The reason we did not pursue this further was that we also could not successfully subculture parasites from an infected HCT8 monolayer to an uninfected monolayer, which in our view is an important prerequisite for the development of a continuous culture system. Instead, we moved forward with utilizing differentiation inhibitors as tools to examine the genetic regulation of *C. parvum* sexual differentiation.

3.3: Potential Follow-up Experiments with Other Compound Classes

The other classes of compounds were theoretically not compatible with our initial goal of establishing a continuous asexual culture. Therefore, we did not acquire representative compounds from other classes for follow up experiments. However, they would be valuable complementary compounds in terms of examining the genetic regulation of sexual differentiation. For example, treatment with differentiation inducers might dysregulate parasite genes in the opposite direction from what we have observed from the differentiation inhibitor treatments. We are currently in the process

of performing detailed dose response curves for some of the other compound classes. After that, we plan to perform mRNA-seq experiments with some of them, analyze the gene expression dysregulation pattern, and compare that to the dysregulation pattern of differentiation inhibitor treatments.

3.4: Other Potential Utilities of Differentiation Inhibitors

Recently, several in vitro culture platforms have been described that support the full *C. parvum* life cycle (9-13). Establishment of an air liquid interface (ALI) condition for mouse intestinal stem cell derived culture produces viable oocysts upon infection that can further excyst and cause additional rounds of infection (13). The ALI condition is associated with substantive genetic and metabolic alteration of host cells compared to non-ALI condition, which led to the suggestion that the host cells under ALI condition provide a better condition for *C. parvum* growth. Additionally, small molecules can be administered in a defined concentration in this culture system (8, 13). Collectively, this platform is superior to test several potential effects of differentiation inhibitors on the *C. parvum* life cycle compared to HCT8 infection model (where the life cycle is not completed) or in vivo animal infection (where it is challenging to maintain a specific concentration of compounds in the target tissue). Our initial attempts to establish a continuous asexual culture in the HCT8 cells might have failed because the host cell became inhospitable for supporting prolonged parasite growth. ALI culture can remove that variable and the effect of differentiation inhibitors would

be interpreted more clearly. Also, the druggability of the parasite differentiation process can be robustly tested with differentiation inhibitors on the ALI culture. If any of our identified differentiation inhibitors block sexual differentiation in ALI cultures in a similar way, inhibition of continuous parasite growth would mean that targeting sexual differentiation would be a viable means for treating cryptosporidiosis. We are currently in the process of establishing this culture system in our laboratory.

3.5: Potential Genetic Validation of The Chemical Genomics Approach

CRISPR/Cas9 dependent genetic modification of *C. parvum* was published in 2015, making the parasite genetically tractable (14). Currently, there is a single validated selectable marker gene. Therefore, genetic modification of multiple loci is not possible at this point. Currently available plasmids are not episomally maintained within the parasite, so transgene expression is only possible by integrating them into the genome. Thymidine kinase has been proven to be a non-essential gene in the parasite, and this locus has been used to integrate transgenes (13-15). Codon optimized nanoluciferase has been used to detect the transgenic parasites. Also, several fluorescent proteins have been successfully expressed and detected in *C. parvum*.

Genetic knockout and allelic exchange using the CRISPR/Cas9 based strategy has been successfully demonstrated (14, 16). Importantly, the generation of transgenic clones requires oocyst formation from transfected sporozoites. Therefore, if a protein is essential in any of the life cycle stages, there is a high chance that direct knockout of

the protein or mutations that affect essential functions of the protein would not be possible. Conditional knockout strategies have yet to be demonstrated for the parasite; however, a properly working Cre-loxP system has been demonstrated using two parasite lines, one constitutively expressing Cre recombinase and the another harboring a floxed site that inhibits expression of a fluorescent gene. Mating of the two lines allowed expression of the fluorescent protein, demonstrating a functional Cre-loxP system (7). This system would only be useful for conditional knockout of genes that are essential between zygote formation to oocyst formation, and can only be studied for a single generation. Inducible promoters or tunable protein translation strategies have yet to be established. Conditional knockdown of protein expression strategies would likely be appropriate for studying the functions of essential genes. Several such strategies have been successful in the related *Plasmodium* and *Toxoplasma* parasites, and these approaches have the potential to work with *C. parvum* also. For example, the integration of a riboswitch at the UTR of a target gene allows inducible knockdown of essential *Plasmodium* genes (17). Induction of the riboswitch by the exogenous administration of the ligand glucosamine results in target mRNA degradation.

Several implications from our screening and RNA-seq experiments can be tested by genetic experiments. Some of them are outlined below:

3.5.1: eIF2 α Phosphorylation Plays a Key Regulatory Role in *C. parvum* Sexual Differentiation

Based on the putative mode of action of the methionine aminopeptidase 2 inhibitors, we proposed that phosphorylation of eukaryotic translation initiation factor alpha (eIF2 α) induces parasite sexual differentiation (Chapter 2, Fig 8). Cgd7_5270 is the annotated eIF2 α of *C. parvum* and sequence alignment with eIF2 α from other organisms suggests serine 57 is the conserved phosphorylation site. Allelic exchange of the gene to make S57A and S57D mutants, followed by their phenotypic characterization, specifically their sexual differentiation efficiency, can potentially be tested with the existing genetic tools. If making one or both constructs become challenging (due to being potentially lethal mutation), the WT and mutated genes can be expressed as a second copy by integrating them in a nonessential locus of the parasite genome. If possible, the inducible expression of such constructs should be attempted. The expression pattern of proteins involved in ribosome biogenesis or structure in eIF2 α mutant parasites could potentially elucidate the proposed link between translational repression and downregulation of ribosome biogenesis.

Knocking out *C. parvum* MetAP2 (cgd2_2480) followed by testing the sexual differentiation phenotype would be a good strategy to validate the mode of action of the MetAP2 inhibitors. The N-terminal lysine-rich domain of the mammalian MetAP2 has been implicated in the protection of eIF2 α from inhibitory phosphorylation (18). A similar poly-lysine stretch is present in cgd2_2480. Therefore, substituting the native

locus with an N-terminal truncated version of MetAP2, which might be a more tolerant genetic modification, could also be used to address the same research question.

3.5.2: ApiAP2 Transcription Factors Regulate *C. parvum* Sexual Differentiation

The expression of several ApiAP2 transcription factors (TFs) was dysregulated with multiple differentiation inhibitor treatments. *cgd2_2670* is the only ApiAP2 TF that is highly downregulated with all of the differentiation inhibitor treatments (Chapter 2, Supplementary Table 3). Among others, the putative binding sites of *cgd2_3490* and *cgd8_3230* are significantly enriched in the promoter regions of the downregulated genes. Each of these three TFs would potentially be interesting genetic knockout or inducible knockdown targets. Also, tagging these proteins with fluorescent proteins or epitope tags could be useful to validate their expression pattern through the parasite lifecycle. Alternatively fluorescent proteins could be expressed under the promoters of these genes. Among the various utilities of epitope tagging, CHIP-seq using anti-tag antibodies could be used to determine the regulome of these TFs.

3.5.3: *C. parvum* DMC1 is a Female Specific Protein Involved in Meiotic Cell

Division of the Zygotes

Analyzing the expression pattern of DMC1 with high temporal resolution would help in determining the development kinetics of macrogamonts. This could be done more comprehensively by live fluorescent imaging compared to staining fixed cells at different time points. Toward that goal, fluorescent tagging of the DMC1 protein or expressing fluorescent proteins under the DMC1 promoter could be attempted. If

successful, such parasite clones would also be useful in tracking sexual differentiation in the ALI culture system or animal model infections and serve as a complementary parasite clone to the already described COWP1-tdTomato parasite clone generated for a similar purpose (7). As the DMC1 protein supposedly functions post-fertilization during sporulation, the Cre-loxP based conditional knockout strategy could be applied for conditional knockout of DMC1. Complete or conditional knockout of the protein would help in its functional characterization. Specifically, it would be interesting to check whether RAD51 can cover for the loss of the DMC1 function.

3.6: Concluding Remarks

The dogmatic view about the *Cryptosporidium* life cycle is that sexual differentiation is an obligatory process. Classically, this view has been established from electron microscopy-based observations of in vivo infection as well as in vitro infection models where gametocytes emerge after a certain period following infection (19-21). Recently, life cycle stage typing using alternative methods also showed that in the HCT8 infection model gametocytes are the predominant parasite population at the later stage of the infection (6-8). In the ALI culture system, it has been reported that oocysts are produced in waves that are separated by time intervals when parasites potentially reset the infection cycle (13). A similar fixed number of asexual replication cycles has been also proposed for *Eimeria*, which most commonly undergo three rounds of asexual replication before sexual differentiation (22). This obligate sexual

differentiation model is fundamentally different from the two other well studied Apicomplexa, *Plasmodium* and *Toxoplasma* (23). In *Plasmodium*, a subset of the asexually replicating parasite population undergoes sexual differentiation, whereas *Toxoplasma* sexual differentiation only takes place within the definitive host, cats. Potential environmental cues for sexual differentiation have also been characterized for *P. falciparum* and *T. gondii* (24, 25). The implication of the defined number of asexual replication cycles in *Cryptosporidium* and *Eimeria* is that a genetic program can sense the number of asexual replications that the parasite has undergone at any given moment; however, molecular characterization of such a sensory mechanism remains elusive. Alternatively, it is possible that some kind of environmental cue actually induces the differentiation process in *Cryptosporidium* and *Eimeria*, and that environmental cue reaches a threshold around the time the parasites complete the defined number of replication cycles. Conceptually, such an environmental cue could be a parasite generated quorum sensing molecule or depletion/fortification of a host factor. An in-depth mechanistic understanding of the regulation of *C. parvum* sexual differentiation would shed light on this interesting unanswered question about *C. parvum* biology.

In this study, we deduced from our RNA-seq analysis that ribosome formation is downregulated during *C. parvum* sexual differentiation and coupled this insight with the putative mode of action of the MetAP2 inhibitors. Another interesting insight that is supported both by our RNA-seq data and the putative identities of the targets of

several differentiation inhibitors is that the sexual stage of the parasite is a more energy-demanding stage compared to the asexual stages. The RNA-seq data supports this theory as it suggests that glycolysis is upregulated following sexual differentiation, which is the most critical energy producing pathway for the parasite in the absence of a fully functional mitochondrion. It is proposed from other studies that *Cryptosporidium* uptake energy equivalents from the host cells directly in the form of purine nucleotides. Therefore, our theory of increased energy demand in the sexual stage is also supported by the observation that inhibitors of host cell oxidative phosphorylation and purine nucleotide biosynthesis, two pathways involved in producing the energy molecules that *Cryptosporidium* can steal from the host, also disproportionately affect the sexual stages of the parasite more. Targeted genetic experiments are needed to test the validity of this hypothesis.




Figure 1: Expression time course of selected genes.

Transcript per million (TPM) values of DMC1, RAD51 and COWP1 mRNAs at different time-points post infection. Each point represents a biological replicate of mRNA-seq. Error bars denote range.




Figure 2: *C. parvum* oocysts stained with anti DMC1 antibody.

DMC1 protein is localized to the inner wall of *C. parvum* oocysts and is stained only when the oocysts are excysted.




Figure 3: Parasite numbers after 7 days post infection with differentiation inhibitor treatments.

(Top) Dose response curves of total parasite and DMC1+ parasite percent inhibition compared to control, determined from drug addition at 3 hpi and imaging at 72 hpi. Concentrations selected for prolonged (7 days) assays are indicated by the dotted vertical lines. (Bottom) Three differentiation inhibitors were added to *C. parvum* infected HCT8 culture at 3 hours post infection at indicated concentrations. Wells were fixed and imaged at 7 days post infection. *Vicia villosa* lectin (VVL) was used to count parasite number and Hoechst staining was used to count host cell nuclei number. Each point indicates data from replicate wells.

3.7: References

1. Crickard JB, Greene EC. The biochemistry of early meiotic recombination intermediates. *Cell cycle (Georgetown, Tex)*. 2018;17(23):2520-30.
2. Lin Z, Kong H, Nei M, Ma H. Origins and evolution of the recA/RAD51 gene family: evidence for ancient gene duplication and endosymbiotic gene transfer. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(27):10328-33.
3. Bishop DK, Park D, Xu L, Kleckner N. DMC1: a meiosis-specific yeast homolog of *E. coli* recA required for recombination, synaptonemal complex formation, and cell cycle progression. *Cell*. 1992;69(3):439-56.
4. Pittman DL, Cobb J, Schimenti KJ, Wilson LA, Cooper DM, Brignull E, et al. Meiotic prophase arrest with failure of chromosome synapsis in mice deficient for Dmc1, a germline-specific RecA homolog. *Molecular cell*. 1998;1(5):697-705.
5. Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;93(13):6236-40.
6. Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, et al. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like *Cryptosporidium* growth inhibitors. *Nature communications*. 2019;10(1):1862.
7. Tandel J, English ED, Sateriale A, Gullicksrud JA, Beiting DP, Sullivan MC, et

- al. Life cycle progression and sexual development of the apicomplexan parasite *Cryptosporidium parvum*. *Nature microbiology*. 2019;4(12):2226-36.
8. Funkhouser-Jones LJ, Ravindran S, Sibley LD. Defining Stage-Specific Activity of Potent New Inhibitors of *Cryptosporidium parvum* Growth In Vitro. *mBio*. 2020;11(2).
9. DeCicco RePass MA, Chen Y, Lin Y, Zhou W, Kaplan DL, Ward HD. Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of *Cryptosporidium parvum*. *Infection and immunity*. 2017;85(3).
10. Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, et al. Continuous culture of *Cryptosporidium parvum* using hollow fiber technology. *International journal for parasitology*. 2016;46(1):21-9.
11. Heo I, Dutta D, Schaefer DA, Iakobachvili N, Artegiani B, Sachs N, et al. Modelling *Cryptosporidium* infection in human small intestinal and lung organoids. *Nature microbiology*. 2018;3(7):814-23.
12. Miller CN, Jossé L, Brown I, Blakeman B, Povey J, Yiangou L, et al. A cell culture platform for *Cryptosporidium* that enables long-term cultivation and new tools for the systematic investigation of its biology. *International journal for parasitology*. 2018;48(3-4):197-201.
13. Wilke G, Funkhouser-Jones LJ, Wang Y, Ravindran S, Wang Q, Beatty WL, et al. A Stem-Cell-Derived Platform Enables Complete *Cryptosporidium* Development In Vitro and Genetic Tractability. *Cell host & microbe*. 2019;26(1):123-34 e8.

14. Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, et al. Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature*. 2015;523(7561):477-80.
15. Sateriale A, Slapeta J, Baptista R, Engiles JB, Gullicksrud JA, Herbert GT, et al. A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity. *Cell host & microbe*. 2019;26(1):135-46 e5.
16. Pawlowic MC, Somepalli M, Sateriale A, Herbert GT, Gibson AR, Cuny GD, et al. Genetic ablation of purine salvage in *Cryptosporidium parvum* reveals nucleotide uptake from the host cell. *Proceedings of the National Academy of Sciences of the United States of America*. 2019;116(42):21160-5.
17. Prommana P, Uthaipibull C, Wongsombat C, Kamchonwongpaisan S, Yuthavong Y, Knuepfer E, et al. Inducible knockdown of *Plasmodium* gene expression using the glmS ribozyme. *PloS one*. 2013;8(8):e73783.
18. Datta R, Choudhury P, Bhattacharya M, Soto Leon F, Zhou Y, Datta B. Protection of translation initiation factor eIF2 phosphorylation correlates with eIF2-associated glycoprotein p67 levels and requires the lysine-rich domain I of p67. *Biochimie*. 2001;83(10):919-31.
19. Petry F. Structural analysis of *Cryptosporidium parvum*. *Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada*. 2004;10(5):586-601.
20. Vetterling JM, Takeuchi A, Madden PA. Ultrastructure of *Cryptosporidium*

wrairi from the guinea pig. *The Journal of protozoology*. 1971;18(2):248-60.

21. Borowski H, Thompson RC, Armstrong T, Clode PL. Morphological characterization of *Cryptosporidium parvum* life-cycle stages in an in vitro model system. *Parasitology*. 2010;137(1):13-26.
22. Walker RA, Ferguson DJ, Miller CM, Smith NC. Sex and *Eimeria*: a molecular perspective. *Parasitology*. 2013;140(14):1701-17.
23. Smith TG, Walliker D, Ranford-Cartwright LC. Sexual differentiation and sex determination in the Apicomplexa. *Trends in parasitology*. 2002;18(7):315-23.
24. Brancucci NMB, Gerdt JP, Wang C, De Niz M, Philip N, Adapa SR, et al. Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the Human Malaria Parasite *Plasmodium falciparum*. *Cell*. 2017;171(7):1532-44 e15.
25. Martorelli Di Genova B, Wilson SK, Dubey JP, Knoll LJ. Intestinal delta-6-desaturase activity determines host range for *Toxoplasma* sexual reproduction. *PLoS biology*. 2019;17(8):e3000364.

COMPREHENSIVE BIBLIOGRAPHY

- Abrahamsen, M. S., et al. "Complete Genome Sequence of the Apicomplexan, *Cryptosporidium Parvum*." *Science* 304.5669 (2004): 441-5. Print.
- Adl, S. M., et al. "Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes." *J Eukaryot Microbiol* 66.1 (2019): 4-119. Print.
- Afgan, E., et al. "The Galaxy Platform for Accessible, Reproducible and Collaborative Biomedical Analyses: 2018 Update." *Nucleic Acids Res* 46.W1 (2018): W537-w44. Print.
- Allison, A. C., and E. M. Eugui. "Mycophenolate Mofetil and Its Mechanisms of Action." *Immunopharmacology* 47.2-3 (2000): 85-118. Print.
- Aly, A. S., et al. "Sap1 Is a Critical Post-Transcriptional Regulator of Infectivity in Malaria Parasite Sporozoite Stages." *Mol Microbiol* 79.4 (2011): 929-39. Print.
- Alzan, H. F., D. P. Knowles, and C. E. Suarez. "Comparative Bioinformatics Analysis of Transcription Factor Genes Indicates Conservation of Key Regulatory Domains among *Babesia Bovis*, *Babesia Microti*, and *Theileria Equi*." *PLoS Negl Trop Dis* 10.11 (2016): e0004983. Print.
- Anders, S., P. T. Pyl, and W. Huber. "Htseq--a Python Framework to Work with High-Throughput Sequencing Data." *Bioinformatics* 31.2 (2015): 166-9. Print.
- Archibald, J. M. "The Puzzle of Plastid Evolution." *Curr Biol* 19.2 (2009): R81-8. Print.
- Arisue, N., and T. Hashimoto. "Phylogeny and Evolution of Apicoplasts and Apicomplexan Parasites." *Parasitol Int* 64.3 (2015): 254-9. Print.
- Arrowood, M. J. "In Vitro Cultivation of *Cryptosporidium* Species." *Clin Microbiol Rev* 15.3 (2002): 390-400. Print.
- Augusto, L., et al. "Effects of Perlestatin Kinase Inhibitor against *Toxoplasma Gondii*." *Antimicrob Agents Chemother* 62.11 (2018). Print.
- Aurrecoechea, C., et al. "Eupathdb: The Eukaryotic Pathogen Genomics Database Resource." *Nucleic Acids Res* 45.D1 (2017): D581-D91. Print.
- Baer, K., et al. "Release of Hepatic *Plasmodium Yoelii* Merozoites into the Pulmonary Microvasculature." *PLoS Pathog* 3.11 (2007): e171. Print.
- Bailey, T. L. "Dreame: Motif Discovery in Transcription Factor Chip-Seq Data." *Bioinformatics* 27.12 (2011): 1653-9. Print.
- Bailey, T. L., et al. "Meme Suite: Tools for Motif Discovery and Searching." *Nucleic Acids Res* 37.Web Server issue (2009): W202-8. Print.
- Balaji, S., et al. "Discovery of the Principal Specific Transcription Factors of Apicomplexa and Their Implication for the Evolution of the Ap2-Integrase DNA Binding Domains." *Nucleic Acids Res* 33.13 (2005): 3994-4006. Print.
- Bancells, C., et al. "Revisiting the Initial Steps of Sexual Development in the Malaria Parasite *Plasmodium Falciparum*." *Nat Microbiol* 4.1 (2019): 144-54. Print.
- Bansal, A., et al. "Pfc1 Is Critical for Malaria Parasite Gametogenesis and Mosquito Infection." *Proc Natl Acad Sci U S A* 115.4 (2018): 774-79. Print.

- Becker, C. A., et al. "Identification of Three Ccp Genes in Babesia Divergens: Novel Markers for Sexual Stages Parasites." *Mol Biochem Parasitol* 174.1 (2010): 36-43. Print.
- Behnke, M. S., et al. "Coordinated Progression through Two Subtranscriptomes Underlies the Tachyzoite Cycle of Toxoplasma Gondii." *PLoS One* 5.8 (2010): e12354. Print.
- Behnke, M. S., et al. "Toxoplasma Gondii Merozoite Gene Expression Analysis with Comparison to the Life Cycle Discloses a Unique Expression State During Enteric Development." *BMC Genomics* 15 (2014): 350. Print.
- Bennink, S., M. J. Kiesow, and G. Pradel. "The Development of Malaria Parasites in the Mosquito Midgut." *Cell Microbiol* 18.7 (2016): 905-18. Print.
- Berto, B. P., D. McIntosh, and C. W. Lopes. "Studies on Coccidian Oocysts (Apicomplexa: Eucoccidiorida)." *Rev Bras Parasitol Vet* 23.1 (2014): 1-15. Print.
- Billker, O., et al. "The Roles of Temperature, Ph and Mosquito Factors as Triggers of Male and Female Gametogenesis of Plasmodium Berghei in Vitro." *Parasitology* 115 (Pt 1) (1997): 1-7. Print.
- Bishop, D. K., et al. "Dmc1: A Meiosis-Specific Yeast Homolog of E. Coli RecA Required for Recombination, Synaptonemal Complex Formation, and Cell Cycle Progression." *Cell* 69.3 (1992): 439-56. Print.
- Bishop, R., et al. "Analysis of the Transcriptome of the Protozoan Theileria Parva Using Mps Reveals That the Majority of Genes Are Transcriptionally Active in the Schizont Stage." *Nucleic Acids Res* 33.17 (2005): 5503-11. Print.
- Blackman, M. J., and L. H. Bannister. "Apical Organelles of Apicomplexa: Biology and Isolation by Subcellular Fractionation." *Mol Biochem Parasitol* 117.1 (2001): 11-25. Print.
- Bohaliga, G. A. R., et al. "Identification of a Putative Methyltransferase Gene of Babesia Bigemina as a Novel Molecular Biomarker Uniquely Expressed in Parasite Tick Stages." *Parasit Vectors* 11.1 (2018): 480. Print.
- Bohaliga, G. A. R., et al. "Identification of Proteins Expressed by Babesia Bigemina Kinetes." *Parasit Vectors* 12.1 (2019): 271. Print.
- Bohne, W., et al. "Cloning and Characterization of a Bradyzoite-Specifically Expressed Gene (Hsp30/Bag1) of Toxoplasma Gondii, Related to Genes Encoding Small Heat-Shock Proteins of Plants." *Mol Microbiol* 16.6 (1995): 1221-30. Print.
- Bohne, W., J. Heesemann, and U. Gross. "Coexistence of Heterogeneous Populations of Toxoplasma Gondii Parasites within Parasitophorous Vacuoles of Murine Macrophages as Revealed by a Bradyzoite-Specific Monoclonal Antibody." *Parasitol Res* 79.6 (1993): 485-7. Print.
- Boisard, J., and I. Florent. "Why the -Omic Future of Apicomplexa Should Include Gregarines." *Biol Cell* (2020). Print.
- Bolger, A. M., M. Lohse, and B. Usadel. "Trimmomatic: A Flexible Trimmer for Illumina Sequence Data." *Bioinformatics* 30.15 (2014): 2114-20. Print.

- Borowski, H., et al. "Morphological Characterization of *Cryptosporidium Parvum* Life-Cycle Stages in an in Vitro Model System." *Parasitology* 137.1 (2010): 13-26. Print.
- Bougdour, A., et al. "Drug Inhibition of Hdac3 and Epigenetic Control of Differentiation in Apicomplexa Parasites." *J Exp Med* 206.4 (2009): 953-66. Print.
- Bozdech, Z., et al. "The Transcriptome of the Intraerythrocytic Developmental Cycle of *Plasmodium Falciparum*." *PLoS Biol* 1.1 (2003): E5. Print.
- Brancucci, N. M. B., et al. "Heterochromatin Protein 1 Secures Survival and Transmission of Malaria Parasites." *Cell Host Microbe* 16.2 (2014): 165-76. Print.
- Brancucci, N. M. B., et al. "Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the Human Malaria Parasite *Plasmodium Falciparum*." *Cell* 171.7 (2017): 1532-44 e15. Print.
- Bruce, M. C., et al. "Commitment of the Malaria Parasite *Plasmodium Falciparum* to Sexual and Asexual Development." *Parasitology* 100 Pt 2 (1990): 191-200. Print.
- Buchholz, K. R., et al. "Identification of Tissue Cyst Wall Components by Transcriptome Analysis of in Vivo and in Vitro *Toxoplasma Gondii* Bradyzoites." *Eukaryot Cell* 10.12 (2011): 1637-47. Print.
- Burg, J. L., et al. "Molecular Analysis of the Gene Encoding the Major Surface Antigen of *Toxoplasma Gondii*." *J Immunol* 141.10 (1988): 3584-91. Print.
- Burrell, A., et al. "Life Cycle Stages, Specific Organelles and Invasion Mechanisms of *Eimeria* Species." *Parasitology* 147.3 (2020): 263-78. Print.
- Caldelari, R., et al. "Transcriptome Analysis of *Plasmodium Berghei* During Exo-Erythrocytic Development." *Malar J* 18.1 (2019): 330. Print.
- Camacho-Nuez, M., et al. "Hap2, a Novel Gene in *Babesia Bigemina* Is Expressed in Tick Stages, and Specific Antibodies Block Zygote Formation." *Parasit Vectors* 10.1 (2017): 568. Print.
- Carreno, R. A., D. S. Martin, and J. R. Barta. "*Cryptosporidium* Is More Closely Related to the Gregarines Than to Coccidia as Shown by Phylogenetic Analysis of Apicomplexan Parasites Inferred Using Small-Subunit Ribosomal Rna Gene Sequences." *Parasitol Res* 85.11 (1999): 899-904. Print.
- Carter, L. M., et al. "Stress and Sex in Malaria Parasites: Why Does Commitment Vary?" *Evol Med Public Health* 2013.1 (2013): 135-47. Print.
- Cerutti, A., N. Blanchard, and S. Besteiro. "The Bradyzoite: A Key Developmental Stage for the Persistence and Pathogenesis of Toxoplasmosis." *Pathogens* 9.3 (2020): 234. Print.
- Chalmers, R. M., A. P. Davies, and K. Tyler. "*Cryptosporidium*." *Microbiology* 165.5 (2019): 500-02. Print.
- Chapman, H. D., T. K. Jeffers, and R. B. Williams. "Forty Years of Monensin for the Control of Coccidiosis in Poultry." *Poult Sci* 89.9 (2010): 1788-801. Print.
- Cheeseman, K. M., and J. B. Weitzman. "[What Makes a Parasite "Transforming"? Insights into Cancer from the Agents of an Exotic Pathology, *Theileria* Spp]." *Bull Soc Pathol Exot* 110.1 (2017): 55-60. Print.
- Chen, L. F., et al. "Comparative Studies of *Toxoplasma Gondii* Transcriptomes: Insights

- into Stage Conversion Based on Gene Expression Profiling and Alternative Splicing." *Parasit Vectors* 11.1 (2018): 402. Print.
- Child, M. A. "Chemical Biology Approaches for the Study of Apicomplexan Parasites." *Mol Biochem Parasitol* 192.1-2 (2013): 1-9. Print.
- Chua, A. C. Y., et al. "Hepatic Spheroids Used as an in Vitro Model to Study Malaria Relapse." *Biomaterials* 216 (2019): 119221. Print.
- Cleary, M. D., et al. "Toxoplasma Gondii Asexual Development: Identification of Developmentally Regulated Genes and Distinct Patterns of Gene Expression." *Eukaryot Cell* 1.3 (2002): 329-40. Print.
- Clemens, M. J. "Initiation Factor Eif2 Alpha Phosphorylation in Stress Responses and Apoptosis." *Prog Mol Subcell Biol* 27 (2001): 57-89. Print.
- Coetzee, N., et al. "Quantitative Chromatin Proteomics Reveals a Dynamic Histone Post-Translational Modification Landscape That Defines Asexual and Sexual Plasmodium Falciparum Parasites." *Sci Rep* 7.1 (2017): 607. Print.
- Coetzee, N., et al. "Epigenetic Inhibitors Target Multiple Stages of Plasmodium Falciparum Parasites." *Sci Rep* 10.1 (2020): 2355. Print.
- Cowman, A. F., et al. "Malaria: Biology and Disease." *Cell* 167.3 (2016): 610-24. Print.
- Cowper, B., S. Matthews, and F. Tomley. "The Molecular Basis for the Distinct Host and Tissue Tropisms of Coccidian Parasites." *Mol Biochem Parasitol* 186.1 (2012): 1-10. Print.
- Crickard, J. B., and E. C. Greene. "The Biochemistry of Early Meiotic Recombination Intermediates." *Cell Cycle* 17.23 (2018): 2520-30. Print.
- Croken, M. M., et al. "Gene Set Enrichment Analysis (Gsea) of Toxoplasma Gondii Expression Datasets Links Cell Cycle Progression and the Bradyzoite Developmental Program." *BMC Genomics* 15 (2014): 515. Print.
- Cui, L., S. Lindner, and J. Miao. "Translational Regulation During Stage Transitions in Malaria Parasites." *Ann N Y Acad Sci* 1342 (2015): 1-9. Print.
- Curra, C., et al. "Malaria Transmission through the Mosquito Requires the Function of the Omd Protein." *PLoS One* 14.9 (2019): e0222226. Print.
- Dalla Venezia, N., et al. "Emerging Role of Eukaryote Ribosomes in Translational Control." *Int J Mol Sci* 20.5 (2019). Print.
- Datta, B., et al. "Treatment of Cells with the Angiogenic Inhibitor Fumagillin Results in Increased Stability of Eukaryotic Initiation Factor 2-Associated Glycoprotein, P67, and Reduced Phosphorylation of Extracellular Signal-Regulated Kinases." *Biochemistry* 43.46 (2004): 14821-31. Print.
- Datta, R., et al. "Protection of Translation Initiation Factor Eif2 Phosphorylation Correlates with Eif2-Associated Glycoprotein P67 Levels and Requires the Lysine-Rich Domain I of P67." *Biochimie* 83.10 (2001): 919-31. Print.
- de Vargas, C., et al. "Ocean Plankton. Eukaryotic Plankton Diversity in the Sunlit Ocean." *Science* 348.6237 (2015): 1261605. Print.
- DeCicco RePass, M. A., et al. "Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium Parvum." *Infect Immun* 85.3 (2017). Print.

- Del Campo, J., et al. "Assessing the Diversity and Distribution of Apicomplexans in Host and Free-Living Environments Using High-Throughput Amplicon Data and a Phylogenetically Informed Reference Framework." *Front Microbiol* 10 (2019): 2373. Print.
- Deligianni, E., et al. "Essential Role of Plasmodium Perforin-Like Protein 4 in Ookinete Midgut Passage." *PLoS One* 13.8 (2018): e0201651. Print.
- Delves, M. J., F. Angrisano, and A. M. Blagborough. "Antimalarial Transmission-Blocking Interventions: Past, Present, and Future." *Trends Parasitol* 34.9 (2018): 735-46. Print.
- Denton, H., et al. "Enzymes of Energy Metabolism in the Bradyzoites and Tachyzoites of *Toxoplasma Gondii*." *FEMS Microbiol Lett* 137.1 (1996): 103-8. Print.
- Donald, R. G., et al. "Toxoplasma Gondii Cyclic Gmp-Dependent Kinase: Chemotherapeutic Targeting of an Essential Parasite Protein Kinase." *Eukaryot Cell* 1.3 (2002): 317-28. Print.
- Donnelly, N., et al. "The Eif2alpha Kinases: Their Structures and Functions." *Cell Mol Life Sci* 70.19 (2013): 3493-511. Print.
- Doskaya, M., et al. "Discovery of New *Toxoplasma Gondii* Antigenic Proteins Using a High Throughput Protein Microarray Approach Screening Sera of Murine Model Infected Orally with Oocysts and Tissue Cysts." *Parasit Vectors* 11.1 (2018): 393. Print.
- Dubey, J. P., and M. C. Jenkins. "Re-Evaluation of the Life Cycle of *Eimeria Maxima* Tyzzer, 1929 in Chickens (*Gallus Domesticus*)." *Parasitology* 145.8 (2018): 1051-58. Print.
- Dubey, J. P., D. S. Lindsay, and M. R. Lappin. "Toxoplasmosis and Other Intestinal Coccidial Infections in Cats and Dogs." *Vet Clin North Am Small Anim Pract* 39.6 (2009): 1009-34, v. Print.
- Dubey, J. P., D. S. Lindsay, and C. A. Speer. "Structures of *Toxoplasma Gondii* Tachyzoites, Bradyzoites, and Sporozoites and Biology and Development of Tissue Cysts." *Clin Microbiol Rev* 11.2 (1998): 267-99. Print.
- Dutta, D., I. Heo, and R. O'Connor. "Studying *Cryptosporidium* Infection in 3d Tissue-Derived Human Organoid Culture Systems by Microinjection." *J Vis Exp*.151 (2019). Print.
- Dzierszinski, F., et al. "Differential Expression of Two Plant-Like Enolases with Distinct Enzymatic and Antigenic Properties During Stage Conversion of the Protozoan Parasite *Toxoplasma Gondii*." *J Mol Biol* 309.5 (2001): 1017-27. Print.
- Dzierszinski, F., et al. "Dynamics of *Toxoplasma Gondii* Differentiation." *Eukaryot Cell* 3.4 (2004): 992-1003. Print.
- Ejigiri, I., and P. Sinnis. "Plasmodium Sporozoite-Host Interactions from the Dermis to the Hepatocyte." *Curr Opin Microbiol* 12.4 (2009): 401-7. Print.
- Eksi, S., et al. "Plasmodium Falciparum Gametocyte Development 1 (Pfgdv1) and Gametocytogenesis Early Gene Identification and Commitment to Sexual Development." *PLoS Pathog* 8.10 (2012): e1002964. Print.
- Elliott, D. A., and D. P. Clark. "Cryptosporidium Parvum Induces Host Cell Actin

- Accumulation at the Host-Parasite Interface." *Infect Immun* 68.4 (2000): 2315-22. Print.
- English, E. D., and B. Striepen. "The Cat Is out of the Bag: How Parasites Know Their Hosts." *PLoS Biol* 17.9 (2019): e3000446. Print.
- Farhat, D. C., et al. "A Morc-Driven Transcriptional Switch Controls Toxoplasma Developmental Trajectories and Sexual Commitment." *Nat Microbiol* 5.4 (2020): 570-83. Print.
- Ferguson, D. J. "Use of Molecular and Ultrastructural Markers to Evaluate Stage Conversion of Toxoplasma Gondii in Both the Intermediate and Definitive Host." *Int J Parasitol* 34.3 (2004): 347-60. Print.
- Filarsky, M., et al. "Gdv1 Induces Sexual Commitment of Malaria Parasites by Antagonizing Hp1-Dependent Gene Silencing." *Science* 359.6381 (2018): 1259-63. Print.
- Florens, L., et al. "A Proteomic View of the Plasmodium Falciparum Life Cycle." *Nature* 419.6906 (2002): 520-6. Print.
- Frankish, A., et al. "Genome Reference Annotation for the Human and Mouse Genomes." *Nucleic Acids Res* 47.D1 (2019): D766-d73. Print.
- Friesen, J., et al. "Identification of Novel Bradyzoite-Specific Toxoplasma Gondii Genes with Domains for Protein-Protein Interactions by Suppression Subtractive Hybridization." *Mol Biochem Parasitol* 157.2 (2008): 228-32. Print.
- Frischknecht, F., and K. Matuschewski. "Plasmodium Sporozoite Biology." *Cold Spring Harb Perspect Med* 7.5 (2017). Print.
- Fritz, H. M., et al. "Transcriptomic Analysis of Toxoplasma Development Reveals Many Novel Functions and Structures Specific to Sporozoites and Oocysts." *PLoS One* 7.2 (2012): e29998. Print.
- Funkhouser-Jones, L. J., S. Ravindran, and L. D. Sibley. "Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium Parvum Growth in Vitro." *mBio* 11.2 (2020). Print.
- Garcia, G. E., et al. "Xanthurenic Acid Induces Gametogenesis in Plasmodium, the Malaria Parasite." *J Biol Chem* 273.20 (1998): 12003-5. Print.
- Garfoot, A. L., et al. "Proteomic and Transcriptomic Analyses of Early and Late-Chronic Toxoplasma Gondii Infection Shows Novel and Stage Specific Transcripts." *BMC Genomics* 20.1 (2019): 859. Print.
- Gissot, M., et al. "High Mobility Group Protein Hmgb2 Is a Critical Regulator of Plasmodium Oocyst Development." *J Biol Chem* 283.25 (2008): 17030-8. Print.
- Gomes-Santos, C. S., et al. "Transition of Plasmodium Sporozoites into Liver Stage-Like Forms Is Regulated by the Rna Binding Protein Pumilio." *PLoS Pathog* 7.5 (2011): e1002046. Print.
- Gough, J. M., W. K. Jorgensen, and D. H. Kemp. "Development of Tick Gut Forms of Babesia Bigemina in Vitro." *J Eukaryot Microbiol* 45.3 (1998): 298-306. Print.
- Grant, C. E., T. L. Bailey, and W. S. Noble. "Fimo: Scanning for Occurrences of a Given Motif." *Bioinformatics* 27.7 (2011): 1017-8. Print.
- Griffith, E. C., et al. "Methionine Aminopeptidase (Type 2) Is the Common Target for

- Angiogenesis Inhibitors Agm-1470 and Ovalicin." *Chem Biol* 4.6 (1997): 461-71. Print.
- Gural, N., et al. "In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites." *Cell Host Microbe* 23.3 (2018): 395-406 e4. Print.
- Han, H. Y., et al. "[Construction of Subtractive Cdna Libraries of the Sporogony Stage of Eimeria Tenella by Suppression Subtractive Hybridization]." *Sheng Wu Gong Cheng Xue Bao* 23.6 (2007): 1005-10. Print.
- Han, H. Y., et al. "Identification of Differentially Expressed Genes in Early Stages of Eimeria Tenella by Suppression Subtractive Hybridization and Cdna Microarray." *J Parasitol* 96.1 (2010): 95-102. Print.
- Harris, J. R., M. Adrian, and F. Petry. "Amylopectin: A Major Component of the Residual Body in Cryptosporidium Parvum Oocysts." *Parasitology* 128.Pt 3 (2004): 269-82. Print.
- Harris, M. T., et al. "A Novel Gcn5b Lysine Acetyltransferase Complex Associates with Distinct Transcription Factors in the Protozoan Parasite Toxoplasma Gondii." *Mol Biochem Parasitol* 232 (2019): 111203. Print.
- Hehl, A. B., et al. "Asexual Expansion of Toxoplasma Gondii Merozoites Is Distinct from Tachyzoites and Entails Expression of Non-Overlapping Gene Families to Attach, Invade, and Replicate within Feline Enterocytes." *BMC Genomics* 16 (2015): 66. Print.
- Heiges, M., et al. "Cryptodb: A Cryptosporidium Bioinformatics Resource Update." *Nucleic Acids Res* 34.Database issue (2006): D419-22. Print.
- Hendrick, H. M., et al. "Phosphorylation of Eukaryotic Initiation Factor-2alpha During Stress and Encystation in Entamoeba Species." *PLoS Pathog* 12.12 (2016): e1006085. Print.
- Heo, I., et al. "Modelling Cryptosporidium Infection in Human Small Intestinal and Lung Organoids." *Nat Microbiol* 3.7 (2018): 814-23. Print.
- Hino, A., et al. "Critical Roles of the Mitochondrial Complex Ii in Oocyst Formation of Rodent Malaria Parasite Plasmodium Berghei." *J Biochem* 152.3 (2012): 259-68. Print.
- Holmes, M. J., et al. "Simultaneous Ribosome Profiling of Human Host Cells Infected with Toxoplasma Gondii." *mSphere* 4.3 (2019). Print.
- Hong, D. P., J. B. Radke, and M. W. White. "Opposing Transcriptional Mechanisms Regulate Toxoplasma Development." *mSphere* 2.1 (2017). Print.
- Howick, V. M., et al. "The Malaria Cell Atlas: Single Parasite Transcriptomes across the Complete Plasmodium Life Cycle." *Science* 365.6455 (2019). Print.
- Hu, D., et al. "Efficient Single-Gene and Gene Family Editing in the Apicomplexan Parasite Eimeria Tenella Using Crispr-Cas9." *Front Bioeng Biotechnol* 8 (2020): 128. Print.
- Hu, D., et al. "Comparative Transcriptome Analysis of Eimeria Maxima (Apicomplexa: Eimeriidae) Suggests DNA Replication Activities Correlating with Its Fecundity." *BMC Genomics* 19.1 (2018): 699. Print.
- Huang da, W., B. T. Sherman, and R. A. Lempicki. "Bioinformatics Enrichment Tools:

- Paths toward the Comprehensive Functional Analysis of Large Gene Lists." *Nucleic Acids Res* 37.1 (2009): 1-13. Print.
- . "Systematic and Integrative Analysis of Large Gene Lists Using David Bioinformatics Resources." *Nat Protoc* 4.1 (2009): 44-57. Print.
- Huang, S., et al. "Toxoplasma Gondii Ap2ix-4 Regulates Gene Expression During Bradyzoite Development." *mSphere* 2.2 (2017). Print.
- Hulden, L., and L. Hulden. "Activation of the Hypnozoite: A Part of Plasmodium Vivax Life Cycle and Survival." *Malar J* 10 (2011): 90. Print.
- Hussein, H. E., et al. "The Babesia Bovis Hap2 Gene Is Not Required for Blood Stage Replication, but Expressed Upon in Vitro Sexual Stage Induction." *PLoS Negl Trop Dis* 11.10 (2017): e0005965. Print.
- Huston, C. D., et al. "A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments." *PLoS Negl Trop Dis* 9.10 (2015): e0003987. Print.
- Ikadai, H., et al. "Transposon Mutagenesis Identifies Genes Essential for Plasmodium Falciparum Gametocytogenesis." *Proc Natl Acad Sci U S A* 110.18 (2013): E1676-84. Print.
- Inselburg, J. "Gametocyte Formation by the Progeny of Single Plasmodium Falciparum Schizonts." *J Parasitol* 69.3 (1983): 584-91. Print.
- Iwanaga, S., et al. "Identification of an Ap2-Family Protein That Is Critical for Malaria Liver Stage Development." *PLoS One* 7.11 (2012): e47557. Print.
- Jalovecka, M., et al. "Stimulation and Quantification of Babesia Divergens Gametocytogenesis." *Parasit Vectors* 9.1 (2016): 439. Print.
- Jalovecka, M., et al. "The Complexity of Piroplasms Life Cycles." *Front Cell Infect Microbiol* 8 (2018): 248. Print.
- Janes, J., et al. "The Reframe Library as a Comprehensive Drug Repurposing Library and Its Application to the Treatment of Cryptosporidiosis." *Proc Natl Acad Sci U S A* 115.42 (2018): 10750-55. Print.
- Janouskovec, J., et al. "A Common Red Algal Origin of the Apicomplexan, Dinoflagellate, and Heterokont Plastids." *Proc Natl Acad Sci U S A* 107.24 (2010): 10949-54. Print.
- Janouskovec, J., et al. "Apicomplexan-Like Parasites Are Polyphyletic and Widely but Selectively Dependent on Cryptic Plastid Organelles." *Elife* 8 (2019). Print.
- Joharapurkar, A. A., N. A. Dhanesha, and M. R. Jain. "Inhibition of the Methionine Aminopeptidase 2 Enzyme for the Treatment of Obesity." *Diabetes Metab Syndr Obes* 7 (2014): 73-84. Print.
- Johnson, W. C., et al. "Analysis of Stage-Specific Protein Expression During Babesia Bovis Development within Female Rhipicephalus Microplus." *J Proteome Res* 16.3 (2017): 1327-38. Print.
- Joice, R., et al. "Plasmodium Falciparum Transmission Stages Accumulate in the Human Bone Marrow." *Sci Transl Med* 6.244 (2014): 244re5. Print.
- Josling, G. A., and M. Llinas. "Sexual Development in Plasmodium Parasites: Knowing When It's Time to Commit." *Nat Rev Microbiol* 13.9 (2015): 573-87. Print.

- Josse, L., et al. "A Cell Culture Platform for the Cultivation of *Cryptosporidium Parvum*." *Curr Protoc Microbiol* 53.1 (2019): e80. Print.
- Joyce, B. R., et al. "Phosphorylation of Eukaryotic Initiation Factor-2(1) Promotes the Extracellular Survival of Obligate Intracellular Parasite *Toxoplasma Gondii*." *Proc Natl Acad Sci U S A* 107.40 (2010): 17200-5. Print.
- Jumani, R. S., et al. "A Suite of Phenotypic Assays to Ensure Pipeline Diversity When Prioritizing Drug-Like *Cryptosporidium* Growth Inhibitors." *Nat Commun* 10.1 (2019): 1862. Print.
- Kafsack, B. F., et al. "A Transcriptional Switch Underlies Commitment to Sexual Development in Malaria Parasites." *Nature* 507.7491 (2014): 248-52. Print.
- Kaiser, G., et al. "Generation of Transgenic Rodent Malaria Parasites by Transfection of Cell Culture-Derived Merozoites." *Malar J* 16.1 (2017): 305. Print.
- Kaiser, K., et al. "Differential Transcriptome Profiling Identifies *Plasmodium* Genes Encoding Pre-Erythrocytic Stage-Specific Proteins." *Mol Microbiol* 51.5 (2004): 1221-32. Print.
- Katrib, M., et al. "Stage-Specific Expression of Protease Genes in the Apicomplexan Parasite, *Eimeria Tenella*." *BMC Genomics* 13 (2012): 685. Print.
- Kawamoto, F., et al. "Possible Roles of Ca²⁺ and Cgmp as Mediators of the Exflagellation of *Plasmodium Berghei* and *Plasmodium Falciparum*." *Mol Biochem Parasitol* 42.1 (1990): 101-8. Print.
- Ke, H., et al. "Genetic Investigation of Tricarboxylic Acid Metabolism During the *Plasmodium Falciparum* Life Cycle." *Cell Rep* 11.1 (2015): 164-74. Print.
- Kedersha, N., et al. "Evidence That Ternary Complex (Eif2-Gtp-Trna(I)(Met))-Deficient Preinitiation Complexes Are Core Constituents of Mammalian Stress Granules." *Mol Biol Cell* 13.1 (2002): 195-210. Print.
- Kent, R. S., et al. "Inducible Developmental Reprogramming Redefines Commitment to Sexual Development in the Malaria Parasite *Plasmodium Berghei*." *Nat Microbiol* 3.11 (2018): 1206-13. Print.
- Khan, A., and M. E. Grigg. "*Toxoplasma Gondii*: Laboratory Maintenance and Growth." *Curr Protoc Microbiol* 44 (2017): 20C 1 1-20C 1 17. Print.
- Khan, S. M., et al. "Proteome Analysis of Separated Male and Female Gametocytes Reveals Novel Sex-Specific *Plasmodium* Biology." *Cell* 121.5 (2005): 675-87. Print.
- Khomtchouk, B. B., J. R. Hennessy, and C. Wahlestedt. "Shinyheatmap: Ultra Fast Low Memory Heatmap Web Interface for Big Data Genomics." *PLoS One* 12.5 (2017): e0176334. Print.
- Kim, D., B. Langmead, and S. L. Salzberg. "Hisat: A Fast Spliced Aligner with Low Memory Requirements." *Nat Methods* 12.4 (2015): 357-60. Print.
- Kim, K., and L. M. Weiss. "*Toxoplasma Gondii*: The Model Apicomplexan." *Int J Parasitol* 34.3 (2004): 423-32. Print.
- Kishore, S. P., J. W. Stiller, and K. W. Deitsch. "Horizontal Gene Transfer of Epigenetic Machinery and Evolution of Parasitism in the Malaria Parasite *Plasmodium Falciparum* and Other Apicomplexans." *BMC Evol Biol* 13 (2013): 37. Print.

- Klimes, B., D. G. Rootes, and Z. Tanielian. "Sexual Differentiation of Merozoites of *Eimeria Tenella*." *Parasitology* 65.1 (1972): 131-6. Print.
- Knuepfer, E., et al. "Generating Conditional Gene Knockouts in *Plasmodium* - a Toolkit to Produce Stable Dicer Recombinase-Expressing Parasite Lines Using Crispr/Cas9." *Sci Rep* 7.1 (2017): 3881. Print.
- Konrad, C., et al. "Inhibitors of Eif2alpha Dephosphorylation Slow Replication and Stabilize Latency in *Toxoplasma Gondii*." *Antimicrob Agents Chemother* 57.4 (2013): 1815-22. Print.
- Konrad, C., R. C. Wek, and W. J. Sullivan, Jr. "Gcn2-Like Eif2alpha Kinase Manages the Amino Acid Starvation Response in *Toxoplasma Gondii*." *Int J Parasitol* 44.2 (2014): 139-46. Print.
- . "A Gcn2-Like Eukaryotic Initiation Factor 2 Kinase Increases the Viability of Extracellular *Toxoplasma Gondii* Parasites." *Eukaryot Cell* 10.11 (2011): 1403-12. Print.
- Kotloff, K. L., et al. "Burden and Aetiology of Diarrhoeal Disease in Infants and Young Children in Developing Countries (the Global Enteric Multicenter Study, Gems): A Prospective, Case-Control Study." *Lancet* 382.9888 (2013): 209-22. Print.
- Kuo, C. H., J. P. Wares, and J. C. Kissinger. "The Apicomplexan Whole-Genome Phylogeny: An Analysis of Incongruence among Gene Trees." *Mol Biol Evol* 25.12 (2008): 2689-98. Print.
- Lal, K., et al. "Proteomic Comparison of Four *Eimeria Tenella* Life-Cycle Stages: Unsporulated Oocyst, Sporulated Oocyst, Sporozoite and Second-Generation Merozoite." *Proteomics* 9.19 (2009): 4566-76. Print.
- Lasonder, E., et al. "Proteomic Profiling of *Plasmodium* Sporozoite Maturation Identifies New Proteins Essential for Parasite Development and Infectivity." *PLoS Pathog* 4.10 (2008): e1000195. Print.
- Lasonder, E., et al. "Integrated Transcriptomic and Proteomic Analyses of *P. Falciparum* Gametocytes: Molecular Insight into Sex-Specific Processes and Translational Repression." *Nucleic Acids Res* 44.13 (2016): 6087-101. Print.
- Le Roch, K. G., et al. "Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle." *Science* 301.5639 (2003): 1503-8. Print.
- Legrand, N., P. Jaquier-Gubler, and J. Curran. "The Impact of the Phosphomimetic Eif2alphas/D on Global Translation, Reinitiation and the Integrated Stress Response Is Attenuated in N2a Cells." *Nucleic Acids Res* 43.17 (2015): 8392-404. Print.
- Leitch, G. J., and Q. He. "Cryptosporidiosis-an Overview." *J Biomed Res* 25.1 (2012): 1-16. Print.
- Lescault, P. J., et al. "Genomic Data Reveal *Toxoplasma Gondii* Differentiation Mutants Are Also Impaired with Respect to Switching into a Novel Extracellular Tachyzoite State." *PLoS One* 5.12 (2010): e14463. Print.
- Lin, Z., et al. "Origins and Evolution of the RecA/Rad51 Gene Family: Evidence for Ancient Gene Duplication and Endosymbiotic Gene Transfer." *Proc Natl Acad Sci U S A* 103.27 (2006): 10328-33. Print.

- Lindner, S. E., et al. "Perturbations of Plasmodium Puf2 Expression and Rna-Seq of Puf2-Deficient Sporozoites Reveal a Critical Role in Maintaining Rna Homeostasis and Parasite Transmissibility." *Cell Microbiol* 15.7 (2013): 1266-83. Print.
- Lindner, S. E., et al. "Transcriptomics and Proteomics Reveal Two Waves of Translational Repression During the Maturation of Malaria Parasite Sporozoites." *Nat Commun* 10.1 (2019): 4964. Print.
- Lippuner, C., et al. "Rna-Seq Analysis During the Life Cycle of Cryptosporidium Parvum Reveals Significant Differential Gene Expression between Proliferating Stages in the Intestine and Infectious Sporozoites." *Int J Parasitol* 48.6 (2018): 413-22. Print.
- Liu, F., et al. "An Mfs-Domain Protein Pb15 Plays a Critical Role in Gamete Fertilization of the Malaria Parasite Plasmodium Berghei." *Front Microbiol* 10 (2019): 2193. Print.
- Liu, M., et al. "Characterization of Protein Arginine Methyltransferase of Tgprmt5 in Toxoplasma Gondii." *Parasit Vectors* 12.1 (2019): 221. Print.
- Love, M. I., W. Huber, and S. Anders. "Moderated Estimation of Fold Change and Dispersion for Rna-Seq Data with Deseq2." *Genome Biol* 15.12 (2014): 550. Print.
- Luder, C. G., et al. "Toxoplasma Gondii in Primary Rat Cns Cells: Differential Contribution of Neurons, Astrocytes, and Microglial Cells for the Intracerebral Development and Stage Differentiation." *Exp Parasitol* 93.1 (1999): 23-32. Print.
- Mahe, F., et al. "Parasites Dominate Hyperdiverse Soil Protist Communities in Neotropical Rainforests." *Nat Ecol Evol* 1.4 (2017): 91. Print.
- Mahmoudi, S., and H. Keshavarz. "Malaria Vaccine Development: The Need for Novel Approaches: A Review Article." *Iran J Parasitol* 13.1 (2018): 1-10. Print.
- Mair, G. R., et al. "Regulation of Sexual Development of Plasmodium by Translational Repression." *Science* 313.5787 (2006): 667-9. Print.
- Mair, G. R., et al. "Universal Features of Post-Transcriptional Gene Regulation Are Critical for Plasmodium Zygote Development." *PLoS Pathog* 6.2 (2010): e1000767. Print.
- Manger, I. D., et al. "Expressed Sequence Tag Analysis of the Bradyzoite Stage of Toxoplasma Gondii: Identification of Developmentally Regulated Genes." *Infect Immun* 66.4 (1998): 1632-7. Print.
- Mans, B. J., R. Pienaar, and A. A. Latif. "A Review of Theileria Diagnostics and Epidemiology." *Int J Parasitol Parasites Wildl* 4.1 (2015): 104-18. Print.
- Marin-Mogollon, C., et al. "The Plasmodium Falciparum Male Gametocyte Protein P230p, a Paralog of P230, Is Vital for Ookinete Formation and Mosquito Transmission." *Sci Rep* 8.1 (2018): 14902. Print.
- Martorelli Di Genova, B., et al. "Intestinal Delta-6-Desaturase Activity Determines Host Range for Toxoplasma Sexual Reproduction." *PLoS Biol* 17.8 (2019): e3000364. Print.

- Matos, L. V. S., et al. "The Transcriptome of *Cryptosporidium* Oocysts and Intracellular Stages." *Sci Rep* 9.1 (2019): 7856. Print.
- Matrajt, M., et al. "Identification and Characterization of Differentiation Mutants in the Protozoan Parasite *Toxoplasma Gondii*." *Mol Microbiol* 44.3 (2002): 735-47. Print.
- Matuschewski, K., et al. "Infectivity-Associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozoite Stage." *J Biol Chem* 277.44 (2002): 41948-53. Print.
- Mauzy, M. J., et al. "The *Cryptosporidium Parvum* Transcriptome During in Vitro Development." *PLoS One* 7.3 (2012): e31715. Print.
- McDonald, V., and M. E. Rose. "Eimeria Tenella and E. Necatrix: A Third Generation of Schizogony Is an Obligatory Part of the Developmental Cycle." *J Parasitol* 73.3 (1987): 617-22. Print.
- McDougald, L. R., and T. K. Jeffers. "Eimeria Tenella (Sporozoa, Coccidia): Gametogony Following a Single Asexual Generation." *Science* 192.4236 (1976): 258-9. Print.
- McRobert, L., et al. "Gametogenesis in Malaria Parasites Is Mediated by the Cgmp-Dependent Protein Kinase." *PLoS Biol* 6.6 (2008): e139. Print.
- Mikolajczak, S. A., et al. "Distinct Malaria Parasite Sporozoites Reveal Transcriptional Changes That Cause Differential Tissue Infection Competence in the Mosquito Vector and Mammalian Host." *Mol Cell Biol* 28.20 (2008): 6196-207. Print.
- Miller, C. N., et al. "A Cell Culture Platform for *Cryptosporidium* That Enables Long-Term Cultivation and New Tools for the Systematic Investigation of Its Biology." *Int J Parasitol* 48.3-4 (2018): 197-201. Print.
- Modrzynska, K., et al. "A Knockout Screen of *Apiap2* Genes Reveals Networks of Interacting Transcriptional Regulators Controlling the Plasmodium Life Cycle." *Cell Host Microbe* 21.1 (2017): 11-22. Print.
- Montes, C., et al. "Selection and Development of a Spanish Precocious Strain of *Eimeria Necatrix*." *Vet Parasitol* 78.3 (1998): 169-83. Print.
- Moore, R. B., et al. "A Photosynthetic Alveolate Closely Related to Apicomplexan Parasites." *Nature* 451.7181 (2008): 959-63. Print.
- Morada, M., et al. "Continuous Culture of *Cryptosporidium Parvum* Using Hollow Fiber Technology." *Int J Parasitol* 46.1 (2016): 21-9. Print.
- Morrison, D. A. "Evolution of the Apicomplexa: Where Are We Now?" *Trends Parasitol* 25.8 (2009): 375-82. Print.
- Morrisette, N. S., and L. D. Sibley. "Cytoskeleton of Apicomplexan Parasites." *Microbiol Mol Biol Rev* 66.1 (2002): 21-38; table of contents. Print.
- Mosqueda, J., et al. "*Babesia Bigemina* Sexual Stages Are Induced in Vitro and Are Specifically Recognized by Antibodies in the Midgut of Infected *Boophilus Microplus* Ticks." *Int J Parasitol* 34.11 (2004): 1229-36. Print.
- Mueller, A. K., et al. "Plasmodium Liver Stage Developmental Arrest by Depletion of a Protein at the Parasite-Host Interface." *Proc Natl Acad Sci U S A* 102.8 (2005): 3022-7. Print.

- Muller, K., K. Matuschewski, and O. Silvie. "The Puf-Family Rna-Binding Protein Puf2 Controls Sporozoite Conversion to Liver Stages in the Malaria Parasite." *PLoS One* 6.5 (2011): e19860. Print.
- Murata, Y., et al. "Identification of Compounds That Suppress *Toxoplasma Gondii* Tachyzoites and Bradyzoites." *PLoS One* 12.6 (2017): e0178203. Print.
- Naguleswaran, A., et al. "*Toxoplasma Gondii* Lysine Acetyltransferase Gcn5-a Functions in the Cellular Response to Alkaline Stress and Expression of Cyst Genes." *PLoS Pathog* 6.12 (2010): e1001232. Print.
- Narasimhan, J., et al. "Translation Regulation by Eukaryotic Initiation Factor-2 Kinases in the Development of Latent Cysts in *Toxoplasma Gondii*." *J Biol Chem* 283.24 (2008): 16591-601. Print.
- Nare, B., et al. "Evaluation of a Cyclic Gmp-Dependent Protein Kinase Inhibitor in Treatment of Murine Toxoplasmosis: Gamma Interferon Is Required for Efficacy." *Antimicrob Agents Chemother* 46.2 (2002): 300-7. Print.
- Ngotho, P., et al. "Revisiting Gametocyte Biology in Malaria Parasites." *FEMS Microbiol Rev* 43.4 (2019): 401-14. Print.
- Nguyen, H. M., et al. "Autophagy Participates in the Unfolded Protein Response in *Toxoplasma Gondii*." *FEMS Microbiol Lett* 364.15 (2017). Print.
- Nguyen, T. T., et al. "Initiated *Babesia Ovata* Sexual Stages under in Vitro Conditions Were Recognized by Anti-Ccp2 Antibodies, Showing Changes in the DNA Content by Imaging Flow Cytometry." *Pathogens* 8.3 (2019). Print.
- Nyagwange, J., et al. "Characterization of the *Theileria Parva* Sporozoite Proteome." *Int J Parasitol* 48.3-4 (2018): 265-73. Print.
- Oberstaller, J., S. J. Joseph, and J. C. Kissinger. "Genome-Wide Upstream Motif Analysis of *Cryptosporidium Parvum* Genes Clustered by Expression Profile." *BMC Genomics* 14 (2013): 516. Print.
- Oberstaller, J., et al. "The *Cryptosporidium Parvum* Apiap2 Gene Family: Insights into the Evolution of Apicomplexan Ap2 Regulatory Systems." *Nucleic Acids Res* 42.13 (2014): 8271-84. Print.
- Oberstaller, J., et al. "The *Cryptosporidium Parvum* Apiap2 Gene Family: Insights into the Evolution of Apicomplexan Ap2 Regulatory Systems." *Nucleic Acids Res* 42.13 (2014): 8271-84. Print.
- Pakos-Zebrucka, K., et al. "The Integrated Stress Response." *EMBO Rep* 17.10 (2016): 1374-95. Print.
- Parmley, S. F., et al. "Molecular Characterization of a 65-Kilodalton *Toxoplasma Gondii* Antigen Expressed Abundantly in the Matrix of Tissue Cysts." *Mol Biochem Parasitol* 66.2 (1994): 283-96. Print.
- Patil, V., et al. "Disruption of the Expression of a Non-Coding Rna Significantly Impairs Cellular Differentiation in *Toxoplasma Gondii*." *Int J Mol Sci* 14.1 (2012): 611-24. Print.

- Patra, K. P., et al. "Proteomic Analysis of Zygote and Ookinete Stages of the Avian Malaria Parasite *Plasmodium Gallinaceum* Delineates the Homologous Proteomes of the Lethal Human Malaria Parasite *Plasmodium Falciparum*." *Proteomics* 8.12 (2008): 2492-9. Print.
- Pawlowic, M. C., et al. "Genetic Ablation of Purine Salvage in *Cryptosporidium Parvum* Reveals Nucleotide Uptake from the Host Cell." *Proc Natl Acad Sci U S A* 116.42 (2019): 21160-65. Print.
- Peatey, C. L., et al. "Effect of Antimalarial Drugs on *Plasmodium Falciparum* Gametocytes." *J Infect Dis* 200.10 (2009): 1518-21. Print.
- Petry, F. "Structural Analysis of *Cryptosporidium Parvum*." *Microsc Microanal* 10.5 (2004): 586-601. Print.
- Pieszko, M., et al. "Apiap2 Factors as Candidate Regulators of Stochastic Commitment to Merozoite Production in *Theileria Annulata*." *PLoS Negl Trop Dis* 9.8 (2015): e0003933. Print.
- Pittman, D. L., et al. "Meiotic Prophase Arrest with Failure of Chromosome Synapsis in Mice Deficient for *Dmc1*, a Germline-Specific RecA Homolog." *Mol Cell* 1.5 (1998): 697-705. Print.
- Pittman, K. J., M. T. Aliota, and L. J. Knoll. "Dual Transcriptional Profiling of Mice and *Toxoplasma Gondii* During Acute and Chronic Infection." *BMC Genomics* 15 (2014): 806. Print.
- Polino, A. J., et al. "Assessment of Biological Role and Insight into Druggability of the *Plasmodium Falciparum* Protease Plasmeprin V." *ACS Infect Dis* (2020). Print.
- Poran, A., et al. "Single-Cell Rna Sequencing Reveals a Signature of Sexual Commitment in Malaria Parasites." *Nature* 551.7678 (2017): 95-99. Print.
- Prommana, P., et al. "Inducible Knockdown of *Plasmodium* Gene Expression Using the *Glms* Ribozyme." *PLoS One* 8.8 (2013): e73783. Print.
- Radke, J. B., et al. "Apiap2 Transcription Factor Restricts Development of the *Toxoplasma* Tissue Cyst." *Proc Natl Acad Sci U S A* 110.17 (2013): 6871-6. Print.
- Radke, J. B., et al. "Transcriptional Repression by Apiap2 Factors Is Central to Chronic Toxoplasmosis." *PLoS Pathog* 14.5 (2018): e1007035. Print.
- Radke, J. R., et al. "Changes in the Expression of Human Cell Division Autoantigen-1 Influence *Toxoplasma Gondii* Growth and Development." *PLoS Pathog* 2.10 (2006): e105. Print.
- Radke, J. R., et al. "A Change in the Premitotic Period of the Cell Cycle Is Associated with Bradyzoite Differentiation in *Toxoplasma Gondii*." *Mol Biochem Parasitol* 131.2 (2003): 119-27. Print.
- Raibaud, A., et al. "Differential Gene Expression in the Ookinete Stage of the Malaria Parasite *Plasmodium Berghei*." *Mol Biochem Parasitol* 150.1 (2006): 107-13. Print.
- Ramakrishnan, C., et al. "An Experimental Genetically Attenuated Live Vaccine to Prevent Transmission of *Toxoplasma Gondii* by Cats." *Sci Rep* 9.1 (2019): 1474. Print.

- Ramakrishnan, C., et al. "The Merozoite-Specific Protein, Tggra11b, Identified as a Component of the Toxoplasma Gondii Parasitophorous Vacuole in a Tachyzoite Expression Model." *Int J Parasitol* 47.10-11 (2017): 597-600. Print.
- Rueckert, S., S. V. Pipaliya, and J. B. Dacks. "Evolution: Parallel Paths to Parasitism in the Apicomplexa." *Curr Biol* 29.17 (2019): R836-R39. Print.
- Sateriale, A., et al. "A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity." *Cell Host Microbe* 26.1 (2019): 135-46 e5. Print.
- Sato, Y., G. N. Montagna, and K. Matuschewski. "Plasmodium Berghei Sporozoites Acquire Virulence and Immunogenicity During Mosquito Hemocoel Transit." *Infect Immun* 82.3 (2014): 1164-72. Print.
- Schindelin, J., et al. "Fiji: An Open-Source Platform for Biological-Image Analysis." *Nat Methods* 9.7 (2012): 676-82. Print.
- Schuster, F. L. "Cultivation of Babesia and Babesia-Like Blood Parasites: Agents of an Emerging Zoonotic Disease." *Clin Microbiol Rev* 15.3 (2002): 365-73. Print.
- . "Cultivation of Plasmodium Spp." *Clin Microbiol Rev* 15.3 (2002): 355-64. Print.
- Schwartz, E. "Prophylaxis of Malaria." *Mediterr J Hematol Infect Dis* 4.1 (2012): e2012045. Print.
- Sebastian, S., et al. "A Plasmodium Calcium-Dependent Protein Kinase Controls Zygote Development and Transmission by Translationally Activating Repressed Mrnas." *Cell Host Microbe* 12.1 (2012): 9-19. Print.
- Serova, M., et al. "Single Agent and Combination Studies of Pralatrexate and Molecular Correlates of Sensitivity." *Br J Cancer* 104.2 (2011): 272-80. Print.
- Shaw, M. K., and L. G. Tilney. "How Individual Cells Develop from a Syncytium: Merogony in Theileria Parva (Apicomplexa)." *J Cell Sci* 101 (Pt 1) (1992): 109-23. Print.
- Shiels, B., et al. "Modulation of Protein Synthesis Relative to DNA Synthesis Alters the Timing of Differentiation in the Protozoan Parasite Theileria Annulata." *J Cell Sci* 110 (Pt 13) (1997): 1441-51. Print.
- Shiels, B., et al. "An Upstream Element of the Tams1 Gene Is a Site of DNA-Protein Interactions During Differentiation to the Merozoite in Theileria Annulata." *J Cell Sci* 113 (Pt 12) (2000): 2243-52. Print.
- Shiels, B., et al. "Disruption of Synchrony between Parasite Growth and Host Cell Division Is a Determinant of Differentiation to the Merozoite in Theileria Annulata." *J Cell Sci* 101 (Pt 1) (1992): 99-107. Print.
- Shirley, M. W., and D. A. Harvey. "A Genetic Linkage Map of the Apicomplexan Protozoan Parasite Eimeria Tenella." *Genome Res* 10.10 (2000): 1587-93. Print.
- Shirley, M. W., V. McDonald, and M. A. Bellatti. "Eimeria Brunetti: Selection and Characteristics of a Precocious (and Attenuated) Line." *Avian Pathol* 15.4 (1986): 705-17. Print.
- Shirley, M. W., et al. "Eimeria Praecox: Selection and Characteristics of Precocious Lines." *Avian Pathol* 13.4 (1984): 669-82. Print.
- Shukla, A., et al. "Glycolysis Is Important for Optimal Asexual Growth and Formation of

- Mature Tissue Cysts by *Toxoplasma Gondii*." *Int J Parasitol* 48.12 (2018): 955-68. Print.
- Sidik, S. M., et al. "A Genome-Wide Crispr Screen in *Toxoplasma* Identifies Essential Apicomplexan Genes." *Cell* 166.6 (2016): 1423-35 e12. Print.
- Silva, P. A., et al. "Translational Control of Uis4 Protein of the Host-Parasite Interface Is Mediated by the Rna Binding Protein Puf2 in *Plasmodium Berghei* Sporozoites." *PLoS One* 11.1 (2016): e0147940. Print.
- Silvestrini, F., P. Alano, and J. L. Williams. "Commitment to the Production of Male and Female Gametocytes in the Human Malaria Parasite *Plasmodium Falciparum*." *Parasitology* 121 Pt 5 (2000): 465-71. Print.
- Silvie, O., et al. "Post-Transcriptional Silencing of Uis4 in *Plasmodium Berghei* Sporozoites Is Important for Host Switch." *Mol Microbiol* 91.6 (2014): 1200-13. Print.
- Silvie, O., K. Goetz, and K. Matuschewski. "A Sporozoite Asparagine-Rich Protein Controls Initiation of *Plasmodium* Liver Stage Development." *PLoS Pathog* 4.6 (2008): e1000086. Print.
- Sinden, R. E. "Developing Transmission-Blocking Strategies for Malaria Control." *PLoS Pathog* 13.7 (2017): e1006336. Print.
- Sinden, R. E., R. H. Hartley, and L. Winger. "The Development of *Plasmodium* Ookinetes in Vitro: An Ultrastructural Study Including a Description of Meiotic Division." *Parasitology* 91 (Pt 2) (1985): 227-44. Print.
- Singh, U., J. L. Brewer, and J. C. Boothroyd. "Genetic Analysis of Tachyzoite to Bradyzoite Differentiation Mutants in *Toxoplasma Gondii* Reveals a Hierarchy of Gene Induction." *Mol Microbiol* 44.3 (2002): 721-33. Print.
- Sinha, A., et al. "A Cascade of DNA-Binding Proteins for Sexual Commitment and Development in *Plasmodium*." *Nature* 507.7491 (2014): 253-57. Print.
- Šlapeta, Jan and Victoria Morin-Adeline. "Apicomplexa Levine 1970. Sporozoa Leucart 1879. Version 18 May 2011." 2011. Web.
- . "Hematozoa Vivier 1982. Aconoidasida Mehlhorn, Peters & Haberkorn 1980. Version 18 May 2011." 2011. Web.
- Smith, T. G., et al. "Commitment to Sexual Differentiation in the Human Malaria Parasite, *Plasmodium Falciparum*." *Parasitology* 121 (Pt 2) (2000): 127-33. Print.
- Smith, T. G., D. Walliker, and L. C. Ranford-Cartwright. "Sexual Differentiation and Sex Determination in the Apicomplexa." *Trends Parasitol* 18.7 (2002): 315-23. Print.
- Soete, M., et al. "*Toxoplasma Gondii*: Kinetics of Bradyzoite-Tachyzoite Interconversion in Vitro." *Exp Parasitol* 76.3 (1993): 259-64. Print.
- Srivastava, A., et al. "Stage-Specific Changes in *Plasmodium* Metabolism Required for Differentiation and Adaptation to Different Host and Vector Environments." *PLoS Pathog* 12.12 (2016): e1006094. Print.
- Stanway, R. R., et al. "Genome-Scale Identification of Essential Metabolic Processes for Targeting the *Plasmodium* Liver Stage." *Cell* 179.5 (2019): 1112-28 e26. Print.

- Sturm, A., et al. "Mitochondrial Atp Synthase Is Dispensable in Blood-Stage Plasmodium Berghei Rodent Malaria but Essential in the Mosquito Phase." *Proc Natl Acad Sci U S A* 112.33 (2015): 10216-23. Print.
- Su, S., et al. "Comparative Transcriptome Analysis of Second- and Third-Generation Merozoites of *Eimeria Necatrix*." *Parasit Vectors* 10.1 (2017): 388. Print.
- Su, S., et al. "Further Confirmation of Second- and Third-Generation *Eimeria Necatrix* Merozoite Degs Using Suppression Subtractive Hybridization." *Parasitol Res* 118.4 (2019): 1159-69. Print.
- Suarez, C. E., et al. "Advances in the Application of Genetic Manipulation Methods to Apicomplexan Parasites." *Int J Parasitol* 47.12 (2017): 701-10. Print.
- Suarez, C. E., and T. F. McElwain. "Stable Expression of a Gfp-Bsd Fusion Protein in *Babesia Bovis* Merozoites." *Int J Parasitol* 39.3 (2009): 289-97. Print.
- Sullivan, W. J., Jr. "Mastering *Toxoplasma* Sex and Sleep." *Nat Microbiol* 5.4 (2020): 533-34. Print.
- Sullivan, W. J., Jr., et al. "Parasite-Specific Eif2 (Eukaryotic Initiation Factor-2) Kinase Required for Stress-Induced Translation Control." *Biochem J* 380.Pt 2 (2004): 523-31. Print.
- Swan, D. G., et al. "Temporal Co-Ordination of Macroschizont and Merozoite Gene Expression During Stage Differentiation of *Theileria Annulata*." *Mol Biochem Parasitol* 113.2 (2001): 233-9. Print.
- Swierzy, I. J., et al. "Divergent Co-Transcriptomes of Different Host Cells Infected with *Toxoplasma Gondii* Reveal Cell Type-Specific Host-Parasite Interactions." *Sci Rep* 7.1 (2017): 7229. Print.
- Talman, A. M., et al. "Proteomic Analysis of the Plasmodium Male Gamete Reveals the Key Role for Glycolysis in Flagellar Motility." *Malar J* 13 (2014): 315. Print.
- Tandel, J., et al. "Life Cycle Progression and Sexual Development of the Apicomplexan Parasite *Cryptosporidium Parvum*." *Nat Microbiol* 4.12 (2019): 2226-36. Print.
- Taylor, C. J., L. McRobert, and D. A. Baker. "Disruption of a Plasmodium Falciparum Cyclic Nucleotide Phosphodiesterase Gene Causes Aberrant Gametogenesis." *Mol Microbiol* 69.1 (2008): 110-8. Print.
- Teng, Y., et al. "Inhibition of Eif2alpha Dephosphorylation Enhances Trail-Induced Apoptosis in Hepatoma Cells." *Cell Death Dis* 5.2 (2014): e1060. Print.
- Timmis, J. N., et al. "Endosymbiotic Gene Transfer: Organelle Genomes Forge Eukaryotic Chromosomes." *Nat Rev Genet* 5.2 (2004): 123-35. Print.
- Toh, B. H., et al. "Role of Cell Division Autoantigen 1 (Cda1) in Cell Proliferation and Fibrosis." *Genes (Basel)* 1.3 (2010): 335-48. Print.
- Tomas, A. M., et al. "P25 and P28 Proteins of the Malaria Ookinete Surface Have Multiple and Partially Redundant Functions." *EMBO J* 20.15 (2001): 3975-83. Print.
- Tomavo, S., and J. C. Boothroyd. "Interconnection between Organellar Functions, Development and Drug Resistance in the Protozoan Parasite, *Toxoplasma Gondii*." *Int J Parasitol* 25.11 (1995): 1293-9. Print.
- Tomita, T., et al. "The *Toxoplasma Gondii* Cyst Wall Protein Cst1 Is Critical for Cyst

- Wall Integrity and Promotes Bradyzoite Persistence." *PLoS Pathog* 9.12 (2013): e1003823. Print.
- Tonui, T., et al. "Transcriptomics Reveal Potential Vaccine Antigens and a Drastic Increase of Upregulated Genes During *Theileria Parva* Development from Arthropod to Bovine Infective Stages." *PLoS One* 13.10 (2018): e0204047. Print.
- Toro-Moreno, M., et al. "Rna-Seq Analysis Illuminates the Early Stages of Plasmodium Liver Infection." *mBio* 11.1 (2020). Print.
- Touray, M. G., et al. "Developmentally Regulated Infectivity of Malaria Sporozoites for Mosquito Salivary Glands and the Vertebrate Host." *J Exp Med* 175.6 (1992): 1607-12. Print.
- Trager, W., et al. "Plasmodium Falciparum: Enhanced Gametocyte Formation in Vitro in Reticulocyte-Rich Blood." *Exp Parasitol* 91.2 (1999): 115-8. Print.
- Tsuzuki, T., et al. "Targeted Disruption of the Rad51 Gene Leads to Lethality in Embryonic Mice." *Proc Natl Acad Sci U S A* 93.13 (1996): 6236-40. Print.
- Tu, V., et al. "Enrichment and Proteomic Characterization of the Cyst Wall from in Vitro *Toxoplasma Gondii* Cysts." *mBio* 10.2 (2019). Print.
- van Schaijk, B. C., et al. "Type Ii Fatty Acid Biosynthesis Is Essential for Plasmodium Falciparum Sporozoite Development in the Midgut of Anopheles Mosquitoes." *Eukaryot Cell* 13.5 (2014): 550-9. Print.
- Vanderberg, J. P. "Development of Infectivity by the Plasmodium Berghei Sporozoite." *J Parasitol* 61.1 (1975): 43-50. Print.
- Vaughan, A. M., and S. H. I. Kappe. "Malaria Parasite Liver Infection and Exoerythrocytic Biology." *Cold Spring Harb Perspect Med* 7.6 (2017). Print.
- Vaughan, A. M., et al. "Complete Plasmodium Falciparum Liver-Stage Development in Liver-Chimeric Mice." *J Clin Invest* 122.10 (2012): 3618-28. Print.
- Vaughan, A. M., et al. "Type Ii Fatty Acid Synthesis Is Essential Only for Malaria Parasite Late Liver Stage Development." *Cell Microbiol* 11.3 (2009): 506-20. Print.
- Vetterling, J. M., A. Takeuchi, and P. A. Madden. "Ultrastructure of Cryptosporidium Wrairi from the Guinea Pig." *J Protozool* 18.2 (1971): 248-60. Print.
- Vinayak, S., et al. "Genetic Modification of the Diarrhoeal Pathogen Cryptosporidium Parvum." *Nature* 523.7561 (2015): 477-80. Print.
- Voorberg-van der Wel, A., et al. "A Comparative Transcriptomic Analysis of Replicating and Dormant Liver Stages of the Relapsing Malaria Parasite Plasmodium Cynomolgi." *Elife* 6 (2017). Print.
- Votýpka, Jan. "Piroplasmorida Wenyon 1926. Version 18 May 2011." 2011. Web.
- Waldman, B. S., et al. "Identification of a Master Regulator of Differentiation in Toxoplasma." *Cell* 180.2 (2020): 359-72 e16. Print.
- Walker, R. A., et al. "Sex and Eimeria: A Molecular Perspective." *Parasitology* 140.14 (2013): 1701-17. Print.
- Walker, R. A., et al. "Rna Seq Analysis of the Eimeria Tenella Gametocyte Transcriptome Reveals Clues About the Molecular Basis for Sexual Reproduction and Oocyst Biogenesis." *BMC Genomics* 16 (2015): 94. Print.

- Walker, R. A., et al. "The Glycosylation Pathway of *Eimeria Tenella* Is Upregulated During Gametocyte Development and May Play a Role in Oocyst Wall Formation." *Eukaryot Cell* 9.1 (2010): 127-35. Print.
- Walker, R., et al. "The *Toxoplasma* Nuclear Factor Tgap2xi-4 Controls Bradyzoite Gene Expression and Cyst Formation." *Mol Microbiol* 87.3 (2013): 641-55. Print.
- Watts, E., et al. "Novel Approaches Reveal That *Toxoplasma Gondii* Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities in Vivo." *mBio* 6.5 (2015): e01155-15. Print.
- Wilke, G., et al. "A Stem-Cell-Derived Platform Enables Complete *Cryptosporidium* Development in Vitro and Genetic Tractability." *Cell Host Microbe* 26.1 (2019): 123-34 e8. Print.
- Wilke, G., et al. "Monoclonal Antibodies to Intracellular Stages of *Cryptosporidium Parvum* Define Life Cycle Progression in Vitro." *mSphere* 3.3 (2018). Print.
- Wong, J. L., and M. A. Johnson. "Is Hap2-Gcs1 an Ancestral Gamete Fusogen?" *Trends Cell Biol* 20.3 (2010): 134-41. Print.
- Woodmansee, D. B. "Studies of in Vitro Excystation of *Cryptosporidium Parvum* from Calves." *J Protozool* 34.4 (1987): 398-402. Print.
- Xu, B., et al. "Screening for Biomarkers Reflecting the Progression of *Babesia Microti* Infection." *Parasit Vectors* 11.1 (2018): 379. Print.
- Xu, P., et al. "The Genome of *Cryptosporidium Hominis*." *Nature* 431.7012 (2004): 1107-12. Print.
- Xue, Y., et al. "A Single-Parasite Transcriptional Atlas of *Toxoplasma Gondii* Reveals Novel Control of Antigen Expression." *Elife* 9 (2020). Print.
- Yang, S., and S. F. Parmley. "*Toxoplasma Gondii* Expresses Two Distinct Lactate Dehydrogenase Homologous Genes During Its Life Cycle in Intermediate Hosts." *Gene* 184.1 (1997): 1-12. Print.
- Yeoh, L. M., et al. "Comparative Transcriptomics of Female and Male Gametocytes in *Plasmodium Berghei* and the Evolution of Sex in Alveolates." *BMC Genomics* 18.1 (2017): 734. Print.
- Young, J. A., et al. "The *Plasmodium Falciparum* Sexual Development Transcriptome: A Microarray Analysis Using Ontology-Based Pattern Identification." *Mol Biochem Parasitol* 143.1 (2005): 67-79. Print.
- Yuda, M., et al. "Global Transcriptional Repression: An Initial and Essential Step for *Plasmodium* Sexual Development." *Proc Natl Acad Sci U S A* 112.41 (2015): 12824-9. Print.
- Yuda, M., et al. "Transcription Factor Ap2-Sp and Its Target Genes in Malarial Sporozoites." *Mol Microbiol* 75.4 (2010): 854-63. Print.
- Yuda, M., et al. "Female-Specific Gene Regulation in Malaria Parasites by an Ap2-Family Transcription Factor." *Mol Microbiol* 113.1 (2020): 40-51. Print.
- Zanghi, G., et al. "A Specific Pfemp1 Is Expressed in *P. Falciparum* Sporozoites and Plays a Role in Hepatocyte Infection." *Cell Rep* 22.11 (2018): 2951-63. Print.

- Zhang, C., et al. "Systematic Crispr-Cas9-Mediated Modifications of Plasmodium Yoelii Apiap2 Genes Reveal Functional Insights into Parasite Development." *mBio* 8.6 (2017). Print.
- Zhang, H., et al. "Transcriptome Analysis Reveals Unique Metabolic Features in the Cryptosporidium Parvum Oocysts Associated with Environmental Survival and Stresses." *BMC Genomics* 13 (2012): 647. Print.
- Zhang, J. H., T. D. Chung, and K. R. Oldenburg. "A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays." *J Biomol Screen* 4.2 (1999): 67-73. Print.
- Zhang, M., et al. "The Plasmodium Eukaryotic Initiation Factor-2alpha Kinase Ik2 Controls the Latency of Sporozoites in the Mosquito Salivary Glands." *J Exp Med* 207.7 (2010): 1465-74. Print.
- Zhang, Z., B. R. Green, and T. Cavalier-Smith. "Phylogeny of Ultra-Rapidly Evolving Dinoflagellate Chloroplast Genes: A Possible Common Origin for Sporozoan and Dinoflagellate Plastids." *J Mol Evol* 51.1 (2000): 26-40. Print.
- Zhu, X., et al. "Plasmodium Berghei Serine/Threonine Protein Phosphatase Pp5 Plays a Critical Role in Male Gamete Fertility." *Int J Parasitol* 49.9 (2019): 685-95. Print.